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Abstract 
ABSTRACT 
The molecular functions of the non-cell cycle-related Cyclin-dependent kinase 5 (Cdk5) have 
been of primary interest within the neuroscience field, but novel undertakings are constantly 
emerging for the kinase in tissue homeostasis, as well as in diseases such as diabetes and cancer. 
Although Cdk5 activation is predominantly regulated by specific non-cyclin activator protein 
binding, additional mechanisms have proved to orchestrate Cdk5 signaling in cells. For 
example, the interaction between the intermediate filament protein nestin and Cdk5 has been 
proposed to determine cellular fate during neuronal apoptosis through nestin-dependent 
adjustment of the sensitive balance and turnover of Cdk5 activators. While nestin constitutes a 
crucial regulatory scaffold for appropriate Cdk5 activation in apoptosis, Cdk5 itself 
phosphorylates nestin with the consequence of filament reorganization in both neuronal 
progenitors and differentiating muscle cells. Interestingly, the two proteins are often found co-
expressed in various tissues and cell types, proposing that nestin-mediated scaffolding of Cdk5 
and its activators may be applicable to other tissue systems as well. In the literature, the 
molecular functions of nestin have remained in the shade, as it is mostly exploited as a marker 
protein for progenitor cells. In light of these studies, the aim of this thesis was to assess the 
importance of the nestin scaffold in regulation of Cdk5 actions in cell fate decisions.  
This thesis can be subdivided into two major projects: one that studied the nature of the Cdk5-
nestin interplay in muscle, and one that assessed their role in prostate cancer. During 
differentiation of a myoblast cell line, the filament formation properties of nestin was found to 
be crucial in directing Cdk5 activity, with direct consequences on the process of differentiation.  
Also the genetic knockout of nestin was found to influence Cdk5 activity, although 
differentiation per se was not affected. Instead, the genetic ablation of nestin had broad 
consequences on muscle homeostasis and regeneration. While the nestin-mediated regulation 
of Cdk5 in muscle was found to act in multiple ways, the connection remained more elusive in 
cancer models. Cdk5 was, however, established as a significant determinant of prostate cancer 
proliferation; a behavior uncharacteristic for this differentiation-associated kinase. Through 
complex and simultaneous regulation of two major prostate cancer pathways, Cdk5 was placed 
upstream of both Akt kinase and the androgen receptor. Its action on proliferation was 
nonetheless mainly exerted through the Akt signaling pathway in various cancer models. In 
summary, this thesis contributed to the knowledge of Cdk5 regulation and functions in two 
atypical settings; proliferation (in a cancer framework) and muscle differentiation, which is a 
poorly understood model system in the Cdk5 field. This balance between proliferation and 
differentiation implemented by Cdk5 is ultimately regulated (where present) by the dynamics of 
the cytoskeletal nestin scaffold.  
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Introduction 
INTRODUCTION 
The stem cells that derive from the inner cell mass of the blastocyst in the developing embryo 
are the precursors to all cells and tissue types in the body. Through the process of 
differentiation, the stem cell loses its totipotency, and acquires instead more specialized 
functions needed by the particular cell type it will differentiate into. Whereas stem cells have the 
capacity to divide limitlessly, most differentiated cell types have lost the capacity of cell division 
in humans, and have entered the quiescent G0-cell cycle phase. During their lifetime, all tissues 
are disposed to constant environmental stress, which is harmful for the cells. For example, in 
response to injury and the consequential loss of cells, tissues need to replenish lost material. 
This typically occurs through the activation and differentiation of tissue-resident progenitor 
cells, with the help of an inflammatory response, which aids in the recruitment of appropriate 
cell types to the site of damage. Thus, most tissues do have the capacity of self-renewal, at least 
to a certain extent. An example of a constantly renewing tissue is skeletal muscle. Skeletal 
muscle is prone to injuries of variable extent, including the microdamage that is induced by 
everyday tasks such as motility and exercise. Exercise-provoked activation of muscle progenitor 
cells heals the damaged myofibers and contributes to muscle mass increase. The muscle 
progenitors have limited renewal capacity, and will eventually deplete with time. Muscle 
resident progenitor cells are also depleted or dysfunctional in disease conditions, such as muscle 
dystrophies. Tissue damage is strictly regulated by the inflammatory environment, and a 
correct response that drives the proliferation and differentiation of all cell types involved is 
necessary for proper healing. A prolonged inflammation can cause stem cell depletion and 
fibrosis, with dire consequences on tissue function. 
An interesting example of flawed differentiation, or rather the lack of differentiation, is cancer. 
Cancerous cells are generated by accumulation of mutations to the cell´s genome. Eventually, 
the mutations provide the cancer cells with growth advantage properties that will allow the cells 
to divide endlessly, defy cell death, resist cell contact-independent growth and acquire a motile 
phenotype required for metastasis. Cancer cells and stem cells resemble each other in their great 
proliferation capacity, which in the case of cancer cells, has gone out of reach of the cellular 
control mechanisms that have evolved to prevent selfish cell behavior. Although limitless 
proliferation is used to define cancer, malignancies that arise in different tissues have unique 
molecular characteristics, different origin and are surrounded by a distinctive environment that 
transforms the cells it surrounds. While mutations in most common oncogenes and tumor 
suppressors occur in most, if not all cancers, tissue-specific tumor founder mutations reflect the 
tissue source. In the case of prostate cancer, which is studied in this thesis, the androgen 
signaling also required for prostate development, plays a key role in prostate carcinogenesis.     
As cells are constantly under the strain of various stress factors of variable severity and type that 
may damage the cells´ proteins and DNA, the cells need a rapid signal transduction system to 
respond to extracellular cues. All the signals that a cell receives are combined and interpreted by 
signaling executors inside the cell, allowing an appropriate cellular response to occur. Protein 
kinases are such crucial components of the cell´s signal transduction system. There are thought 
to be approximately 500 kinases in humans, which are further subcategorized according to 
sequence and functional homology (Manning et al., 2002) (Figure 1). These kinases have evolved 
to mediate highly specialized functions within the cell. They regulate target protein function, 
localization and activity through addition of negatively charged phosphate groups on serine, 
threonine or tyrosine residues on target proteins. Thus, phosphorylation, a form of post-
translational modification, is a quick and reversible modification that transfers cellular signals 
within minutes inside the cell, but can also be sustained for extended periods. Protein 
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phosphorylation is actively counteracted by 
de-phosphorylation by protein 
phosphatases such as the Ser/Thr 
phosphatases PP2A and PP1. In addition to 
phosphorylation, other forms of post-
translational modifications (such as 
ubiquitination, SUMOylation, glycosylation, 
methylation and acetylation) are thought to 
be equally powerful in the functional 
alterations of proteins, and can function as 
efficient on/off switches for cellular 
responses.  
Protein kinases regulate most signal 
transduction pathways, and have vast effects 
on cell division, apoptosis, differentiation, 
growth, migration and invasion. 
Deregulation of phosphorylation patterns 
are acknowledged to contribute to diseases 
such as neurodegenerative conditions as 
well as cancer, making protein kinases 
attractive pharmaceutical targets. Kinase 
inhibitors are in fact one of the most 
investigated cancer drug types due to their 
potential to be very selective, and the fact 
that many cancer types are often highly dependent on a few signaling pathways, in other words 
they are “oncogene-addicted”. Most oncogenic kinases have broad (pro-proliferative, pro-
migratory, anti-apoptotic) and inter-connected functions; therefore, in the case of one-pathway 
addiction, single kinase inhibitors may have desirable effects in patients. Acquired resistance in 
response to chemotherapy is, however, common, and leads to adaptation of cancer cells to a 
new environment. Functional compensation by other oncogenic pathways that were not 
initially targeted may require further actions and lead to re-design of medication. Thus, to 
target specific protein kinases for pharmacological purposes, we first need to understand how 
these kinases work in different contexts, how they are regulated and how they connect with 
other signaling pathways.   
This thesis aimed to understand the roles and regulation of the atypical protein kinase cyclin-
dependent kinase 5 (Cdk5) in two model systems: muscle and prostate cancer. On one hand, I 
have studied how the cytoskeletal protein nestin affects Cdk5 signaling in muscle progenitor 
cell cultures and in animals lacking nestin. Here I describe that nestin is an essential part of the 
Cdk5-regulatory axis in muscle differentiation, as it fine-tunes the early stages of the 
differentiation process and acts as a dynamic scaffold for the kinase. The other project has 
focused on the role of Cdk5 in prostate cancer proliferation. Although Cdk5 is classically 
considered to be a key component of neuronal differentiation, recent studies have revealed that 
Cdk5 plays an essential part in many tissue types during homeostasis and disease. In this work, 
I depict how this differentiation-related kinase also has pro-proliferative effects on cancer cell 
growth through its mutual effects on the oncogenic kinase Akt and androgen signaling. 
Together these studies have assessed some less well understood functions of Cdk5 and have 
broadened the view of typical Cdk5 functions.  
Figure 1 Classification of human kinases. The 
approximately 500 human kinases are classified into 9 major 
groups based on sequence comparison. The groups are 
further sub-categorized into families (the number of kinase 
families per group is marked in parentheses). In addition, 
the atypical kinases consist of 8 groups, containing a total of 
15 families. Cdk5 belongs to the CMGC group of kinases, 
which also includes the GSK and MAPK families. Here, the 
Cdks are classified into three functionally different groups 
(not homology-based). Modified from Manning et al., 2002. 
11 
 
Review of the Literature 
REVIEW OF THE LITERATURE 
1 Cyclin-dependent kinase 5 in development and disease  
The Cyclin-dependent kinases (Cdks) are a group of more than 20 Ser/Thr protein kinases in 
humans. They are mainly activated, as their name suggests, through their association with 
cyclins or cyclin-like proteins. Cdk4, Cdk6, Cdk2 and Cdk1 (Cdc2) are involved in the 
progression of mammalian cell cycle (G1 phase; G1 phase; G1/S transition, S and G2 phases; M-
phase, respectively) and are activated through the association with their cognate cyclin partners 
(D-cyclins; D-cyclins; E- and A-cyclins; B-cyclins, respectively). The Cdk family also contains 
members that are involved in transcription through their interactions with RNA polymerase II 
(Cdk7, Cdk8, Cdk9 and Cdk11). Unlike the other kinase family members, Cdk5 was originally 
described as a master regulator of neuronal differentiation and death, but further studies have 
revealed complex roles for the kinase in several tissue types, with functions in cellular secretion, 
survival and motility.  
1.1 The molecular structure of Cdk5 
The 33-kDa Cdk5 was originally categorized in the subfamily of cyclin-dependent kinases 
according to sequence homology to Cdk1 (~58%) and Cdk2 (~61%) (Hellmich et al., 1992). 
Formerly known as neuronal cdc2-like kinase (nclk) or PSSALRE, Cdk5 was first cloned from 
rat brain lysates (Hellmich et al., 1992). In addition, Cdk5 has been identified in most studied 
animals, including human (Meyerson et al., 1992). Cdk5 is, in fact, highly conserved in 
mammals (~99%), suggesting an important cellular function for the protein (Tsai et al., 1993). 
For comparison, Drosophila Cdk5 shows 77% sequence homology to mammalian genes 
(Hellmich et al., 1994). In addition, evidence point towards the existence of a functional Cdk5-
homolog in yeast: the Pho85-kinase deletion phenotype can be rescued with Cdk5 expression, 
at least in terms of restoration of actin cytoskeleton organization and nutrient sensing, which 
include some of the functions of Pho85 (Huang et al., 1999). 
Despite its close structural resemblance to other Cdks, Cdk5 shows unique features that 
distinguishes it from the other family members. Firstly, all Cdks contain a distinctive amino 
acid sequence in between the small N-terminal lobe and the α-helical C-terminus, which in the 
case of Cdk5 is the one letter amino acid sequence PSSALRE (Meyerson et al., 1992); hence its 
original name. In between the N- and C-termini of all Cdks lies an adenosine triphosphate 
(ATP)-directing activation loop that also contributes to substrate specificity. In contrast to 
other Cdk family members, Cdk5 can associate with certain cyclins, but is mainly activated by 
non-cyclin proteins. The third major factor that distinguishes Cdk5 from cell cycle Cdks is its 
independence of activation loop phosphorylation upon activation, a crucial step in classical Cdk 
activation. Instead, activator binding promotes an active conformation of Cdk5, while 
simultaneously affecting kinase substrate specificity (Qi et al., 1995; Tarricone et al., 2001). 
Classically, c-Abl (Zukerberg et al., 2000) and Fyn kinase (Sasaki et al., 2002)-mediated 
phosphorylation of Cdk5 Tyr15 is thought to promote kinase activity in neurons, while the 
phosphorylation of the corresponding residues on classical Cdks has a strong inhibitory effect 
on kinase activity. On the other hand, recent data suggests that Fyn increases Cdk5 activity by 
promoting p35 stability, and that Tyr15-phosphorylated Cdk5 could in fact reside in an inactive 
monomeric state (Kobayashi et al., 2014). Thus, phospho-antibodies directed at Cdk5 Tyr15 are 
not a suitable tool for assessing the Cdk5 activation state. In addition, Cdk5 activity has been 
suggested to be post-translationally repressed by S-nitrosylation of Cys83 in the ATP binding 
12 
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pocket, a motif not present in other Cdks (Zhang et al., 2010b). While these structural features 
differentiate Cdk5 from its family members, the substrate consensus phosphorylation sequence 
of these kinases is strikingly similar. Cdk5 phosphorylates serines (Ser) and threonines (Thr) 
followed by a proline (Pro) on substrates that contain the consensus sequence 
(Ser/Thr)ProX(Lys/His/Arg), where X is any amino acid that is followed by one of the basic 
amino acids lysine, histidine or arginine (Songyang et al., 1996). Thus, Cdk5 and Cdk1 do share 
several substrates.  
In 2010, two independent reports indicated the presence of a ubiquitously expressed novel 
Cdk5 splice variant (Cdk5-SV) (Kim et al. 2010; Li et al. 2010). The truncated Cdk5-SV has a 
molecular weight of 29 kDa, and shows a prominent nuclear/perinuclear localization (Kim et al. 
2010; Li et al. 2010). Interestingly, Kim and co-authors (2010) reported that exogenous Cdk5-
SV co-localized with centrosomes, which according to the authors, possibly signified a cell 
division-related role. It should be highlighted in this context that Cdk5-SV is detected by most 
commercial antibodies (including those described in this thesis). Thus, it is impossible to 
distinguish between the functions of the distinct splice variants from previous literature, as 
most studies are investigating endogenous Cdk5. However, there is currently no evidence of 
Cdk5-SV kinase activity in tissues. 
1.2 Mechanisms of Cdk5 activation 
Cdk5 activation unconditionally requires binding of activator proteins. The certainly most 
studied activation mechanism of Cdk5 is through its interaction with p35, as well as its cleavage 
product p25, which is generated by calpain-dependent cleavage of the mother protein. The 
Cdk5 interaction with p35 occurs between amino acids 138 and 291 on p35 (Amin et al., 2002; 
Poon et al., 1997). Recent studies have expanded on the mechanisms that regulate Cdk5 
activation also beyond classical neuronal models and challenged the previous view of the 
activation process.  
1.2.1 p35 and its proteolytic cleavage products 
Cdk5 and p35 (as well as its proteolytic cleavage product p25) were first discovered by pull-
down of the active complexes from brain lysates (Lew et al., 1992a; Lew et al., 1994; Tsai et al., 
1994). p35 (also known as CDK5R1, and previously nck5a) is unrelated to the cyclin protein 
family; yet the crystal structure of p25 reveals that the three dimensional conformation shows 
striking similarities to cyclin A, as the activator contains a cyclin box fold-like motif in the 
Cdk5-binding region (Tarricone et al., 2001). Hence the tertiary structure of the holokinase 
allows comparable interactions between the subunits similar to classical cyclin-Cdk pairs; an 
interaction, which advances ATP-binding and substrate recognition. Activator binding to Cdk5 
occurs through interactions with the kinase activation loop and the Cdk5-specific PSSALRE-
region (Tarricone et al., 2001).  
Cleavage of p35 to p25 by calpains has broad consequences on Cdk5 activity through effects on 
both the stability and localization of the active kinase complex. p35 is normally associated with 
the plasma membrane, but can also be detected in perinuclear areas in the cytoplasm. If the p35 
myristoylation site Gly2 is mutated, the intracellular localization of p35 is dramatically altered, 
shifting towards a diffuse cytoplasmic and partially nuclear pool (Asada et al., 2008). As calpain 
cleavage removes the myristoylated p35 N-terminus, the direct outcome of calpain activity is 
generation of freely motile kinase-p25 complexes, which tend to accumulate in the nucleus 
(Figure 2). The myristoylation of the N-terminal Gly2 on p35 is adequate for membrane 
recruitment, but positively charged Lys residues further stabilize the membrane association 
(Asada et al., 2008). The N-terminal Lys cluster has dual functionality, as the cluster also 
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interacts with importins 
to facilitate nuclear 
import of the protein (Fu 
et al., 2006). Therefore, 
the classical view of p35 
activator localization has 
been challenged. Nuclear 
p35 is known to be 
important for Cdk5-
mediated neuronal cell 
cycle suppression also in 
the nucleus (Zhang et al., 
2010a), supporting the 
notion that its nuclear localization may have a true biological function.   
The second important distinction between p35 and p25 is the difference in their half-life. p35 is 
rapidly degraded by the proteasome and has a half-life of 20-30 minutes, while p25 shows a 
notable increase (2-3 times) in protein stability (Patrick et al., 1998a). It is believed that the p10 
fraction of p35 contains degradation elements that promote both proteasomal degradation and 
calpain cleavage at the membrane (Minegishi et al., 2010). The first evidence of calpain-
mediated cleavage of p35 came from evidence of neurotoxic (ischemia, amyloid β-peptide and 
hydrogen peroxide-induced) insults in mice and cultured neurons (Kusakawa et al., 2000; Lee et 
al., 2000), and the results paved the way for a whole era of intensive Cdk5 research within the 
area of neurodegenerative diseases.  
Calpains are a family of calcium-dependent cysteine proteases that are crucial executors of 
signaling processes including apoptosis, cell motility and differentiation, through the 
modification of cytoskeletal structures and signaling proteins, and the calpains are thought to 
play a role in many pathological events, such as neurotoxicity (reviewed in Goll et al. 2003; 
Sorimachi & Ono 2012; Sorimachi et al. 2010). Calpains are also important for maintenance of 
muscle physiology, and calpain mutations have been detected in muscle wasting patients 
(reviewed in Beckmann & Spencer 2008; Kramerova et al. 2007). Calpains differ in their 
functionality from the other protein degrading machineries in the cell (e.g. the ubiquitin-
proteasome system) in that they are retained inactive in cells, and are quickly activated upon 
calcium binding, without the need of additional components. Interestingly, it is thought that 
calpain substrates are recognized based on the spatial structure rather than primary consensus 
sequence. Both of the ubiquitously expressed classical calpains, µ-calpain (calpain 1) and m-
calpain (calpain 2), cleave p35 (Lee et al., 2000).   
In a complex auto-regulatory loop, Cdk5 itself regulates p35 processing through 
phosphorylation. By dual actions, the Cdk5-mediated p35 phosphorylation (Ser8 and/or 
Thr138) makes the activator more prone to ubiquitination and proteasomal degradation, while 
simultaneously decreasing its susceptibility to calpain cleavage in order to suppress p25 
generation (Kamei et al., 2007; Patrick et al., 1998b; Saito et al., 2003). In this way, Cdk5 can 
restrict its own activity to prevent unfavorable kinase activity. In addition to Cdk5 itself, two 
protein kinase C (PKC) isoforms, namely δ (Zhao et al., 2009) and ζ (de Thonel et al., 2010), are 
known to phosphorylate p35 and regulate its turnover. Whereas PKCζ phosphorylation of 
Ser33 promotes p25 generation in a myogenic context (de Thonel et al., 2010), PKCδ appears to 
phosphorylate p35 on serines 59, 65 and/or 124 (a specific site has not been determined), 
having a stabilizing effect on the activator in neurons (Zhao et al., 2009). In this fashion, PKCδ 
acts upstream of Cdk5 during the developmental radial migration of cortical neurons. Ser91 in 
turn is phosphorylated by Ca2+/calmodulin-dependent protein kinase II (CamKII) in neurons 
Figure 2 Cdk5 activity and localization is regulated by activator binding. The 
processing of p35 affects both the activation of Cdk5 as well as its localization. Both 
p35 and p25 do have physiological functions, but detrimental and disease-related p25 
generation is an important mechanism in neurodegenerative disease. NMJ: 
neuromuscular junction. 
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(Hosokawa et al., 2010) and salt-inducible kinase 2 (Sik2) in pancreatic β-cells (Sakamaki et al., 
2014), which negatively regulates p35 stability in the latter case. The phosphorylation sites are 
highlighted in Figure 3.  
The expression of p35 is under 
the control of an array of 
extracellular signals (e.g. through 
laminin-induced integrin 
activation) and growth factor 
stimulation (such as nerve growth 
factor) (Harada et al., 2001; Li et 
al., 2000). The transcription factor 
Early growth response 1 (Egr1) 
has in neuronal PC12 cells been 
shown to induce p35 mRNA 
expression in response to nerve 
growth factor or tumor necrosis 
factor α (TNFα) (Harada et al., 
2001; Utreras et al., 2009). Also, 
the transcription factor heat 
shock factor 2 directly binds to the p35 gene promoter and is essential for proper p35 
expression and Cdk5 activity in cortical neurons (Chang et al., 2006). Thus, the cell can 
accommodate its p35 levels and Cdk5 activity needs in response to environmental changes 
through a multitude of pathways, which are highly dependent on the cellular environment.  
In contrast to Cdk5-/- mice that die perinatally (Ohshima et al., 1996), the deletion of p35 in 
mice causes less dramatic phenotypes. p35-/- mice are viable and show no gross body changes, 
but they do have defects in cortical lamination due to abnormal neuronal migration, as well as 
structural changes in some other areas of the brain (Chae et al., 1997). The p35 null mice do 
show a compensatory increase in the expression of the Cdk5 activator p39 in brain (Takahashi 
et al., 2003), which is likely to alleviate certain phenotypic characteristics. Compared to WT 
mice, the p35 knockout mice showed increased adult lethality probably caused by spontaneous 
seizures (Chae et al., 1997). Other organs, such as skeletal muscle, have not been studied in 
detail. Outside the central nervous system (CNS), p35 is expressed in the developing myotome 
from embryonic day 12 (E12) (Zheng et al., 1998), among many other tissues. It should, 
however, be noted that Cdk5 activator levels (mRNA or protein) are generally relatively low in 
most other tissues compared to brain lysates (Lew et al., 1994; Tsai et al., 1994). Therefore, the 
role of p35 in other tissues was long overlooked, as it was challenging to detect its expression, 
especially at a basal level. In many tissues, a specific stimulus or stress is often required for up-
regulation of Cdk5 activators and Cdk5 activity.  
1.2.2 Cdk5 activation by p39  
Studies on the Cdk5 activator p39 (CDK5R2) have been hampered by the lack of well-
functioning antibodies, and most likely the early found strong disease association of p35/p25, as 
well as the accompanying interest in that specific research area. Sequence alignment of p39 and 
p35 reveals 57% amino acid similarity between the proteins (Tang et al., 1995). The two 
proteins are processed analogously by calpains (Patzke and Tsai, 2002b). The calpain cleaved 
fragment of p39 is correspondingly termed p29, and is like p25, not targeted to the membrane 
due to loss of its N-terminal myristoylated residue upon proteolytic cleavage (Asada et al., 
2008). The biological role and regulation of calpain-dependent cleavage of p29 is not well 
understood. Compared to p35, the half-life of p39 is significantly longer (Minegishi et al., 2010), 
Figure 3 The processing of p35 to p25. Calpains cleave p35 to create two 
fragments; p25 and p10. Due to loss of the myristoylated Gly2, p25 is 
freely motile within the cells. Known phosphorylation sites of p35 are 
marked in yellow. The Cdk5 interaction site on p35 is highlighted with a 
bracket. 
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but the contrary, the Cdk5/p39 interaction is weak compared to the Cdk5/p35 complex (Saito et 
al., 2013). Interestingly, the in vitro substrate specificity of Cdk5/p39 is also different 
(preferentially tau) from that of Cdk5/p35 (preferentially histone H1) (Takahashi et al., 2003), 
but it is not clear if p35 and p39 have separate functions in vivo. 
Whereas disruption of the p39 gene does not cause apparent phenotypes, the p35-/-/p39-/- 
double knockout mice (Ko et al., 2001) are identical to mice lacking Cdk5 (Ohshima et al., 
1996), demonstrating the need of either p35 or p39 in regulation of Cdk5 activity during 
neuronal differentiation. As restoration of one allele of p35 to the double-knockout restores 
partial neuronal functionality, while one allele of p39 does not, p35 is believed to be the major 
Cdk5 activator in neuronal models (Ko et al., 2001). Both p35 and p39 are expressed widely in 
the CNS during embryonic development, but some spatial and temporal differences can be 
detected between the two proteins, such as the prevalent p39 expression in the spinal cord 
during embryogenesis (Zheng et al., 1998) and the postnatal increase in p39 mRNA in the 
cerebral cortex (Takahashi et al., 2003). Cdk5/p39 interaction and activity has been described in 
neurons and the complex may functionally be coupled to growth cone maintenance (Humbert 
et al., 2000). Cdk5/p39 also phosphorylates the cytoskeletal protein tau during brain 
development (Takahashi et al., 2003). Phosphorylated tau shows less affinity towards 
microtubules (possibly reducing microtubule stability), and the complex may therefore be 
involved in the developmental regulation of microtubule dynamics. Cdk5/p39 also regulates 
lamellipodial actin dynamics through Rac1 (Ito et al., 2014). In addition, Cdk5/p39 is 
implicated in oligodendroglial (the myelinating cell of CNS) differentiation (Bankston et al., 
2013). In contrast to p35, p39 mRNA expression has not been reported in muscle tissue, but the 
protein has been detected with antibody recognition in rat primary myotubes (Johansson et al., 
2005). Both activators have also been described at mRNA and protein levels in pancreatic β-
cells (Lilja et al., 2001).  
1.2.3 Cdk5 and cyclin partners 
Podocytes are specialized epithelial cells that surround the vasculature of glomeruli in the 
kidney. Their characteristic highly branched appearance is reflective of their function; by 
wrapping their foot protrusions around blood vessels, the cells selectively filter blood and 
constitute a crucial part of the kidney´s homeostatic machinery. The expression of Cdk5/p35 
correlates with the differentiated state of podocytes and both proteins can be distinguished at 
the edges of the podocyte protrusions (Griffin et al., 2004). Cdk5 is thought to have two main 
functions in podocyte biology. As the inhibition or downregulation of Cdk5 causes a collapse of 
podocyte protrusions, possibly as a consequence of actin filament reorganization, its presence at 
the cell periphery may be required for maintenance of podocyte morphology (Griffin et al., 
2004). Intriguingly, active Cdk5 also acts as a pro-survival factor after podocyte injury in vivo, a 
process which is controlled not only by the classical activator p35, but also by the atypical cyclin 
I (Brinkkoetter et al., 2009). Cyclin I is the only identified cyclin partner with the ability to 
activate Cdk5 (Brinkkoetter et al., 2009; Brinkkoetter et al., 2010). Although both activators 
seem to be present in podocytes, the Cdk5/p35 and Cdk5/cyclin I complexes differ in their 
functionality. The substrate specificity of Cdk5 in vitro is shifted towards tau rather than 
histone H1 when complexed with cyclin I (Brinkkoetter et al., 2009). This may also explain the 
differences in the involved cell survival signaling pathways in p35 and cyclin I null mice, even 
though both conditions sensitize podocytes to injury in a glomerulonephritis-disease model 
(Brinkkoetter et al., 2009; Taniguchi et al., 2012). While p35 null podocytes have less anti-
apoptotic Bcl-2, cyclin I null cells show suppressed Extracellular signal-regulated kinase (ERK)-
signaling and decreased levels of anti-apoptotic Bcl-XL (Brinkkoetter et al., 2009; Brinkkoetter 
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et al., 2010; Taniguchi et al., 2012). Whether the structural and survival-related roles of Cdk5 in 
podocytes are linked, needs to be clarified.  
Another independent study regarding the post-translational regulation of cyclin I during cell 
cycle was reported by Nagano and colleagues (2013). They showed that cyclin I protein levels 
are regulated by ubiquitin-proteasome-mediated degradation during G2-M phases of the cell 
cycle, and that its presence is required for normal HeLa cell proliferation (Nagano et al., 2013). 
Curiously, the protein levels of Cdk5 in synchronized HeLa cells oscillated with cyclin I levels, 
suggesting that Cdk5 may, after all, be actively regulated during cell cycle, at least in cancer 
cells. The function and activity of Cdk5 during HeLa cell cycle, and the nature of the 
Cdk5/cyclin I complex remain elusive.  
The fact that Cdk5 activation can occur through association with a novel cyclin partner does 
evoke many questions, and may simultaneously expose exciting new prospects in the research 
field. As demonstrated by Brinkkoetter and co-authors (2009), the binding of atypical activator 
partners may shift the substrate specificity of the Cdk5 kinase. This observation defies the 
classical Cdk5 activity assay, where Cdk5 activity is measured by histone H1 phosphorylation. 
Thus, the fact that Cdk5 activity has not been detected in most tissues or cell lines (Tsai et al., 
1993) should be interpreted with caution. Furthermore, it was demonstrated that Cdk5/p35 and 
Cdk5/cyclin I complexes can co-exist in cells, and they may simultaneously regulate survival 
signaling pathways at different levels. Thus, the generality of the actions of the Cdk5/cyclin I 
complex should be revisited, as cyclin I is present in most tissues, at least at mRNA level (Jensen 
et al., 2000).  
In addition to cyclin I, also E- and D-type cyclins are known to bind to Cdk5. Nevertheless, 
Cyclin E seems to act as a suppressor of Cdk5 activity, perhaps through inhibition of Cdk5/p35-
complex formation by competition (Odajima et al., 2011). The Cdk5/cyclin E complex lacks 
kinase activity towards histone H1, Retinoblastoma protein (pRb) and synapsin 1, all of which 
are potent Cdk5 substrates. As a consequence of cyclin E knockout, Cdk5 activity was boosted, 
causing a reduction of dendritic spine and synapse number in vivo (Odajima et al., 2011). 
Cyclin D has been co-immunoprecipitated with Cdk5, but the complex has no activity 
measured by histone H1 phosphorylation (Guidato et al., 1998; Zhang et al., 1993); rather, 
cyclin D may function, similarly to the E-isoform, as a p35 competitor. 
Several research papers collectively infer that Cdk5, in fact, does regulate the cell cycle, although 
in a somewhat indirect fashion, and does therefore in many aspects behave similarly to its 
protein family members. Overexpression studies of WT and inactive Cdk5 in HeLa cells 
revealed that Cdk5 can localize to the midbody during cytokinesis (Lee et al., 2010). 
Intriguingly, Cdk5-/- mouse embryonic fibroblasts (MEFs) show increased occurrence of 
aneuploidy, possibly suggesting that the presence of Cdk5 may be important for proper cell 
cycle progression (Lee et al., 2010). p35-/-/p39-/- mice are also smaller in body size, pointing to a 
growth defect in affected mice (Ko et al., 2001). Thus, in certain contexts, Cdk5 may act to 
substitute at least some classical Cdk functions in more differentiated cell types. 
1.3 Developmental and physiological functions of Cdk5 
The actions of Cdk5 have mainly been studied in neuronal models, where a wide range of Cdk5 
substrates have been characterized. Cdk5 mRNA and protein are expressed most abundantly in 
the brain, but can in fact be detected in most tissues (including heart, skeletal muscle, kidney 
and pancreas) and in many cell lines at varying levels (Meyerson et al., 1992; Tsai et al., 1993). 
Yet Cdk5 activity, as measured by immunoprecipitation and subsequent phosphorylation of 
histone H1, is relatively limited in many tissues and cells compared to neurons (Tsai et al., 
1993). As mentioned previously, Cdk5 activity may not in all cases be directed towards histone, 
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and therefore, the lack of Cdk5 activity by histone H1 kinase assay does not exclude a function 
for the kinase. In addition, Cdk5 functions have often been revealed only after stress situations, 
whereas it may have no evident role under normal circumstances. Many surprising new 
functions for Cdk5 have been proposed in recent years. The classical functions of Cdk5 in 
neurons will not be the prime focus of this overview and are only briefly summarized in the 
following section. Instead, I will highlight some of its more atypical and less understood 
functions in mammalian physiology. 
1.3.1 Cdk5 - a major regulator of neuronal development and function 
The first evidence for a role for Cdk5 in neuronal function came from primary neuronal 
cultures, when expression of dominant negative Cdk5 (Asp145→Asn or Lys34→Thr) was found 
to robustly decrease dendrite length of cultured rat neurons (Nikolic et al., 1996). Genetic 
targeting of Cdk5 confirmed its role in neuronal development: most Cdk5-/- mice show 
embryonic lethality at E18.5, and the few mice that survive until birth die within the first 12 
hours (Ohshima et al., 1996). The principal cause for the high prenatal death rate is the severe 
cortical layering defect caused by the absence of Cdk5 signaling (Ohshima et al., 1996). Also 
Cdk5 or p35 disruption in the fruit fly causes axon patterning complications and locomotion 
problems (Connell-Crowley et al., 2000; Connell-Crowley et al., 2007; Kissler et al., 2009). To 
date, a large number of Cdk5 substrates have been identified in neurons, and together they have 
uncovered that Cdk5 indeed acts at several levels of neurogenesis (Table 1).  
 
Table 1 Summary of neuronal Cdk5 substrates.  
 Selected substrates Implications References 
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ct
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e FAK, doublecortin, 
Ndel1, Dixdc1 
Microtubule dynamics and neuronal 
migration 
(Niethammer et al., 2000; Singh et al., 
2010; Tanaka et al., 2004a; Xie et al., 
2003) 
Mst3, p27Kip1 RhoA-mediated actin reorganization and 
motility 
(Tang et al., 2014; Kawauchi, Chihama, 
Nabeshima, & Hoshino, 2006) 
Neurofilaments Intermediate filament organization (Pant et al., 1997; Sun et al., 1996) 
β-catenin N-cadherin-dependent cell adhesion (Kesavapany et al., 2001; Kwon et al., 
2000) 
Sy
na
ps
e s
ig
na
lin
g 
PSD-95, NMDAR, 
DARPP-32 
Regulation of pre- and postsynaptic 
dopaminergic and glutaminergic 
neurotransmission 
(Chergui et al., 2004; Li et al., 2001; 
Morabito et al., 2004) 
Munc-18/dynamin 1, 
amphiphysin 1 
Exocytosis/endocytosis at the synapse (Fletcher, 1999; Tan et al., 2003; 
Tomizawa et al., 2003) 
Ephexin 1, WAVE 1 Synaptic plasticity and spine formation (Fu et al., 2007; Kim et al., 2006) 
Synapsin 1 Presynaptic vesicle number and 
trafficking 
(Verstegen et al., 2014) 
D
ea
th
 an
d 
su
rv
iv
al
 
p53, ATM, pRb, MEF2 Positive regulation of apoptosis during 
neurotoxicity 
(Zhang, Krishnamurthy, & Johnson, 
2002; Tian, Yang, & Mao, 2009; 
Hamdane et al., 2005; Gong et al., 2003) 
JNK3, Bcl-2 Advancing neuronal survival (Li et al., 2002; Cheung, Gong, & Ip, 
2008) 
p27Kip1, E2F1 Neuronal cell cycle suppression and 
cytoprotection (kinase activity 
independent) 
(Zheng et al., 2010a) 
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Cdk5 is acknowledged to exert its kinase activity towards a large repertoire of cytoskeletal 
components in neurons, and thereby the kinase effectively molds neuronal architecture and 
regulates neuronal differentiation. Through phosphorylation of multiple substrates linked to 
the microtubule cytoskeleton, Cdk5 is believed to directly modulate the migratory capability of 
cortical neurons, with the consequence of the severely disrupted cortical architecture that was 
originally observed in the Cdk5 null mouse (Ohshima et al., 1996). In addition, Cdk5 has actin-
linked substrates that affect motility of neurons, but more prominently, its actin-regulating 
substrates are implicated in remodeling of neuronal processes and the maintenance of synaptic 
structures. At the synapse, the Cdk5-mediated phosphorylation of the secretory machinery and 
the neurotransmitter pathway is essential for proper neuronal communication, and in doing so, 
the kinase directly affects the processes of learning, memory formation and addiction (Table 1 
and references therein). Recently, conditional knockout of Cdk5 in the oligodendrocyte lineage 
has revealed a role for Cdk5 in oligodendrocyte maturation and axonal myelination during 
development and injury through regulation of the Akt-mammalian target of Rapamycin 
(mTOR) signaling pathway (Luo et al., 2014; Yang et al., 2013). In contrast to neurons, Cdk5-
dependent myelination seems to be driven by p39 rather than p35 (Bankston et al., 2013). 
Hyperactivation and re-localization of Cdk5 causes hyperphosphorylation of several of the 
targets described in Table 1, which has dramatic consequences on ischemia- and stroke-triggered 
brain injury, and the accompanied neuronal loss in the pathology of neurodegenerative diseases 
(e.g. Alzheimer´s disease, Parkinson´s disease, amyotrophic lateral sclerosis). In fact, most of 
these processes involve p25 generation. Ever since the Cdk5/p25 complex was connected to the 
pathological hallmarks of Alzheimer´s disease and neuronal death (Patrick et al., 1999), there 
has been an active search for mechanisms that underlie the observed pathology. Enormous 
efforts have been put into the understanding of the apparently dual roles of Cdk5 in neuronal 
apoptosis, and the kinase is today portrayed as both a major executor of neurotoxic apoptosis, 
as well as a neuroprotective kinase under specific conditions. Cdk5 activator cleavage and 
degradation that change kinase activity and intracellular localization, are under strict regulation 
within the cell, and are essential in determination of the anti- and pro-apoptotic functions of 
Cdk5 (Lee et al., 2000; Patrick et al., 1999). Not only is Cdk5 an indispensable component of the 
neuronal differentiation and death signaling machinery, but several research papers have 
highlighted a role in pain signaling, where Cdk5 activity is regulated by inflammation in 
peripheral neurons (Pareek et al., 2006). Depletion of Cdk5 activity causes a delayed nociceptive 
heat response in p35 null transgenic mice (Pareek et al., 2006). Several pain-linked Cdk5 
substrates have been identified in peripheral nerves that contribute to nociceptive signaling, 
including the protein kinesin-3 family member 13B that transports synaptic cargo (Xing et al., 
2012) and the calcium channel transient receptor potential vanilloid 1 (Pareek et al., 2007).  
1.3.2 Cdk5 in muscle development and differentiation 
Given the dramatic brain phenotype of the Cdk5 knockout mouse and the fact that the mouse is 
perinatally lethal, the function of Cdk5 in non-CNS tissues has remained in the shade. As 
follows, the information on Cdk5 molecular functions in muscle is restricted. A few key 
research articles contributed to early findings that did however place Cdk5 as an important 
player in muscle differentiation and development. Lazaro and colleagues (1997) first 
demonstrated that Cdk5 is indeed expressed and active during serum withdrawal-induced 
differentiation of murine C2C12 and rat L6 myoblasts, and that expression of a dominant 
negative (DN-Cdk5) in myoblasts inhibited differentiation. Cdk5 activity peaks at circa 48 
hours after initiation of differentiation, when myotubes are readily forming and actively fusing 
(Lazaro et al., 1997). In Philpott et al. (1997), a different approach was utilized; they took 
advantage of microinjection of DN-Cdk5 to Xenopus embryos with the consequence of 
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disruption of somite development and patterning in the animals. This effect could be rescued 
with simultaneous expression of WT plasmid. Intriguingly, DN-Cdk5 expression robustly 
abrogated the expression of the myogenic factor MRF-4, as well as MyoD (albeit the latter to a 
lesser extent), without any obvious effect on Myf-5, suggesting that Cdk5 acts also at the level of 
myoblast commitment. However, Cdk5 does not seem to phosphorylate MyoD in vitro 
(Kitzmann et al., 1999). While Cdk5 activity peaks at 48 hours of differentiation in C2C12 
myoblasts, it is possible that the kinase has multiple functions and substrates during 
differentiation, explaining the observed effect on both early commitment as well as later 
differentiation. Interestingly, superfluous Cdk5 activity established through p35 expression also 
seems to hamper proper muscle development (Philpott et al., 1997), suggesting that proper 
regulation of Cdk5 activity is crucial for myogenesis. In addition, one report demonstrates that 
Cdk5 or p25 overexpression negatively affects an activatory auto-phosphorylation site of 
CamKII in C2C12 myoblasts, an observation that may predominantly be relevant for 
neuromuscular junction signaling rather than differentiation per se (Zhu et al., 2013).  
The PKC superfamily consists of a large group of Ser/Thr kinases with functions in most 
aspects of cell biology, including proliferation, differentiation, migration as well as in the 
processes of inflammation and cancer (Hirai, 2003; Rosse et al., 2010). PKCs are further 
subcategorized according to their activation mechanism into typical and novel PKCs that are 
activated by diacylglycerol binding, and atypical PKCs (including PKC ζ), which are 
diacylglycerol-independent. The activity of the atypical PKCζ isoform, is required for myoblast 
differentiation (de Thonel et al., 2010), where it controls the process of differentiation through 
phosphorylation-mediated regulation of p35 turnover (de Thonel et al., 2010). During myoblast 
differentiation, PKCζ is required for Cdk5 activation by dual mechanisms: firstly, PKCζ directly 
phosphorylates Ser33 of p35, thereby increasing its cleavage to p25. The phosphodeficient S33A 
p35 mutant is indeed more resistant to calpain cleavage. Secondly, PKCζ phosphorylates and 
affects the activity of calpains 1 and 3. Inhibition of calpain activity, which obstructs p25 
cleavage, hampers myogenic differentiation (de Thonel et al., 2010). Therefore, PKCζ is a major 
upstream regulator of Cdk5 activity and muscle cell differentiation. 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) phosphorylates plasma membrane 
phosphatidylinositols to create the second messenger phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), to which pleckstrin homology domain containing proteins (such as Akt) can anchor to. 
Through activation of Akt and other downstream effectors, the PI3K pathway regulates a 
plethora of signaling events affecting cell proliferation, survival, motility, metabolism and 
differentiation (reviwed in Brazil & Hemmings 2001; Manning et al. 2002). In muscle, Akt 
activity is important especially for muscle fiber anabolic growth (Blaauw et al., 2009; Bodine et 
al., 2001) and glucose metabolism (Bouzakri et al., 2006; Cleasby et al., 2007), but the kinase is 
also involved in muscle differentiation (Gardner et al., 2012; Héron-Milhavet et al., 2006; 
Rotwein and Wilson, 2009). The inhibition of Akt kinase activity with the PI3K inhibitor 
LY294002 during L6 rat myoblast differentiation was, interestingly, found to disturb Cdk5 
activity (Sarker and Lee, 2004). Although a detailed mechanism for the observed phenomenon 
has not been described, the work indicates that PI3K-Akt signaling may directly or indirectly be 
involved in Cdk5 activation. Akt activity is increased rapidly upon induction of differentiation 
(within 24 hours) (Sarker and Lee, 2004; Tamir and Bengal, 2000), placing it temporally 
upstream of the reported maximal Cdk5 activation. As the PI3K pathway positively affects 
PKCζ activity in other model systems (Mendez et al., 1997; Neri et al., 1999; Standaert et al., 
1997), it is tempting to speculate that they all would lay within the same signaling network also 
in myocytes.  
Up to the present time, the only described association partners of Cdk5 in differentiating 
myoblasts are the sarcomere-associated protein Bin1 (Fernando et al., 2009) and the 
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cytoskeletal intermediate filament protein nestin (Sahlgren et al., 2003) (described further in: 
2.3.2 Interplay between Cdk5 and nestin in muscle models). Although Cdk5 can be 
immunoprecipitated with Bin1 from differentiating myoblasts, there is no further data on the 
details of the interaction. Bin1 seems to be crucial for sarcomere assembly, and the authors 
propose a possible titin-Bin1-Cdk5 interaction that nevertheless remains unconfirmed 
(Fernando et al., 2009). Titin is a sarcomeric protein, which is heavily phosphorylated during 
myoblast differentiation on Cdk consensus sites (Gautel et al., 1993), but Cdk5-dependent 
phosphorylation has never been shown. Surprisingly, there are no other published studies to 
date addressing the actual targets of Cdk5 in differentiating myoblasts that would rationalize 
the observed muscle phenotype in various models, leaving a significant area of Cdk5 research 
unrecognized.  
1.3.3 Differentiation of neuromuscular junctions requires Cdk5 activity  
Skeletal muscle is innervated by motor axons at specialized intersections, termed 
neuromuscular junctions (NMJs). NMJs are not only important for muscle contraction, but are 
essential for the active maintenance of muscle mass throughout the lifespan of the organism. 
The postsynaptic (muscle) side of the NMJ consists of a specialized cluster of signaling proteins 
that transduce signals from the synaptic cleft to the muscle. Acetylcholine receptors (AChR), 
which bind the neurotransmitter acetylcholine (ACh), are dynamically regulated by positive 
and negative signals that cluster or disperse the transmembrane proteins during NMJ 
formation. Through binding to its cognate ErbB receptors and consequent activation of ERK-
signaling, the neuronally secreted Neuregulin-1 (NRG) promotes transcription of postsynaptic 
genes, including AChR. The proteoglycan agrin is one of the central molecules that positively 
regulate AChR clustering through interactions with the muscle specific kinase (MuSK) 
receptor. MuSK-initiated signaling maintains the AChR clusters on the post-synaptic side of the 
junction. The active regulation of the NMJ during development allows a flexible spatiotemporal 
innervation pattern of muscle where it is most required.  
The expression of Cdk5 in muscle is concentrated most obviously at NMJs, and both Cdk5 and 
p35 are regulated by NRG-induced signaling (Fu et al., 2001). Cdk5 was shown to 
phosphorylate and activate ErbB2/3 receptor tyrosine kinase signaling in response to NRG 
treatment, thus positively regulating AChR transcription both in vitro and in vivo (Fu et al., 
2001; Fu et al., 2005). Genetic ablation of Cdk5 causes an increase of embryonic NMJ width and 
dispersion in both diaphragm and skeletal muscle, consequently impeding motor skills of the 
few newborn pups that survive until birth (Fu et al., 2005). In addition, Cdk5 directly 
phosphorylates the transcription factor signal transducer and activator of transcription 3 
(STAT3), and promotes its activity after NRG stimulation of C2C12 myotubes (Fu et al., 2004). 
Through these mechanisms, Cdk5 is involved in the positive regulation of NMJ development.  
On the other hand, also ACh, which acts as to disperse AChR clusters, induces Cdk5 activity 
(Lin et al., 2005). Thus, acting in an opposing manner, Cdk5 activity also increases AChR 
dispersion, unless the receptors are stabilized by specific cluster-promoting signals (Lin et al., 
2005). The exact mechanism has not been identified yet, but is unlikely to involve direct AChR 
phosphorylation by Cdk5. Thus, the Cdk5-mediated AChR clustering occurs in conjunction 
with agrin signaling; if the AChR clusters are on the other hand not stabilized by agrin, Cdk5 
acts instead negatively on the AChR clusters in an ACh-dependent manner (Figure 4).  
Moreover, Cdk5 knockout mice also show Schwann cells defects (Fu et al., 2005), and genetic 
disruption of Cdk5, or DN-Cdk5 expression in the muscle, causes increased presynaptic 
neurotransmitter release, and more frequent generation of postsynaptic potentials (Fu et al., 
2005; Zhu et al., 2013). These observations highlight that Cdk5 is required for NMJ 
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maintenance at both the pre- and postsynaptic sides of the junction. In addition, postsynaptic 
Cdk5 activity is involved in regulation of presynaptic events, perhaps through regulation of 
retrograde nitrogen oxide signaling (Zhu et al., 2013). Cdk5/p35 also phosphorylates and binds 
to the Cdk-related kinase Pctaire-1, which is localized to NMJs, but the biological relevance of 
the interaction is not comprehended (Cheng et al., 2002). Although Cdk5 kinase activity is 
required for proper NMJ development, the NMJ signaling pathway that is regulated by the 
kinase is likely to be distinct from the one involved in myogenic differentiation, which involves 
NMJ-independent myoblast determination and differentiation. 
 
1.3.4 Cdk5 actions in male and female reproductive organs 
The testes contain a variety of cell types that are involved in sperm maturation. In seminiferous 
tubules, germ cells develop into motile haploid spermatozoa in a differentiation process termed 
spermatogenesis. Within the seminiferous tubules lie also the Sertoli cells that provide a 
structural support, secret sustaining hormones and provide nursery for developing 
spermatozoa. Sertoli cells are connected to each other through tight junctions, thereby 
separating the germ cells from the blood and creating the blood-testis barrier. Thus, similarly to 
the brain, the testis is a highly protected organ. In the interstitial space, located outside of the 
seminiferous tubules, lie the principal androgen-producing cells of the body, the Leydig cells. 
The androgen production in Leydig cells is mainly controlled by a complex feedback 
mechanism, which is ultimately orchestrated by the pituitary through secretion of the 
hormones Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH).  
Figure 4 Cdk5 signaling at the postsynaptic neuromuscular junction. Cdk5 acts to both promote and suppress 
acetylcholine receptor (AChR) clustering during NMJ differentiation. Firstly, neuregulin (NRG) binds to its cognate 
receptor, which promotes Cdk5 activation at the synapse (1). Cdk5 activity potentiates activation of the pathway through 
phosphorylation of the ErbB-receptor (2) as well as the STAT3 transcription factor (3). Through these mechanisms, 
Cdk5 positively stimulates AChR transcription and NMJ development. Meanwhile, the main positive signal that 
stabilizes AChR clusters is agrin, and it is counteracted actively by acetylcholine (ACh). Interestingly, also ACh induces 
Cdk5 activity (4), which acts to disperse AChRs (5) that have not been stabilized by agrin. The signals that promote 
AChR cluster formation are depicted in green, while negative (dispersive) signals are highlighted in red.  
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Only a handful of studies have examined Cdk5 in the testicles. Cdk5 and p35 (but not p39) are 
expressed in the developing and adult testes in rodents and humans, mainly in Leydig and 
Sertoli cells (Musa et al., 2000; Rosales et al., 2004a; Session et al., 2001). Cdk5 protein is 
detected in the Sertoli (TM4) and Leydig (TM3) mouse cell lines, and shows histone-targeted, 
p35-dependent kinase activity in cells as well as in testes lysates (Musa et al., 1998; Musa et al., 
2000; Rosales et al., 2004a). Interestingly, Cdk5 activity coincides with p35 expression and peaks 
at postnatal day 40 in rats, around the time when animals reach sexual maturity (Rosales et al., 
2004a). Cdk5 activity was also found to correlate with serum, epidermal growth factor (EGF), 
LH, and human chorionic gonadotropin (hCG) stimulation of TM3 Leydig cells (but not TM4 
Sertoli cells), possibly indicating that Cdk5 may have a role in Leydig cell proliferation, 
differentiation or testosterone production, which followed the treatments (Lin et al., 2009; 
Musa et al., 1998; Musa et al., 2000). The hCG-dependent testosterone production was 
counteracted by roscovitine treatment and Cdk5 small interfering RNA (siRNA), possibly 
through the protein Steroidogenic acute regulatory protein (StAR), which is involved in 
testosterone production (Lin et al., 2009). In addition to Sertoli and Leydig cell expression, 
Cdk5 is found in spermatids where it is thought to phosphorylate sperm tail structural proteins 
called outer dense fibers, at least in vitro (Rosales et al., 2004a; Session et al., 2001).  
In the female reproductive organs, Cdk5/p35 is expressed and active in developing and adult 
ovary oocytes (Lee et al., 2004). It seems as Cdk5 does have some target proteins in the organ, as 
shown by phosphorylation of ovary lysates, but they remain yet unidentified.  
1.3.5 Cdk5 in metabolic control  
The pancreas is both an exocrine and endocrine organ that regulates the secretion of digestive 
enzymes and metabolic hormones in separate parts of the gland. The endocrine tissue is 
organized in specific structures called islets of Langerhans, which in turn are composed of a 
variety of cell types, including the insulin secreting β-cells and glucagon secreting α-cells. While 
insulin secretion lowers blood glucose, glucagon counteracts its effect in a delicately regulated 
signaling process that affects whole body metabolism.  
Cdk5, p35 and p39 proteins are expressed in β-cells, where they partly co-localize with insulin 
(Lilja et al., 2001; Lilja et al., 2004; Ubeda et al., 2004). The proteins have not been described in 
other parts of the pancreas. The role of Cdk5 in insulin secretion has been a matter of debate, as 
it has shown both inhibitory and stimulatory effects on the glucose-stimulated insulin pathway; 
the discrepancies seem to derive from the use of different model systems, differences in 
experimental setup (glucose concentrations and treatment times), and possibly Cdk5 activator 
specificity. Early studies did suggest that Cdk5 activity is required for glucose-stimulated insulin 
secretion in β-cells isolated from both lean and obese mice (Lilja et al., 2001). Also, high glucose 
stimulation caused and increase in p35 levels and Cdk5 activity (Ubeda et al., 2004; Ubeda et al., 
2006), which however, in this particular context may in fact link Cdk5 to high glucose induced 
β-cell apoptosis (glucotoxicity) rather than insulin secretion. Indeed, p25 generation, and the 
consequent hyperactivation of Cdk5, does induce caspase-3 cleavage, as has been independently 
demonstrated by Zheng and collaborators (2013). Exogenous p25 was, however, found to 
suppress insulin secretion (Zheng et al., 2013), highlighting that the experimental setup and the 
condition of the cells needs to be considered with care when interpreting data. Interestingly, 
p39 expression seems to induce general β-cells exocytosis more strongly than p35 expression 
(Lilja et al., 2004), suggesting that p35 is not the sole Cdk5 activator in β-cells. 
On the other hand, many recent publications show that Cdk5 negatively regulates insulin 
secretion both in vitro and in vivo. Cdk5 phosphorylates the L-type voltage-dependent Ca2+ 
channel (L-VDCC) in β-cells, affecting its interactions with endogenous inhibitors (Wei et al., 
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2005). If β-cell Cdk5 activity is inhibited with olomoucine, L-VDCC conductance capability is 
increased, with the consequence of boosted insulin secretion in glucose stimulated conditions 
(Wei et al., 2005). The cellular experiments were supported by experimental glucose-tolerance 
tests in the p35 knockout mouse, showing that KO mice have higher insulin levels after 
intraperitoneal glucose injection, and consequently lower blood glucose (Wei et al., 2005). Basal 
blood glucose levels were unchanged in the animals. Another study supporting the previous 
data, demonstrated that glucose-induced Sik2-kinase activation in β-cells caused 
phosphorylation-dependent degradation of p35, and an elevated insulin secretion (as did also 
Cdk5 inhibition) (Sakamaki et al., 2014). Moreover, p35 levels were reduced in islets isolated 
from high-fat diet fed mice (Sakamaki et al., 2014). Thus these in vivo-data convincingly 
support that Cdk5/p35 are important negative regulators of glucose-triggered insulin secretion, 
thereby affecting whole body metabolism. Meanwhile, Cdk5/p25 may preferably be involved in 
acute β-cell glucotoxicity. 
In the 3T3-L1 adipocyte model, insulin treatment promotes Cdk5 activity (Lalioti et al., 2009; 
Okada et al., 2008). Both Cdk5 and p35 are expressed in white adipose tissue and differentiated 
3T3-L1 adipocytes, where Cdk5 is involved in Glucose transporter type 4 (GLUT-4)-mediated 
and insulin-induced glucose uptake (Lalioti et al., 2009; Muruáis et al., 2009). Inhibition of 
Cdk5 activity with roscovitine or siRNA hampered glucose uptake (Lalioti et al., 2009; Muruáis 
et al., 2009), suggesting that Cdk5 is required for insulin-mediated glucose import. GLUT-4 is 
expressed only in insulin sensitive tissues, such as white fat and skeletal muscle. Insulin 
stimulates GLUT-4 expression at the cell membrane, allowing increased glucose uptake in the 
target cells. Some discrepancy exists in the literature describing the exact mechanism of 
adipocyte signaling, as Cdk5 siRNA is also reported to promote GLUT-4 membrane 
translocation induced by TNFα (Nohara et al., 2011; Okada et al., 2008). On the contrary, 
Muruáis and co-authors (2009) failed to detect a Cdk5-dependent difference in GLUT-4 
intracellular localization in response to insulin. 
1.4 Pathological deregulation of Cdk5 
The correct regulation of Cdk5 activity at the right time and in the right place has proven to be 
crucial for normal cell function and prevention of diseases. Stress insults and other 
environmental- or intracellular stimuli affect the expression and turnover of Cdk5 and its 
activators, with the consequence of unfavorable Cdk5 hyperactivation (or sometimes 
hypoactivation), re-localization, and altered substrate specificity. p25-associated Cdk5 activity is 
indeed detrimental in many diseases of the brain, but the function of other activators in other 
tissues and disease contexts have remained more abstract, or have not always been questioned. 
Thus, Cdk5 is currently emerging as an attractive drug target in various diseases beyond the 
brain.  
1.4.1 Neurodegenerative diseases and hyperactivation of Cdk5  
Cdk5 has been strongly linked to the pathological neurodegeneration of a number of diseases, 
including Alzheimer´s disease (AD), Parkinson´s disease, Huntington´s disease and 
amyotrophic lateral sclerosis (reviewed in Patzke and Tsai, 2002b; Su and Tsai, 2011; Shukla et 
al., 2012). These diseases are characterized by elevated neuronal death, and despite the common 
disease prevalence, the mechanisms that contribute to the pathology are not completely 
understood due to their complex nature. A key factor that causes neuronal loss in these 
disorders is the accumulation of neurotoxic aggregates, such as amyloid-β plaques and 
neurofibrillary tangles in AD, generated by the aberrant activities of multiple kinases. In 
neurodegenerative pathogenesis, Cdk5 regulates both directly and indirectly the 
phosphorylation of such proteins that are involved in aggregate formation, including amyloid 
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precursor protein (Liu et al., 2003) and the microtubule stabilizing protein tau (Cruz et al., 
2003; Noble et al., 2003; Piedrahita et al., 2010). In addition, Cdk5 is important for 
neurofilament (NF) transport in axons through a phosphorylation-dependent mechanism, 
which may in a disease context lead to NF aggregation (Ahlijanian et al., 2000; Rudrabhatla et 
al., 2010; Shea et al., 2004). Especially in AD, Cdk5 seems to act at many levels of disease 
progression through phosphorylation of several cytoskeletal targets, thereby contributing to the 
accumulation of both neurotoxic amyloid-β plaques and neurofibrillary tangles; the two 
hallmarks of AD-brain. Cdk5 does not act alone in neuronal pathogenesis, and it seems that a 
detrimental feed-forward loop of external cytotoxic insults promote Cdk5 neurotoxic activity 
even further (Lee et al., 2000).  
It is well established that the calpain-mediated generation of p25, with the consequent 
deregulation of Cdk5, is in many ways neurotoxic (Ahlijanian et al., 2000; Lee et al., 2000; 
Patrick et al., 1999). While p25 generation is considered to be a direct cause of cell death in the 
abovementioned diseases, Cdk5/p35 does not seem to be capable of induction of apoptosis in 
neurons. Thus, calpain-mediated cleavage of p35 to p25, which can be induced by neurotoxic 
stimuli, ultimately determines whether Cdk5 acts as a neuron-sustaining kinase or a neuronal 
killer. Intriguing novel data indicates that p25 can, independently of Cdk5, bind to, activate and 
alter the substrate specificity of glycogen synthase kinase 3β (GSK3β) in neurons and thereby 
contribute to a neurodegenerative phenotype characterized by hyperphosphorylated tau and 
apoptosis (Chow et al., 2014). Recently, there has been significant interest towards the p10 
fragment, which is generated from the p35 N-terminus during calpain cleavage. p10 has been 
shown to both promote (Zhang et al., 2012) and inhibit (Chew et al., 2010) Cdk5/p25-mediated 
apoptosis. The neuroprotective roles of various p35 peptide fragments have also been proposed 
to have an interesting clinical potential (Zheng et al., 2002; Zheng et al., 2010b).  
1.4.2 Cdk5 in muscle pathology 
Increased expression of Cdk5 or its activators have been associated with a few types of muscular 
diseases. Until now, there is no information whether the increased expression actually relates to 
an active role for Cdk5 in myopathic processes, or if the expression is simply reflecting a 
regenerating myogenic stage of the organ. Cdk5 has, for example, been detected in vacuolated 
myofibers in inclusion-body myositis (Nakano et al., 1999; Wilczynski et al., 2000). 
Interestingly, the disease resembles AD in that the degenerating myofibers contain AD-like 
hyperphosphorylated tau-inclusions that stain Cdk5 positive, possibly suggesting its 
involvement in the pathological progress of the disease (Wilczynski et al., 2000). In addition, 
increased p25 expression and Cdk5 activity have been reported in muscles from a mouse model 
for congenital endplate acetylcholinesterase deficiency (a type of myasthenic syndrome), which 
is characterized by loss of NMJ function (Zhu et al., 2013; Zhu et al., 2014). Denervation and 
necrotizing injury of skeletal muscle are also known to cause p35 expression and Cdk5 activity 
in the muscle, which most likely mimics a regenerative response that involves differentiation of 
muscle cells (Fu et al., 2002; Sahlgren et al., 2003). Thus, based on these few reports one cannot 
speculate further on an active role of Cdk5 in the generation of muscle pathology per se, but 
nonetheless, the kinase does seem to play some part in muscle healing and regeneration. 
1.4.3 Type 2 diabetes and obesity: the Cdk5 connection 
In type 2 diabetes (T2D) and T2D-associated obesity, Cdk5 has been found to promote the 
disease in at least two different cell types: in white adipose tissue and pancreatic β-cells. In a 
high fat diet-induced obesity mouse model, Cdk5 activity and p25 expression were shown to be 
induced in white adipose tissue after the mice were subjected to a 7-week long high fat diet 
(Choi et al., 2010). Interestingly, the Cdk5-mediated phosphorylation of peroxisome 
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proliferator-activated receptor γ (PPARγ) was required for the obesity-linked metabolic 
changes. Either Cdk5 inhibition with roscovitine or shRNA, or expression of the Cdk5 
phosphosite-deficient S273A mutant PPARγ, increased expression of the anti-adipocytic 
adiponectin and adipsin that negatively regulate fat content (Choi et al., 2010). Hence, 
interrupting the Cdk5-mediated PPARγ phosphorylation has been considered as a novel anti-
obesity strategy (Choi et al., 2011). PPARγ phosphorylation was additionally induced in 
adipocytes treated with cytokines TNFα and interleukin 6 (IL-6), suggesting that the obesity-
provoked inflammatory response may drive the pathway described above (Choi et al., 2010). 
On the contrary, adipocyte-specific knockout of Cdk5 was found to cause a compensatory 
hyperactivation of ERK activator kinase 2 (MEK2)-ERK1/2-signaling, as well as PPARγ Ser273 
phosphorylation by ERK1/2 (Banks et al., 2014). Intriguingly, due to the aforementioned 
mechanism, the high-fat diet fed adipocyte-specific Cdk5 knockout mice exhibit increased 
insulin levels and glucose intolerance (Banks et al., 2014), underscoring the two-faced actions of 
Cdk5 in the fat cell diabetic phenotype (Figure 5). Thus, the mechanisms that are controlled by 
Cdk5 in obesity are complex. Currently there is no further information on whether Cdk5 could 
contribute to maintenance of body homeostasis and glucose metabolism in other disease-
related metabolic tissues, such as skeletal muscle. 
Figure 5 The diabetogenic actions of Cdk5 in T2D-associated pathology. The signaling functions of Cdk5 in diabetes 
are controversial. Accumulated data do point towards a pro-diabetogenic generation of Cdk5/p25. In pancreatic β-cells, 
high glucose induces Cdk5 activity (1), which in turn seems to inhibit insulin release, at least in vivo (2). While 
Cdk5/p35 seems to have a cytoprotective role under certain situations, high glucose causes generation of toxic 
Cdk5/p25, which is fatal for β-cells (3). Cdk5 activity is also induced by insulin in white adipocytes, where the kinase is 
involved in glucose transport (4). The generation of Cdk5/p25 can in turn be observed after high fat diet (HFD), or 
treatment of adipocytes with inflammatory cytokines. This excessive Cdk5 activity is involved in PPARγ 
phosphorylation and progression of diabetes through the increased expression of obesity-linked genes and promotion 
of insulin resistance (5). Thus, the data collectively suggests that while Cdk5/p35 has important physiological functions 
in both pancreas and fat tissue, the disease-induced Cdk5/p25 may have a critical role in generation of a diabetogenic 
phenotype in both β-cells and adipocytes. Therefore, an analogy in Cdk5 signaling can be drawn between 
neurodegeneration and diabetes. 
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Another aspect of T2D is the loss of function and eventual death of pancreatic β-cells. The 
hyperactivation of Cdk5 in β-cells with either exogenous p35 or p25 seems to cause high 
glucose-induced apoptosis in Min6 cells (Zheng et al., 2010c; Zheng et al., 2013). On the 
contrary, Cdk5 is also described to possess cytoprotective functions in rat insulinoma INS 
832/13 cells (β-cell origin) and in isolated rat islets, where its downregulation causes increased 
apoptosis already in non-induced cells, but maximally upon islet treatment with amyloid 
polypeptide (Daval et al., 2011). In INS cells, Cdk5 or p35 downregulation caused a repression 
of the Focal adhesion kinase (FAK)-Akt survival pathway, which culminated in increased 
apoptosis. The contradicting results from Daval et al. (2011) and Zheng et al., (2010c, 2013) 
may be attributed to the use of different death-inducing stimuli and cell lines, or alternatively, 
by distinct functions of p35 and p25. Being cancer-derived, the cells may initially rely on 
different mechanisms to support proliferation and inhibit cell death. As in neuronal models, 
also the localization and proper amount of Cdk5 activity, which is regulated by the different 
activators, is critical for determination of Cdk5 kinase function; therefore both too little and too 
much activity may be unfavorable for β-cell survival signaling. Together these results illustrate 
the complexity of Cdk5 mechanisms in the pathogenesis of T2D, suggesting that it may regulate 
disease formation in several cell types simultaneously. 
1.4.4 The multifaceted roles of Cdk5 in cancer 
With the extending life-span of humans, we are confronted with an increasing amount of age-
dependent cancer cases in the clinics. Different cancer types vary significantly in the molecular 
mechanisms that drive the uncontrollable proliferation of the cancer cells, the one property that 
initially caused malignancies to be classified into one disease category. Therefore, cancers 
actually seem to constitute a range of different diseases. Regarding their molecular 
characteristics and therapy options, we are in reality dealing with a broad spectrum of diseases 
that show variation not only at patient level, but also in terms of cellular heterogeneity within 
the tumor itself. According to Hanahan and Weinberg (2011), there are several key traits that 
portray cancer cell properties: the cells evade growth suppression, maintain cell proliferation, 
avoid immune destruction, deregulate cell energy metabolism, resist cell death, enable 
replicative immortality, activate invasion and metastasis, induce angiogenesis and accumulate 
mutations that stimulate genomic instability. The current consensus is that the tumor 
microenvironment and cancer-associated cells play a key role in tumorigenesis by allowing a 
cancer-permissive environment for the cancerous cells, including an inflammatory surrounding 
that drives oncogenesis (Hanahan and Weinberg, 2011). Thus, the cancer cells are not the sole 
targets for cancer therapy, as tumors are concurrently driven by cell-cell interrelationships and 
their dynamic environment over a long time that often spans an entire human lifetime.  
Cdk5 has been connected with progression of at least melanoma (Abdullah et al., 2011), 
multiple (plasma cell) myeloma (Zhu et al., 2011), prostate cancer (Strock et al., 2006) and 
pancreatic cancer (Eggers et al., 2011), when evaluated by Cdk5 immunoreactivity in cancer 
patient samples. In addition, Cdk5 is significantly overexpressed at RNA level in breast, ovarian, 
lung, bladder and colorectal cancers, as well as in sarcomas, myelomas and lymphomas 
(Levacque et al., 2012). Cdk5 is also detected in Western blot samples from glioblastoma 
patients (Catania et al., 2001). The CDK5 promoter was found hypomethylated in mantle-cell 
lymphoma patients (Leshchenko et al., 2010), whereas CDK5 was found to be co-amplified with 
components of the epidermal growth factor receptor (EGFR)-Akt pathway in non-small cell 
lung cancer (Lockwood et al., 2008). Also polymorphisms in the CDK5 regulatory elements 
have been identified in lung cancer (Choi et al., 2009).  
There are a few fundamental features in the molecular regulation of Cdk5 activity that challenge 
the analysis of its activation status in disease versus healthy tissue. Whereas several proteins are 
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over- or under-expressed in cancerous tissue, the expression levels of Cdk5 RNA or protein 
does not give an accurate picture of its functionality. As this is often the strategy of cancer tissue 
arrays, the involvement of proteins that are under complex regulation like Cdk5, may be 
underrepresented in such datasets. Therefore, the expression of its activators at protein level 
give a better understanding of the activity status of Cdk5, but even this approach seems to be 
obscured by the limited information on how the specific activators work in extra-neuronal 
tissue and how they are processed. In addition, there are no phospho-antibodies that could be 
used as reliable markers for Cdk5 activation, as is the case with many other well-studied 
kinases. As illustrated by prostate cancer, there is mixed information on the expression levels of 
Cdk5 in patient samples (Hsu et al., 2011; Levacque et al., 2012) that may have affected its 
appreciation as a feasible cancer drug target. 
1.4.4.1 Regulation of cancer cell motility by Cdk5 
As in neurons, where Cdk5 is an essential part of the signaling network that regulates migrating 
neurons´ cytoarchitecture, also cancer cells seem to utilize similar signaling pathways to drive 
migration, invasion and metastasis. In pancreatic cancer, K-Ras-mediated cell transformation 
promotes Cdk5 activity and migration through upregulation of p35, p39 and their cleavage 
products (Eggers et al., 2011; Feldmann et al., 2010). Most pancreatic tumors (67%) seem to 
have upregulated expression of Cdk5, p35 or p39, highlighting that the pathway is 
hyperactivated in patients (Eggers et al., 2011). Cdk5 is also important for invadopodia 
formation in head and neck squamous cell carcinomas (Quintavalle et al., 2011). In 
glioblastoma, Cdk5 is essential for cell migration and invasion through the stimulatory 
phosphorylation of Isoform A of phosphatidylinositol 3-kinase enhancer (PIKE-A), which acts 
upstream of the Akt-signaling pathway (Liu et al., 2008). Cdk5/p35 is also important for lung 
cancer cell migration (Demelash et al., 2012).  
In breast cancer patients, Cdk5 and p35 levels are found to be upregulated and to correlate with 
higher tumor grade (Levacque et al., 2012; Liang et al., 2013). In fact, the proteins were also 
upregulated in transforming growth factor β-induced epithelial-mesenchymal transition of 
MCF10A cells, and Cdk5 was found to play an important role in the differentiation process 
through phosphorylation of FAK (Liang et al., 2013). Interestingly, Cdk5 has also been 
suggested to phosphorylate a microtubule-associated pool of FAK in melanoma cells that 
contributes to microtubule stability and mitosis (Rea et al., 2013), whereas phosphorylation of 
the same site in neurons affects microtubule-dependent migration (Xie et al., 2003). FAK seems 
to lie downstream of Cdk5 also in pancreatic cancer (Eggers et al., 2011). 
1.4.4.2 Cdk5 in cancer cell proliferation and survival  
Although Cdk5 activity is primarily linked to physiological differentiation processes, many 
cancer studies are supporting a novel role for Cdk5 in regulation of the cell cycle of malignant 
cells. For instance, Cdk5/p25 is crucial for medullary thyroid carcinoma formation in vivo, 
possibly through the phosphorylation of the tumor suppressor pRb, which promotes 
transcription of cell cycle regulators to promote proliferation (Pozo et al., 2013). Cdk5 has also 
been suggested to act through STAT3 in medullary thyroid carcinoma proliferation in cellular 
experiments (Lin et al., 2007). In SAOS-2 osteosarcoma cells, Cdk5 activity has on the contrary 
been implicated in an induced senescence cell model, where the phosphorylation of the actin-
linked protein ezrin promotes the typical flattened senescent phenotype, and thus regulates 
actin polymerization through Rac-inhibition (Alexander et al., 2004; Yang and Hinds, 2006). A 
role for Cdk5 in senescence has not been established in other cell lines.  
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There is also accumulating evidence that Cdk5 functions as a pro-survival kinase in cancer cells. 
In leukemic Jurkat T-cells, Cdk5 was shown to phosphorylate Noxa on Ser13 upon glucose 
stimulation (Lowman et al., 2010). Noxa is a pro-apoptotic member of the Bcl-2 protein family, 
which is activated by p53 in response to DNA damage (Oda et al., 2000). Ser13 phosphorylation 
suppressed the apoptosis-inducing functions of Noxa and promoted cell survival (Lowman et 
al., 2010). The authors proposed an interesting hypothesis, where Cdk5 acts as a glucose-
sensing master switch in lymphocyte cell survival. Cdk5 is also involved in T-cell activation and 
the following actin polarization in encephalomyelitis (Pareek et al., 2010). 
Most studies support the fact that Cdk5 would sustain cancer progression by different 
mechanisms and there is less evidence on the roles of Cdk5 as a pro-apoptotic and anti-
proliferative kinase in cancer. In HeLa cells, Cdk5 inhibition was suggested to promote cell 
survival, but direct evidence was lacking in both cases (Ajay et al., 2010; Kuo et al., 2009). In 
astrocytoma cells, Cdk5 overexpression promoted apoptosis of heat shocked cells, whereas 
expression of dominant negative Cdk5 did not (Gao et al., 2001). In the end, most studies 
support that Cdk5 promotes carcinogenesis through various pathways, many of them linked to 
cytoskeletal elements. 
1.4.4.3 Prostate cancer: major signaling pathways and therapeutic challenges  
Prostate cancer initially originates from the frequent age-dependent benign prostatic 
hyperplasia, which may eventually transform into prostatic intraepithelial neoplasia and further 
into full blown carcinoma (Figure 6). Thus, prostate cancer is most frequently diagnosed in men 
beyond 70 years. Main risk factors that contribute to disease development are age, race and 
familial susceptibility, but also dietary factors may facilitate disease progression. In Finland, 
prostate carcinoma is today the most common cancer type in the whole population with 4600 
new cases registered in 2012 (Finnish cancer registry), which is nearly 30% of all male cancers. 
Of all cancer deaths in male patients, prostate cancer stands for almost 14% (or 855 in total). 
Prostate cancer has a high 5-year survival rate of 97%, but once it develops into castration-
Figure 6 The development of prostate cancer. The pre-carcinogenic prostate hypertrophy and prostate intraepithelial 
neoplasia can, upon accumulation of mutations, develop into localized adenocarcinoma. Eventually the otherwise 
androgen dependent cells become androgen independent through mutations in the androgen pathway. At this stage 
the disease is termed castration resistant prostate carcinoma (CRPC), which cannot be treated. Prostate cancers are 
typically diagnosed at a stage when they are relatively harmless (localized prostate carcinoma), and can then be treated 
with prostatectomy. Eventually relapse may occur, to which the only treatment is androgen deprivation therapy 
(ADT). Unfortunately, ADT drives the development of CRPC, which is non-responsive to any treatment. Therefore, 
current therapy forms only stall disease progression and they eventually cease in effectiveness. 
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resistant prostate cancer, current therapies can only limitedly stall disease progression. Hence, 
there is a need to develop new therapies against the frequent and less aggressive androgen 
responsive carcinoma, to prevent its progression into castration resistant cancer. More 
importantly, there is an acute demand for novel drugs targeting the androgen independent 
state.   
There are a few central signaling pathways that sustain prostate cancer proliferation (Figure 7). 
The androgen receptor (AR) is activated by cognate ligand binding (such as testosterone), and 
regulates prostate development, as well as secondary male gender characteristics. AR is 
amplified in 80% of prostate cancers and is thought to be the key regulator of prostate 
oncogenesis. As the AR is frequently amplified in prostate cancer, it is considered to be the 
main target for castration resistant tumor evolution, as it regulates a variety of  pro-proliferative 
genes, anti-apoptotic players and promotes pathways required for invasion (reviewed in Green 
et al., 2012; Waltering et al., 2012). In addition, growth-promoting and apoptosis-inhibiting 
signaling cascades that are commonly found in a spectrum of cancers, are also deregulated in 
prostate cancer, including the PI3K-Akt and Ras-MAPK pathways, p53, c-Myc, pRb, etc. 
(Abate-Shen, 2000; Barbieri et al., 2013; Feldman and Feldman, 2001; Majumder and Sellers, 
2005). For example, deregulation of the PI3K-Akt pathway occurs in 42% of primary prostate 
cancers, while mutations are found in 100% of metastatic cases, emphasizing the key role of this 
pathway in prostate cancer progression (Taylor et al., 2010). Further complexity of cancer 
signaling is achieved by cross-talk between pathways, as exemplified by partial functional 
compensation between AR and Akt (Carver et al., 2011; Thomas et al., 2013; Zhu and 
Kyprianou, 2008). In the case of inactivation of either pathway, feedback mechanisms can 
promote the activity of the other (Carver et al., 2011), while inhibition of both was shown to 
synergistically prevent tumor growth (Zhang et al., 2009). The Akt-AR interaction is, however, 
complex and not fully understood. The heterogeneity of prostate cancer mutations and the poor 
knowledge of patient stratification have hampered both the understanding of disease 
progression as well as prostate cancer drug development. 
Figure 7 Central signaling pathways frequently deregulated in prostate cancer. One of the hallmarks of prostate cancer 
is the deregulated androgen signaling. AR is often amplified or mutated to allow ligand-independent activation or 
promiscuous activation by other hormones, or in other cases, AR co-factors are deregulated. Tumors can also sustain their 
own (intra-tumoral) hormone synthesis as an adaptation mechanism. Although AR drives many targets involved in cell 
proliferation, anti-apoptosis and migration, essential for prostate growth, also more general tumorigenic pathways 
(receptor tyrosine kinases, PI3K-Akt signaling, Wnt signaling) have been associated with prostate carcinogenesis. 
Commonly mutated tumor suppressors in prostate cancer are highlighted in red, whereas oncogenic proteins are in green.    
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 1.4.4.4 Cdk5 signaling in prostate cancer  
Implied by studies in other cancer models, Cdk5 has also been reported to regulate prostate 
cancer cell behavior. Inhibition of Cdk5 with either chemical inhibitors (roscovitine) or 
expression of dominant negative kinase strongly inhibits the migration and invasion of prostate 
cancer cells (Strock et al., 2006; Wissing et al., 2014). Decreased numbers of lung metastases in a 
xenograft mouse model agreed with cell-based results (Strock et al., 2006). Cdk5 also seemed to 
be important for tubulin polarization at wound edges in a cellular wound healing assay, 
suggesting that depletion of Cdk5 disturbs microtubule architecture (Strock et al., 2006). In a 
later study, Cdk5 targets were assessed in more detail, and Cdk5 was found to promote talin 
Ser425 phosphorylation in a metastatic subclone of PC-3 prostate cancer cells (Jin et al., 2014). 
Phosphorylated talin promoted β1-integrin activation and invasion both in vitro and in vivo, 
and reduced cancer cell susceptibility to anoikis (Jin et al., 2014). In SH-SY5Y neuroblastoma 
cells, the Cdk5-dependent talin Ser425 phosphorylation decreased proteasomal talin-
degradation, increased optimal focal adhesion assembly and promoted cell migration (Huang et 
al., 2009a). Therefore, phosphorylation of talin by Cdk5 may be relevant in multiple diseases.  
As previously discussed, one of the major pathways that contribute to prostate cancer 
proliferation is the AR-signaling axis. Experiments in LNCaP prostate cancer cells showed that 
Cdk5 promoted AR stabilization and Ser81 phosphorylation of the receptor (Hsu et al., 2011). 
Cdk5 also phosphorylates other members of the steroid hormone family, such as glucocorticoid 
receptor (Kino et al., 2007) and mineralocorticoid receptor (Kino et al., 2010), both of them 
resembling AR in terms of structure and activation mechanisms. The Cdk5-AR pathway is 
proposed to contribute to cell proliferation and prostate cancer xenograft growth (Hsu et al., 
2011). Paradoxically, there is at least one publication reporting that Cdk5 does not 
phosphorylate AR Ser81 (Gordon et al., 2010). Both abovementioned reports are based on the 
use of phospho-specific antibodies. Instead, Cdk1 (Chen et al., 2006) and Cdk9 (Chen et al., 
2012b; Gordon et al., 2010) are shown to phosphorylate AR Ser81, causing strong AR activation 
and chromatin binding. Given that Cdk5 can promote Cdk1 activity in neurons through 
phosphorylation of cell division cycle 25 phosphatases (Chang et al., 2012), the possibility for 
crosstalk between the Cdks should be considered when interpreting results, and special caution 
should be employed with use of pan-Cdk inhibitors. In addition, Cdk5 seems to promote 
STAT3 phospho-Ser727 immunoreactivity and target gene transcription in prostate cancer cells 
(e.g. junB, c-Myc), which could support a Cdk5-STAT3 signaling pathway in prostate cancer 
cell proliferation (Hsu et al., 2013). STAT3 Ser727 phosphorylation does additionally seem to 
correlate with prostate cancer grade (Qin et al., 2008).  
Studies conducted in DU145 prostate cancer cells have on the other hand demonstrated that the 
cytotoxic activities of digoxin and retinoic acid induce calpain-mediated p25 cleavage, Cdk5 
activation and apoptosis (Chen et al., 2012a; Lin et al., 2004). Downregulation or inhibition of 
Cdk5 decreases apoptotic marker expression, proposing that Cdk5 may relate to cell death 
signaling as well, but conceptually the results conflict with data described above, which portray 
Cdk5 as a tumor promoting kinase (Hsu et al., 2011; Hsu et al., 2013; Jin et al., 2014; Strock et 
al., 2006). The controversial results from prostate cancer model systems have left the Cdk5-
regulated mechanisms debatable.  
In many contexts, the complex regulation of signaling processes by Cdk5 has generated a large 
number of research papers, many of which are contradictory and require further investigation. 
The common use of high concentrations of roscovitine, especially in the cancer field, has 
hampered the credibility of many Cdk5-research papers, and they should be interpreted and re-
cited with caution. Nevertheless, the view of Cdk5 functions is expanding. The intention of this 
review was to highlight its complex functions that have emerged in recent years, not only in 
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pathology, but also during tissue homeostasis. Exciting discoveries of novel Cdk5 activators 
have added to the knowledge of its complex regulatory mechanisms. Although Cdk5 and p35 
were originally described to be found at highest levels in neurons, it has become apparent that 
even modest amounts of Cdk5 may be adequate for powerful and specific regulation of its target 
proteins. The work on Cdk5 activation mechanisms needs to be expanded in the future. 
Interestingly, in many cases Cdk5 and the mitotic Cdks appear to have similar substrates, 
although their functions rarely overlap temporally. Thus, Cdk5 could be considered to have 
evolved as a differentiation-linked Cdk also at a functional level. In many disease conditions, 
the Cdk5 hyperactivity gained by proliferating (cancer) cells or differentiated cell types drives 
inappropriate functions that were not intended for during tissue homeostasis.  
2 The intermediate filament protein nestin in cell signaling 
The cytoskeleton forms a core inside cells and is essential for cell motility, cell division and 
morphology. The mammalian cytoskeleton is divided into three structurally unrelated, and 
functionally different, classes; actin filaments (microfilaments), microtubules and intermediate 
filaments (IFs). In contrast to the early perception that the IF cytoskeleton only maintains 
cellular integrity and structure by acting as an immobile intracellular frame, it is today 
acknowledged to receive signals from outside cues, affect cellular signaling pathways and 
transmit or modify signals according to the cell´s needs. While protein kinases actively re-mold 
the cytoskeleton through the phosphorylation of cytoskeletal components and various 
regulatory proteins, the kinases are themselves subjected to regulation by their scaffolds in a 
continuous feedback loop.  
2.1 Intermediate filament essentials: structure and dynamics  
Compared to the generic actin and microtubules, which are found in all (eukaryotic) cell types, 
IFs show a cell type-specific expression pattern. The more than 70 members of IFs have evolved 
to perform highly specialized functions within their particular operative niche, and they are 
often conveniently used as markers for distinct cell types. Most metazoan cells have two 
separate IF networks; one in the cytoplasm, which is mainly accumulated around the nucleus, 
and the nuclear lamina, made up of the type V IF proteins lamins. Cytoplasmic IFs are 
important in organizing intracellular compartments and are vital components of desmosomes 
and other adhesive structures. The IF proteins (IFPs) are classified into subtypes (I-VI) 
according to sequence homology (Table 2). Although IFs vary in in terms of expression pattern, 
and share as little as 20% sequence homology among themselves, there is striking functional 
similarity between the different IF classes. Whereas actin and microtubule polymerization is a 
highly regulated energy-requiring process, IFs assemble spontaneously without the need of 
external energy. This feature stems from the secondary structure of the IF proteins (IFPs) and 
their apolar character. All IFs have a roughly similar central α-helical rod domain containing a 
repetitive pattern of hydrophobic amino acids that together with ionic interactions allow the 
formation of stable coiled-coil dimers of two IF monomers. The rod is subdivided into four 
domains that are separated by three non-α-helical linker regions, termed L1, L1-2 and L2. Many 
IFPs (such as nestin) cannot form homodimers in the initial head-to-head dimerization stage, 
but require the presence of another IFP type (such as vimentin and desmin in the case of 
nestin). Also keratins assemble through pair-formation between two different classes, while 
vimentin and desmin readily form homodimers. Two homo/heterodimers associate head-to-tail 
to form tetramers, which assemble into 16-dimer unit-length filaments and further into 
filaments, where the last step involves condensation of the structure to the final functional 10 
nm thick filament. Although the rod domain contains the structural elements required for IF 
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polymerization, also the N-terminus is thought to play an important role in the actual filament 
formation by stabilizing the dimer structure. The most variable domains of IFs are in fact the 
N- and C-termini (heads and tails, respectively) that characterize the individual proteins. 
(Fuchs and Weber, 1994; Strelkov et al., 2003; Godsel et al., 2008; Herrmann et al., 2009.) 
 
Table 2 Classification of Intermediate filament proteins and their associated diseases. 
Class IFPs Expression Associated diseases 
Type I & II Keratins Epithelia, hair EBS, hyperkeratosis 
Type III 
Desmin Skeletal and cardiac muscle Myopathy, cardiomyopathy 
GFAP Astrocytes Alexander disease 
Vimentin Mesenchymal cells Cataract 
Peripherin PNS neurons ALS 
Type IV 
Nestin CNS progenitor cells, muscle  
Neurofilament H, L and M Neurons ALS, PD, CMT  
Synemin α and β Skeletal muscle  
α-internexin Neurons  
Type V 
Lamin A/C Most differentiated cells Progeria, myopathy, cardiomyopathy 
Lamin B1 and B2 All eukaryotic cells Lipodystrophy 
Type VI Phakinin Lens Cataract 
 Filensin Lens  
Abbreviations: EBS: Epidermolysis bullosa simplex, CMT: Charcot-Marie-Tooth disease, ALS: Amyotrophic lateral 
sclerosis, PD: Parkinson´s disease, GFAP: Glial fibrillary acidic protein. Source: Human Intermediate filament database, 
www.interfil.org (accessed 4.11.2014). 
 
The importance of the IF cytoskeleton is underscored by the nearly 100 human diseases 
associated with IF mutations, some of which are summarized in Table 2. For example, several 
myopathic conditions of skeletal muscle and heart have been associated with desmin and lamin 
A/C mutations (Lu et al., 2011; Paulin and Li, 2004; Paulin et al., 2004). The lamin myopathy 
mutations can severely disrupt the stress-tolerance of myoblasts at the level of cellular signaling 
(Muchir et al., 2009; Muchir et al., 2013). Lamin A/C mutations are also implicated in the force 
endurance of cells, suggesting that the nuclear IFs may regulate the physical stress-tolerance of 
cells in myopathic conditions (Zwerger et al., 2013). Desmin on the other hand, is an important 
structural component of muscle found at Z-disks, NMJs, myotendinous junctions, as well as 
heart intercalated disks, and desmin null-mutation causes severe heart and skeletal muscle 
phenotypes, including cardiomyopathy and skeletal muscle weakness due to loss of muscle 
architecture and mitochondrial abnormalities (Li et al., 1997; Milner et al., 1996). Taking into 
consideration its role as a structural protein of mouse muscle, it is perhaps not surprising to 
find the many human myopathy mutations in the gene encoding desmin. 
2.1.1 The IF protein nestin 
Nestin is categorized as a class IV IFP due to similarities in intron positioning with the genes 
encoding neurofilaments (Dahlstrand et al., 1992a) and was first identified with the Rat-401 
antibody in developing CNS (Hockfield and McKay, 1985). The rat nestin protein is 1805, 
mouse 1864 and human only 1621 amino acids long, and the C-terminus is the prime domain 
for inter-species variability (Yang et al., 2001). The human nestin protein is slightly shorter than 
in rodents, due to the loss of 11-amino acid repeats in the nestin C-terminus (41 vs. 18 copies in 
humans) (Dahlstrand et al., 1992a). Although the repeat copy number varies, the repeats 
themselves are highly conserved. The nestin N-terminus is curiously only 8 amino acids, while 
the tail is unusually long compared to other IFPs (1307 amino acids in humans). For 
comparison, the typical vimentin head/tail domains are 103/54 amino acids in length, 
respectively. Thus, the exceptional nestin tail, protruding from the filament structure, is 
accessible to PTMs and protein interactions. Nestin is conserved in mammals, but is found in 
both zebrafish (Chen et al., 2010) and birds (where it is termed transitin) (Jalouli et al., 2010; 
Wakamatsu et al., 2007), and both animals have been used as model systems to study nestin 
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functions in neuronal and muscle development. Opposed to transitin, zebrafish nestin is not 
expressed in developing muscles (Mahler and Driever, 2007). The closest human IF homologs 
to nestin is synemin, which has a similar short head/long tail protein structure (Guérette et al., 
2007; Titeux et al., 2001). Synemin is enriched in skeletal muscle tissue where it polymerizes 
with desmin and vimentin (Titeux et al., 2001). Recently it was shown that synemin null mice 
show muscle hypertrophy and muscle membrane defects (Zhenlin et al., 2014). Also paranemin 
has been described as a high-molecular weight IF protein that resembles nestin by its rod-
domain and long tail as well as its synemin-like expression pattern (Hemken et al., 1997), but it 
may actually be a splice variant of transitin. 
Many IFPs, such as synemin (Xue et al., 2004) and GFAP (Middeldorp and Hol, 2011) have 
isoforms that are not only expressed in a tissue and developmental-stage specific manner, but 
also seem to have unique functions within the cells. Two nestin isoforms have been described so 
far: Nes-S and Nes-SΔ107-254, which are exclusively expressed in the otherwise nestin-negative 
dorsal ganglia (Su et al., 2013a; Wong et al., 2013). Nes-S incorporates into filaments in rat 
postnatal dorsal root ganglia sensory and motor neurons from postnatal day 5 (P5) onwards, 
and is not expressed elsewhere (including e.g. kidney and muscle tissue). Nes-S is alternatively 
spliced from the nestin gene so that exon 4, encoding part of the C-terminus, is lacking, giving 
rise to a protein of 49,5 kDa, with a 94 amino acid long tail containing a Nes-S-specific 32 
amino acid tail domain (Su et al., 2013a). Nes-S-vimentin filament structures form in SW13 
cells, while in dorsal root ganglia, Nes-S seems to form a filamentous network with the IFs 
peripherin and neurofilament-H (Su et al., 2013a). It is intriguing to speculate that Nes-S might 
have evolved in this particular cell type to perform nestin-like functions. Nes-SΔ107-254 on the 
other hand is missing most of its rod domain and cannot form filaments (Wong et al., 2013). 
Although present in dorsal root ganglia at low levels, it may lack a physiological function. An 
N-terminally GFP-tagged Nes-SΔ107-254 by Wong and colleagues (2013) did form cytotoxic 
aggregates when overexpressed, but this does not truly reflect a pathological function either. 
Due to its short N-terminus, nestin needs another IFP partner to form filaments. Vimentin is 
thought to be the major polymerization partner of nestin in most cell types (Eliasson et al., 
1999). In muscle cells, nestin co-polymerizes mainly with desmin (Sjöberg et al., 1994b), but 
interestingly, nestin distribution seems to be unaltered at NMJs and myotendinous junctions in 
desmin-/- muscle, suggesting that there are possibly other IFs compensating for desmin filament 
ablation in vivo (Carlsson et al., 1999). It should be noted that the desmin-/- NMJs are, however, 
more diffuse in their organization compared to wildtypes (Agbulut et al., 2001). Nestin can also 
form filaments in vitro with the neuronal IFP α-internexin (Steinert et al., 1999).  
Although vimentin complements the structure that nestin is lacking in filament formation, also 
nestin seems to have a regulatory role in the heteropolymers. In vitro filament formation occurs 
optimally at a nestin:vimentin ratio of 1:4 (Steinert et al., 1999), and disruption of the ratio with 
high nestin concentrations has a negative effect on vimentin assembly. The same is true when 
nestin is overexpressed in mitotic cells: while overexpression of nestin shifts vimentin to a more 
soluble pool, nestin downregulation may promote vimentin filament formation around the 
mitotic spindle (Chou et al., 2003). However, nestin expression did not cause vimentin 
solubilization during cell division when the mitotic vimentin N-terminal phosphorylation site 
Ser56, required for vimentin filament reorganization, was mutated to alanine (Chou et al., 
2003). Not only is vimentin required for nestin filament formation, but it seems like the nestin-
vimentin interaction plays a role in regulation of vimentin organization through altered 
dimerization properties in vitro, as well as changed cellular signaling functions of vimentin. 
Thus, depending on the cellular context, nestin incorporation into major IF networks may 
drastically change the nature of the IF cytoskeleton in terms of functionality. Also nestin is 
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phosphorylated during mitosis on Thr316 by Cdk1, which alters its organization during cell 
division (Sahlgren et al., 2001). 
2.1.1.1 Factors that control nestin expression 
The nestin promoter is located in the 5´-untranslated region and its expression is mainly driven 
by the zinc-finger Sp1 and Sp3 transcription factors in most tissues (Cheng et al., 2004). Nestin 
expression is not regulated by upstream elements, but instead by enhancers in two of its three 
introns in a tissue-specific fashion. Nestin expression in the somites and myotome is regulated 
by the first intron, while the second intron regulates CNS-specific nestin expression 
(Kawaguchi et al., 2001; Zimmerman et al., 1994). The CNS-directed enhancer in the second 
intron of nestin is under the control of SOX- and Pit-1/Oct/Unc-86-family of transcription 
factors and contains hormone response elements that may add to the tissue specific fine-tuning 
of nestin expression (Josephson et al., 1998; Tanaka et al., 2004b). 
Although the genetic regulation of nestin is crucial for its timely expression in specific tissues, 
nestin is, like most IFPs, strictly regulated at the post-translational level. The phosphorylation 
and ubiquitination of nestin (Sahlgren et al., 2001; Sahlgren et al., 2003; Sahlgren et al., 2006) 
allows its rapid reorganization in response to extracellular and intracellular stimuli. For 
example, nestin expression is under the control of stem cell-associated Notch during neuronal 
differentiation in glioma cells (Mellodew et al., 2004; Shih and Holland, 2006). In response to 
induction of differentiation, nestin is rapidly degraded by the ubiquitin-proteasome pathway 
(Mellodew et al., 2004). Notch signaling is by no means the only factor to regulate its 
expression, but also a variety of growth factors that inhibit or promote differentiation processes, 
regulate nestin. For example, nestin protein expression is under the control of the growth 
factors thrombin, EGF and platelet-derived growth factor and FGF-2 (Chang et al., 2013; 
Huang et al., 2008; Huang et al., 2009b). Also noteworthy is the strict regulation of nestin 
protein expression during muscle differentiation (Sahlgren et al., 2003; Vaittinen et al., 2001), 
which is immediately initiated upon growth factor withdrawal in cell culture systems. It is likely 
that both genetic and PTM-mediated stabilization occur simultaneously to regulate nestin 
protein levels in most systems. Depending on the context, the regulation of nestin may be 
direct, or alternatively, a response to initiation of a differentiation or de-differentiation 
program. It is not well understood what role nestin plays in the active maintenance of a 
progenitor-like state. Experiments in liver cancer tumorigenesis have revealed that nestin 
expression is regulated by p53-Sp1 signaling as an essential part of tumor initiation 
(Tschaharganeh et al., 2014), suggesting that nestin expression may in fact drive an oncogenic 
de-differentiation program in this particular setup, and proposing that nestin may be more than 
a mere marker of immature cells.  
2.1.1.2 Dynamic expression of nestin during development and tissue pathology 
Nestin is best known for its protein expression in neuroepithelial progenitor cells in the CNS 
and peripheral nervous system from early development (E7 neural ectoderm detected with GFP 
reporter; Kawaguchi et al., 2001), in a cell lineage that contributes to both neurons and glial 
cells (astrocytes, oligodendroglia). Nestin expression is not correlated with stem cell-like 
indefinite self-renewal and proliferation, but rather with a restricted proliferative capacity 
typical of progenitor cells (Wiese et al., 2004), which is why it is regularly used as a marker for 
those. In the embryonic muscle-forming somites, nestin LacZ-reporter activity (directed by 
intron 1) is apparent in E9 somite myotomes (Zimmerman et al., 1994), and nestin protein is 
detected from E9.5 (Kachinsky et al., 1994; Sejersen and Lendahl, 1993). Although nestin 
expression in the somites is directed by elements in the first intron, nestin intron 2-driven GFP 
reporter expression (Mignone et al., 2004) is detected in a few different progenitor cell types in 
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adult muscle (Birbrair et al., 2011; Birbrair et al., 2013b; Day et al., 2007). Using this (intron 2-
directed) GFP mouse model, it was shown that the quiescence of muscle satellite cells goes 
strictly hand-in-hand with neuronal nestin-GFP reporter activity (Day et al., 2007). Nestin-GFP 
reporter expression in skeletal muscle also characterizes pericytes with myogenic precursor 
capacity, which contribute to muscle repair (Birbrair et al., 2013b), as well as neuronal lineage-
committed precursors that resemble oligodendrocyte precursor cells (NG2-glia, which also 
express nestin protein) (Birbrair et al., 2011; Birbrair et al., 2013a). Nestin-protein is also 
expressed in the highly proliferative myoblasts (neuronal nestin-GFP negative; Day et al., 2007), 
which are expanding from satellite cells, as well as in differentiating myotubes (Kachinsky et al., 
1994). In addition, nestin protein expression is induced when the adipogenic 3T3-L1 cell line is 
forced to differentiate into a myogenic lineage through exogenous expression of muscle 
transcription factors myogenin or MyoD (Kachinsky et al., 1994). Together these facts suggest 
that nestin expression is indeed highly linked to the muscle lineage. In the heart, nestin protein 
is transiently expressed in myocytes during E9-10.5 (Kachinsky et al., 1995).  
Besides these major organ systems, nestin protein is expressed in some specific cell types during 
development and maturation, but has also been repeatedly reported in adult tissue resident 
progenitor cells (mostly mesenchymal stem cells; MSCs) that assist in tissue repair and renewal 
(Table 3, and references therein). It should be noted that the expression of nestin at protein level 
has not been carefully addressed in most research papers focusing on GFP reporter activity. The 
cases in Table 3 include examples where nestin protein has specifically been detected, unless 
indicated otherwise. Nestin protein is also expressed in certain myofibroblast populations, such 
as in breast myoepithelial cells, in the propria mucosa of colon and intestine, as well as in the 
endometrium (Kishaba et al., 2010). A more detailed description of nestin expression pattern is 
summarized in Table 3.  
With the induction of tissue stress and injury, nestin protein has been found to be re-expressed 
at protein level at least in regenerating muscle after injury and in myodegeneration (Sjöberg et 
al., 1994a; Vaittinen et al., 1999), astrogliosis after CNS injury (Frisén et al., 1995), regenerating 
testes (during Leydig cell differentiation from vascular smooth muscle cells and pericytes) 
(Davidoff et al., 2004), healing kidney after nephritis (in mesangial cells and podocytes) (Daniel 
et al., 2008; Perry et al., 2007), as well as myocardium after infarction (Scobioala et al., 2008). 
Nestin is also upregulated in neoangiogenic blood vessels in re-molding tissue during 
development, injury and cancer (Mokrý et al., 2004). In addition to its expression in tumor 
vessels, nestin is found in many tumor cells, some of which are presented in Table 3. It is not clear 
whether nestin can be used as a cancer stem cell marker, although its expression in healthy 
tissue is associated with progenitor cell-like features. The expression of nestin in tumors has 
recently evoked plenty of interest due to its potential use as a clinical marker in certain cancers 
and as a possible therapeutic target. Nestin expression has been found to correlate with poor 
prognosis in at least melanoma and breast cancer (Ishiwata et al., 2011a), but the underlying 
function is incompletely understood.  
2.2 Post-translational regulation of intermediate filament assembly 
The prominent PTMs of IFs have in recent years been of utmost interest in the field, as virtually 
every member of the family is subjected to PTM. While PTM-forms such as ubiquitination is 
fundamental in regulation of IF protein levels, the PTMs additionally fine-tune the 
polymerization process of IF filaments, usually by increasing their solubility. The assembly of 
IFs is by no means a static process, but the turnover of filaments occurs constantly, although the 
proteins themselves might be stable proteins.  
 
36 
 
Review of the Literature 
Table 3 Expression of nestin in various tissues. 
Organ system Specification Physiological context Pathological implications References 
Skeletal muscle Satellite cells Satellite cells (GFP 
reporter), myoblasts 
 (Day et al., 2007; Kachinsky 
et al., 1994) 
 NMJ and MTJ Constitutive expression Denervation-regulated (Carlsson et al., 1999; 
Vaittinen et al., 1999) 
 Myotubes Developing muscle Regenerating myofibers (Sejersen and Lendahl, 1993; 
Sjöberg et al., 1994a) 
 Pericytes Myogenic progenitors 
(GFP reporter) 
 (Birbrair et al., 2013b) 
Cardiovascular Cardiomyocyte Developmental 
expression 
Infarcted myocardium (Kachinsky et al., 1995; 
Scobioala et al., 2008) 
 Neovasculature Smooth muscle and 
endothelial cells 
Tumor angiogenesis (Mokrý et al., 2004; Oikawa 
et al., 2010) 
CNS Neural stem 
cells 
Common marker in 
early development 
Correlation with various 
high-grade brain tumors 
(Dahlstrand et al., 1992b; 
Dahlstrand et al., 1995; 
Lendahl et al., 1990) 
 Astrocytes  Reactive astrocytes in CNS 
injury, astrocytoma 
(Frisén et al., 1995) 
Renal Glomeruli Podocytes 
(constitutive) 
Kidney injury in podocytes, 
mesangial cells 
(Daniel et al., 2008; Ishizaki 
et al., 2006; Perry et al., 2007) 
Male 
reproductive 
organs 
Testis Developing (and less 
mature) Leydig and 
Sertoli cells 
Testicular cancer (Davidoff et al., 2004; 
Fröjdman et al., 1997; Lobo et 
al., 2004) 
 Prostate  Prostate cancer (variably) (Gu et al., 2007) 
Female 
reproductive 
organs 
Ovary  Ovarian cancer (He et al., 2013) 
Mammary 
gland 
Myoepithelial cells Basal epithelial breast 
cancer 
(Li et al., 2007; Liu et al., 
2010) 
Digestive 
system 
Teeth Tooth development and 
mature odontoblasts 
Odontogenic tumors (About et al., 2000; Fujita et 
al., 2006; Terling et al., 1995) 
 Gastrointestinal 
tract 
 Expressed in various tumors (Ishiwata et al., 2011a; 
Tsujimura et al., 2001) 
Lung (Myo)fibroblast  Injury-induced 
myofibroblast, lung cancer 
(Chen et al., 2014; Kishaba et 
al., 2010; Ryuge et al., 2011) 
Liver and 
pancreas 
Liver Mesenchymal 
progenitor cells 
Stellate  cells, 
hepatocellular- and 
cholangiocarcinoma 
(Herrera et al., 2006; Niki et 
al., 1999; Tschaharganeh et 
al., 2014) 
 Pancreas Endocrine and exocrine 
precursor cells, stellate 
cells 
Pancreatic cancer (Bernardo et al., 2006; 
Lardon et al., 2002; Matsuda 
et al., 2011; Zulewski et al., 
2001) 
Endocrine 
organs 
Adrenal cortex Reticular layer  Cancer (Lachenmayer et al., 2009) 
Skeletal MSCs Osteoblast progenitors Osteosarcoma (Méndez-Ferrer et al., 2010; 
Ono et al., 2014; Veselska et 
al., 2008) 
Hematopoietic MSCs Bone-marrow resident 
mesenchymal stem cells 
Multiple myeloma (Méndez-Ferrer et al., 2010; 
Svachova et al., 2011) 
Adipose MSCs mRNA in isolated 
MSCs 
 (Timper et al., 2006) 
Skin Progenitor cells Hair follicle and skin-
derived progenitor cells 
Skin cancers (e.g. 
melanoma) 
(Akiyama et al., 2013; 
Flørenes et al., 1994; Li et al., 
2003; Toma et al., 2005) 
Sensory Eye Developing lens and 
retina, Müller cells 
 (Lee et al., 2012b; Yang et al., 
2000) 
 Taste Fungiform papilla stem 
cells (GFP reporter) 
 (Mii et al., 2014) 
 Ear Progenitor cells in 
cochlea (GFP reporter) 
 (Kojima et al., 2004) 
 Olfactory Olfactory mucosa stem 
cells 
 (Tomé et al., 2009) 
 
IFs are mainly phosphorylated on the head and tail domains, which protrude from the filament 
structure. The addition of phosphate groups dramatically affect the solubility of IFPs and 
mediates re-organization of the filament structure that is required e.g. during mitosis. For 
example, mitotic kinase activity is crucial for the solubilization of both cytoplasmic IFs, such as 
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vimentin (Yamaguchi et al., 2005), as well as the nuclear lamina (Peter et al., 1990). Also cell 
stress often causes prominent IF phosphorylation. As an example, keratin 8 can function in a 
cytoprotective manner in liver injury by attracting stress-kinase phosphorylation, a process 
which is thought to re-target harmful kinase activity away from apoptotic substrates (Ku and 
Omary, 2006). In addition, phosphorylation is important in the regulation of IF interactions. 
Also the significance of other PTMs (e.g. SUMOylation, glycosylation, acetylation, 
farnesylation), and their inter-dependence, is becoming more evident in the IF-field (Snider 
and Omary, 2014). Nestin has been found to be phosphorylated, ubiquitinated (Sahlgren et al., 
2001; Sahlgren et al., 2003; Sahlgren et al., 2006) and glycosylated (Grigelioniené et al., 1996). 
To date, no other PTMs of nestin have been described in literature, but it would be surprising if 
nestin was not modified in a similar complex manner as other IFs. In addition, nestin 
antibodies often detect multiple differently migrating bands by Western blotting, suggesting the 
prominent existence of nestin splicing-, degradation- or PTM-isoforms. 
2.2.1 Intermediate filaments as targets of Cdk5 
Not different from other kinases, also Cdk5-mediated phosphorylation of IF networks affects 
the dynamics of IF assembly. Due to the close relation of Cdk phosphorylation motifs, many 
mitotic sites on IFs have been found to be regulated by Cdk5 during interphase. Thus, when a 
non-cycling cell meets a challenge that requires acute reorganization of the IF network, Cdk5 
can be envisioned to substitute for the functions of classical Cdks in this context, allowing the 
cell to respond accordingly. Deregulation of Cdk5 activity can have serious consequences on IF 
assembly through the promotion of aggregate formation.  
Neurofilaments  
Cdk5, alike other members of the kinase family, phosphorylates multiple Lys-Ser-Pro (KSP) 
motifs on the C-terminus of neurofilament (NF) M and H isoforms (Lew et al., 1992b; Pant et 
al., 1997). The NF-H C- terminus contains over 50 KSP-repeats and is a heavily phosphorylated 
protein (Sun et al., 1996). The physiological importance of Cdk5 in regulation of NF 
localization was first demonstrated in the Cdk5-/- mouse model (Ohshima et al., 1996), and 
later, the phosphorylation has indeed been shown to regulate axonal transport of the IFs 
(Ackerley et al., 2003; Shea et al., 2004). Deregulated Cdk5 is believed to cause NF 
hyperphosphorylation in many neurodegenerative diseases, such as Parkinson’s disease 
(Nakamura et al., 1997), amyotrophic lateral sclerosis (Nguyen et al., 2001), and Niemann-Pick 
type C disease (Bu et al., 2002), which has a neuronal pathology that resembles AD. Most Cdk5-
related neurodegenerative phenotypes are, however, not single-handedly caused by NF 
hyperphosphorylation.  
Nestin  
A series of reports have described the interplay between nestin and Cdk5. Identified by in vitro 
phosphorylation and mass spectrometry, Cdk5 was shown to phosphorylate nestin on Thr316 
and Thr1495, which is involved in remodeling of the nestin cytoskeleton (Sahlgren et al., 2003). 
Additionally, Thr316 is phosphorylated by Cdk1 during mitosis, causing reorganization of 
nestin filaments (Sahlgren et al., 2001). Also nestin Ser1837 phosphorylation (a Cdk5 consensus 
site) was reported to be downregulated in E18.5 Cdk5-/- brain in a phosphoproteomic-study, 
possibly implying it may be a Cdk5 site in vivo (Contreras-Vallejos et al., 2014). The 
phosphoregulation of nestin has vast consequences on Cdk5 itself, and the detailed signaling 
mechanism is discussed further in forthcoming chapters.  
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Lamins 
Lamin phosphorylation during cell division is essential for disruption of the physical nuclear 
lamina, allowing proper chromosome segregation to occur (Heald and McKeon, 1990; Peter et 
al., 1990). Some major mitotic sites (e.g. Ser22, Ser392) have also been found to exist in a 
phosphorylated status during interphase (Kochin et al., 2014), and thus, they are believed to be 
crucial in determination of lamin solubility. In a neuronal model of glutamate- or amyloid-β-
induced apoptosis, Cdk5 was suggested to promote phosphorylation of lamin A on Ser392 and 
Ser22 (as well as of the equivalent sites on lamin B1) (Chang et al., 2011). Chang and colleagues 
(2011) postulated that upon neurotoxic insults, the hyperactivation of Cdk5 kinase activity 
drives the solubilization of the nuclear lamina as an early step of neuronal apoptosis. In fact, 
mutation of Ser392 to alanine did reduce neurotoxicity, suggesting that lamins are important 
targets of hyperactivated Cdk5, and that the nuclear dispersion is not solely a consequence of 
cell death (Chang et al., 2011).  
Vimentin 
Vimentin Ser56 was originally found to be phosphorylated by Cdk1 during mitosis, allowing 
rearrangement of vimentin filaments during cell division (Chou et al., 1991). Upon artificial 
neutrophil activation, Cdk5 was shown to phosphorylate vimentin on Ser56, causing a 
polarization of the vimentin cytoskeleton (Lee et al., 2012a). The phosphorylation-mediated 
remodeling of vimentin was proposed to be the key factor for Cdk5-dependent neutrophil 
secretion (Lee et al., 2012a; Rosales et al., 2004b).  
2.3 Intermediate filaments as signaling scaffolds 
Not only is the IF cytoskeleton constantly being remodeled as a response to the cell 
differentiation stage, but the solubility, altered intracellular localization and organization have 
dramatic effects on IF interaction partners. In recent years, it has come to the attention of the 
field that the IFs actively regulate functions and positioning of organelles, and are involved cell 
migration, adhesion, differentiation and mitosis; processes which are highly dependent on the 
flexibility of the cells´ cytoskeleton. Many IFs are crucial for the stress tolerance of cells when 
they are challenged to a particular strain.  
Because of their strict differentiation-regulated expression pattern, it is perhaps not completely 
unexpected that IFPs act at the gates of differentiation processes. The differentiation of muscle 
is an interesting example, as the different stages are characterized by the dynamic expression of 
many IFPs. Myoblasts lacking lamin A/C differentiate at a slower rate due to the decreased 
expression of  the myogenic determinant MyoD (Frock et al., 2006). Nucleoplasmic lamin A/C-
lamina-associated polypeptide 2α (LAP2α)-pRb complexes suppress proliferation and enhance 
differentiation of at least adipocytes and muscle stem cells at initial stages of commitment 
(Dorner et al., 2006; Gotic et al., 2010). Thus, the lamin A/C-regulated differentiation of muscle 
cells is likely to be under strict control of not only lamin protein levels, but by the solubility 
state of lamins. As the PTMs are essential for regulation of lamin solubility, it would be highly 
interesting to assess the function of lamin phosphorylation during muscle differentiation. As 
another example, the genetic depletion of synemin increases the myogenic commitment of  
muscle stem cells (Zhenlin et al., 2014). Desmin, in turn, does not seem to play an essential role 
in muscle differentiation or fusion in a knockout-approach (it is likely that some its functions 
can be substituted by other similar proteins), but the organization of the sarcomeric structure of 
muscle (Li et al., 1997; Milner et al., 1996), as well as organelle distribution, are severely 
devastated. Conversely, the transient downregulation of desmin inhibits myoblast 
differentiation very potently, suggesting that desmin is nevertheless required for earlier 
processes of muscle differentiation (Li et al., 1994). Together these results illustrate the 
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importance of IFPs and their solubility state in regulation of myogenic differentiation. 
Naturally, this is not the only differentiation model where IFPs are essential for cell fate 
determination. The roles of IFPs in regulation of the proliferation/differentiation switch are of 
special interest in the context of cancer.  
2.3.1 The physiological functions of nestin 
The function of nestin has remained somewhat unclear, with the only very recent generation of 
three distinct mouse models lacking nestin. The first one to be published targeted the coding 
region of nestin exon 1 by homologous recombination and the mice showed perinatal lethality 
(Park et al., 2010); a relatively uncommon, but not unheard of, phenotype in the field of IF 
knockout models. These nestin knockout mice died due to high apoptosis-rate of neuronal 
precursors during development (Park et al., 2010). Later, Mohseni and colleagues (2011) 
published a viable and grossly normal nestin knockout mouse, where most of exon 1 and part of 
the 5´-untranslated region were deleted by gene targeting. The knockout mouse by Mohseni et 
al. (2011) did, however, show aberrant NMJ structure and motor coordination problems. Both 
knockouts were in C57BL/6 background (Mohseni et al., 2011; Park et al., 2010). In line with 
Mohseni et al. (2011), a third nestin deficient mouse was generated by ubiquitous lentiviral 
expression of nestin shRNA plasmid, causing a disruption of NMJ organization in nestin 
downregulated mice (Yang et al., 2011). Also the shRNA mouse was viable. As two independent 
mouse strains lacking nestin were viable, and because the deletions of minor IFPs are rarely 
deadly, it seems probable that the embryolethal knockout model generated by Park and 
coauthors (2010) may have suffered from some unidentified defect, which eventually may have 
caused the observed lethality.  
As nestin expression is generally linked to highly proliferative tissues, such as developing 
neuroepithelium and several types of cancer, there has been an interest to understand the role 
of nestin as a regulator of progenitor cell proliferation. One interesting aspect was provided by 
Reimer and colleagues (2009), when they reported an interplay with the steroid hormone 
receptor family member glucocorticoid receptor (GR) and the nestin-vimentin IF network. 
They proposed that this IF cytoskeleton is important for sequestration of the glucocorticoid 
receptor to the cytoplasm: depletion of nestin promoted nuclear accumulation of the GR, while 
its overexpression resulted in GR cytoplasmic sequestration (Reimer et al., 2009). As the 
shRNA-mediated downregulation of nestin correlated with cell cycle arrest, the authors 
suggested that in the absence of nestin, the growth inhibitory effects of nuclear GR were 
amplified. Nestin and GR co-expression has also been reported in melanoma patient samples 
(Lai et al., 2013). 
The nestin/vimentin-scaffold also regulates the activity of the ubiquitous insulin degrading 
enzyme (IDE). Besides insulin and amyloid-β, also ubiquitin belongs to the substrates of IDE 
(Ralat et al., 2011). IDE bound specifically to the soluble pool of the nestin-vimentin 
cytoskeleton in a phosphorylation-dependent fashion, but also separately to the nestin tail 
fragment 641–1177 in vitro (Chou et al., 2009). Soluble nestin-vimentin reduced IDE-activity 
towards insulin and ubiquitin, while stimulating degradation of the small substrate peptide V 
(Chou et al., 2009; Ralat et al., 2011). Together these results indicate that the solubility of the 
nestin-vimentin filaments control the activity and substrate specificity of this enzyme. Taking 
into consideration the numerous and highly potent substrates of IDE, the IF phosphorylation 
status can have extensive effects on cell physiology.  
Studies on transitin, the bird ortholog of nestin, have revealed roles in both proliferating bird 
myoblasts and neuroepithelial cells. While knockdown of transitin in chick myoblast prevents 
differentiation and promotes proliferation (Jalouli et al., 2010), transitin knockdown in 
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neuronal progenitors promotes neuronal differentiation at the expense of proliferation 
(Wakamatsu et al., 2007). In fact, transitin binds to the Notch inhibitor Numb and directs its 
asymmetrical division during mitosis of neuronal progenitors, which may underlie the observed 
effect of transitin knockdown on neuronal progenitor fate (Wakamatsu et al., 2007).  
2.3.2 Interplay between Cdk5 and nestin in muscle models 
Nestin and Cdk5 were first shown to interact in the rat-derived neuronal progenitor cell line 
ST15A (Sahlgren et al., 2003). Expression of Cdk5/p35 strongly promoted nestin 
phosphorylation on Thr316, but several phosphosites that remained unidentified, seemed to be 
induced (Sahlgren et al., 2003), suggesting that nestin is heavily phosphorylated by the kinase. 
The nestin-Cdk5 interaction was confirmed to occur also in differentiating myoblasts, where 
both nestin protein expression and Cdk5 activity are induced strongly at later stages of 
differentiation (Sahlgren et al., 2003). The organization of nestin during muscle differentiation 
is highly dynamic, when the typical perinuclear nestin found in proliferating cells reorganizes 
into long filaments that follow the shape of the elongated and fused myotubes (Sahlgren et al., 
2003). The transport of nestin (and other muscle IFs) to the tips of myotubes is regulated by the 
kinesin-motor protein family member Kif5b during myoblast differentiation (Wang et al., 
2013), but the reorganization is otherwise phosphorylation-dependent (Sahlgren et al., 2003). 
Phospho-Thr316 on nestin was found to exist exclusively in soluble fractions in differentiating 
myoblasts, suggesting that Cdk5-mediated nestin phosphorylation releases a pool of soluble 
nestin. The strong induction of nestin protein levels and filament re-organization during 
differentiation are also dependent on Cdk5 activity (Sahlgren et al., 2003). Therefore, there were 
clear indications of Cdk5-mediated regulation of nestin organization in myocytes. Interestingly, 
the inhibition of Cdk5 with roscovitine increased the association between nestin and p35, 
suggesting that Cdk5 activity regulates the scaffolding properties of nestin towards its own 
activator. Later, PKCζ, which is an essential upstream regulator of Cdk5 activity, was also 
demonstrated to be important for nestin filament organization and induction of nestin protein 
levels during the process, as Cdk5 remains essentially inactive in the absence of functional 
PKCζ (de Thonel et al., 2010).  
In mature muscle, nestin is localized directly underneath the postsynaptic plasma membrane of 
the NMJ (Vaittinen et al., 1999; Vaittinen et al., 2001), where it extends into sarcomeres in the 
vicinity of the NMJs and surrounds the junctional myonuclei (Kang et al., 2007). Nestin 
expression at the postsynaptic NMJ is regulated by innervation, causing nestin mRNA to be 
transcribed in the synaptic myonuclei (Kang et al., 2007). Although the regulation of nestin in 
muscle is not completely understood, it seems as nestin expression is regulated by several 
factors.  
As nestin is present at NMJs, and co-localizes with the postsynaptic AChRs together with Cdk5 
(Sahlgren et al., 2003), it is perhaps not surprising that nestin-mediated scaffolding of Cdk5 is 
essential in determination of its kinase activity at the NMJs. As discussed previously, Cdk5 acts 
at several levels of NMJ development to regulate both positive (NRG-induced AChR 
transcription) and negative signals (ACh-mediated Cdk5 activity disperses AChR clusters, 
which are not stabilized by agrin) that act on AChR clustering (Fu et al., 2001; Fu et al., 2005; 
Lin et al., 2005). As a response to ACh agonists, C2C12 myotubes upregulate Cdk5 activity, 
induce p35 membrane recruitment and consequently trigger nestin Thr316 phosphorylation 
(Yang et al., 2011). Downregulation of nestin, or expression of phospho-deficient T316A 
mutant nestin, causes suppression of Cdk5 activation and a reduction in ACh agonist-
dependent NMJ dispersion, showing that (phosphorylated) nestin is required for Cdk5-
mediated AChR dispersion (Yang et al., 2011) (summarized in Figure 8). Nestin shRNA mice that 
were generated by Yang et al., (2011) did show an increase in AChR cluster number, indicating 
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that nestin is required for optimal NMJ dispersion. The results were supported by a genetic 
nestin deletion mouse model, which similarly to the shRNA mice, showed an increase in AChR 
cluster number and size, causing motor coordination problems in the nestin deficient mice 
when measured by the Roto-Rod test (Mohseni et al., 2011).  
2.3.3 Cdk5 and nestin in neuronal cell death and survival 
A cytoprotective role for nestin was first demonstrated in the neuronal ST15A cells (Sahlgren et 
al., 2006). When the cells were treated with hydrogen peroxide to induce apoptosis, nestin was 
found to undergo proteasomal degradation at the time of cell death, and intriguingly, 
downregulation of nestin increased apoptosis further, while expression of exogenous nestin had 
a strong cytoprotective effect (Sahlgren et al., 2006). Cdk5 turned out to be the executor of 
apoptosis in this particular model, and expression of DN-Cdk5 rescued the increased apoptosis 
of nestin-downregulated cells (Sahlgren et al., 2006). In fact, exogenous expression of nestin 
protected p35 from ubiquitination and proteasomal degradation, while reducing its calpain 
cleavage to p25 during apoptosis. Studies that were based on expression of N-terminally green 
fluorescent protein (GFP)-tagged nestin truncations showed that the nestin tail contributes 
strongly to its own degradation; the nestin truncation containing amino acids 1-640 of rat 
nestin (Nest-640) is considerably more stable compared to full length forms (Sahlgren et al., 
2006). Immunoprecipitation studies also revealed that Cdk5/p35 binds to the nestin C-terminus 
(between amino acids 314-640) next to the rod domain (Sahlgren et al., 2006). Finally, Sahlgren 
and colleagues (2006) showed that while expression of Nest-640 did not increase steady-state 
p35 protein levels as such, its intracellular localization (and thus Cdk5 activity) shifted towards 
a soluble pool as determined by cellular fractionations. Thus it is believed that a soluble pool of 
Nest-640, which exists in significant amounts in the transfected cells, sequesters Cdk5 activity 
to the cytoplasm and protects p35 from ubiquitination, thereby preventing cytotoxic Cdk5/p25 
activity in the nucleus. Importantly, the nestin-Cdk5 interplay occurred in both directions: 
while nestin was shown to regulate p35 turnover, disruption of Cdk5 activity with roscovitine 
or DN-Cdk5 significantly retarded the H2O2-induced nestin degradation (Sahlgren et al., 
2006). As Cdk5-mediated nestin phosphorylation promotes filament solubilization (Sahlgren et 
al., 2003), the evidence from both neuronal and muscle systems imply that Cdk5 itself acts to 
regulate the turnover of p35 through nestin, to prevent unwanted kinase activity. The signaling 
events at the NMJ and during apoptosis are recapitulated in Figure 8.  
The novel Nes-S isoform was also seemingly interacting with Cdk5 when overexpressed in N2a 
neuroblastoma cells that are intrinsically Nes-S deficient (Su et al., 2013a). In support of nestin-
Cdk5 interplay in neurons, expression of Nes-S promoted survival after H2O2 treatment (Su et 
al., 2013a). In addition, Nes-S downregulation seemed to impair primary dorsal root ganglia 
viability. Although further evidence is required to understand the interplay between Nes-S and 
Cdk5, these results nicely support the nestin-Cdk5 interaction, which has been under intense 
investigation in muscle and neurons previously. Also in zebrafish, the downregulation of nestin 
causes an increase in apoptosis of neuronal precursors during development of brain and eye, 
leading to severely malformed and small-sized brains and hydrocephalus (Chen et al., 2010). In 
rat vascular smooth muscle cells nestin downregulation enhances H2O2-induced apoptosis 
similarly to the ST15A model system, but the link to Cdk5 remained unclear from this 
particular study (Huang et al., 2009c). Results suggested that Cdk5 may have acted as an anti-
apoptotic kinase instead in this particular model system, leaving the details unclear.  
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Figure 8 The role of the nestin scaffold in the regulation of Cdk5 signaling. In a model by Yang et al. (2011) and 
Mohseni et al. (2011) (upper panel), nestin is required for Cdk5 activation at the NMJ membrane, where Cdk5 kinase 
activity acts to disperse non-stabilized AChRs. ACh itself drives Cdk5 activation. Activated Cdk5 phosphorylates nestin, 
which stabilizes Cdk5/p35 transiently at the membrane. Eventually, the phosphorylated nestin is degraded. If nestin is 
completely removed from the system, Cdk5 is not activated as efficiently, resulting in increased AChR clustering, as 
observed in the nestin deficient mice. A similar regulatory scaffold determines Cdk5-mediated neuronal apoptosis 
(Sahlgren et al., 2006) (lower panel). In the presence of nestin, oxidative stress induces Cdk5 activity, which is targeted 
towards the nestin filaments. The consequential phosphorylation-mediated nestin solubilization protects Cdk5/p35 at the 
expense of Cdk5/p25. Eventually, nestin is degraded. In the case nestin is removed by shRNA, p35 is uncontrollably 
processed and Cdk5/p25-generation is favored, resulting in increased apoptosis when the death-inducing Cdk5 activity is 
unleashed. 
2.3.4 The role of nestin in podocyte signaling 
As highlighted before, Cdk5 activation by p35 and/or cyclin I is important for renal podocyte 
survival through the maintenance of adequate levels of anti-apoptotic proteins (Brinkkoetter et 
al., 2009; Griffin et al., 2006; Taniguchi et al., 2012). In transgenic mice lacking either p35 or 
cyclin I, podocyte apoptosis was increased compared to WT mice during podocyte stress, and 
kidney function was further impaired in the double knockout mice (Brinkkoetter et al., 2009; 
Brinkkoetter et al., 2010; Taniguchi et al., 2012), proposing that the activators could partly 
compensate for each other´s functions, although Cdk5 may have altered substrate specificity 
depending on which activator it is bound to. Baseline kidney function and podocyte apoptosis 
was normal in all mice. Also a pro-apoptotic role for Cdk5 in high glucose-treated cultured 
podocytes has been suggested in opposition to the abovementioned observations (Zhang et al., 
2014). In a streptozotocin-induced model of rat diabetic nephropathy, Cdk5 expression was 
found to be induced in injured glomeruli (Liu et al., 2013). Furthermore, Cdk5/p35 expression 
and activity was promoted by high glucose treatment, but apoptosis was found to be only 
modestly inhibited in the presence of relatively high concentrations of roscovitine (50 µM) or 
specific Cdk5 targeting (Liu et al., 2012; Zhang et al., 2014).  
Intriguingly, nestin is also expressed in fetal and adult podocytes, where it co-localizes with 
Cdk5 in immunostainings (Bertelli et al., 2002). In the adult organism, podocytes are one of the 
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few places where nestin and Cdk5 are strongly expressed under homeostasis and can be studied 
jointly, implying that together they may have highly specialized functions in that particular cell 
type. In fact, downregulation of nestin in cultured podocytes caused a modest increase in the 
apoptotic population (Liu et al., 2012), suggesting that it may have neuron-like cytoprotective 
scaffolding functions for Cdk5 during podocyte apoptosis (Sahlgren et al., 2006). The nestin-
Cdk5 signaling axis has not been studied in further detail in renal systems. Nestin expression 
levels are known to respond to podocyte injury in different injury models and kidney disease 
patients, but both up- and downregulation has been observed, probably due to different models 
used and differences in the degree of injury (Su et al., 2007; Wagner et al., 2006; Zou et al., 
2006). Nestin is also expressed in intraglomerular mesangial cells (specialized pericytes) upon 
specific injury towards these cells (Daniel et al., 2008). When depleted, the mesangial cells 
proliferate and repopulate their niche and depletion of nestin with siRNA suppresses their 
proliferation to some extent (Daniel et al., 2008). 
2.3.5 Nestin - more than a marker in cancer 
Nestin is expressed in a variety of cancers. The downregulation of nestin seems to negatively 
affect the cell migration/invasion of at least pancreatic cancer cells (Matsuda et al., 2011), 
glioma cells (Ishiwata et al., 2011b), lung cancer cells (Takakuwa et al., 2013) and melanoma 
cells (Akiyama et al., 2013). In prostate cancer cell models, two separate studies have questioned 
the role of nestin in migration and invasion. While Kleeberger and colleagues (2007) found that 
nestin downregulation inhibited migration and invasion, a later study argued that nestin 
downregulation promotes invasion through regulation of focal adhesion component turnover 
and integrin membrane expression (Hyder et al., 2014). The downregulation of nestin also 
promotes melanoma cell invasion and matrix-metalloprotease upregulation (Lee et al., 2014). 
Some reports suggest that nestin expression might be linked to epithelial-mesenchymal 
transition, at least in pancreatic (Su et al., 2013b) and breast (Zhao et al., 2014) cancer cell 
models. In many types of cancer cells the knockdown of nestin has been found to interfere with 
cell growth and viability, including lung cancer cells (Takakuwa et al., 2013), liver and breast 
cancer cells (Tschaharganeh et al., 2014; Zhao et al., 2014) and in melanoma (Akiyama et al., 
2013). These, and many other publications, do support that nestin plays a role in tumorigenesis 
and cancer cell motility, but the effects are cancer cell line-specific and the mechanisms are in 
many cases not understood well, if at all. Also the aspects of nestin as a potential regulator and 
target for tumor angiogenesis (Ishiwata et al., 2011a; Matsuda et al., 2013) have showed growing 
interest in the past years, as nestin is highly expressed in pericytes and endothelial cells in 
neovasculature.  
The specificity of nestin expression in mesenchymal stem cells, neuronal progenitors and 
cancer have created an interest to understand its expression pattern in more detail, possibly 
even including its use as a clinical marker. There are, however, only a limited number of 
research articles that address in detail the functionality of nestin and the significance of its 
presence in tumors. Given its surprisingly abundant, but highly specific expression, which has 
expanded in recent years, there is an increasing need to understand better the molecular 
functions of nestin. 
3 Myogenesis 
Skeletal muscle contributes to approximately 40% of the total body weight in mammals. Limb 
skeletal muscles originate from the embryonic somites of mesodermal origin, which reside in 
pairs on both sides of the developing vertebrae. The somites are sites of myoblasts expansion, 
from where the myogenic cells migrate to the myotome, where primitive skeletal muscle tissue 
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is formed. First somites appear around E8 in mouse development, after which they multiply to a 
final number of more than 60 somite pairs. During the three first postnatal weeks in mice, 
muscle stem cells proliferate actively and build up muscle tissue, after which muscle enters a 
steady-state where muscle mass increase occurs only in response to stress in form of injury or 
exercise. Muscle stem cells are activated upon cell stress to answer the demand created by 
injury-mediated tissue loss, but the cells only have a restricted regenerative potential, which 
gradually decreases with age.  
3.1 Skeletal muscle stem cells and muscle differentiation 
Satellite cells are tissue-resident stem cells of skeletal muscle that reside mitotically quiescent on 
top of myofibers, underneath the basal lamina. Satellite cells are typically found in large 
numbers in the vicinity of NMJs, at the ends of myofibers, and close to blood vessels. Satellite 
cells, and their progeny, are a heterogeneous group of cells in terms of the expression of muscle 
stem cell markers (such as Myf5, M-cadherin, integrin-α7, CD34), as individual cells express a 
different setup of molecular markers and also show variability in the expression levels of 
myogenic proteins (Sacco et al., 2008). The expression of the transcription factor Pax7 is, 
however, a ubiquitous and well-established marker for all quiescent and proliferating satellite 
cells in all muscle types across species (Seale et al., 2000). The molecular variability of satellite 
cells (within a muscle and between muscle types) is considered to stem from environmental 
factors that mold the satellite cell niche, generating differences in the differentiation potential of 
individual cells. Also the amount of satellite cells varies between muscle types. In addition to 
satellite cells, several other types of myogenic stem cells exist that can readily contribute to 
muscle differentiation and regeneration. Examples of such are the muscle resident 
PW1+/Pax7− interstitial cells (Mitchell et al., 2010) and pericytes (Dellavalle et al., 2007). 
Homing of bone marrow-originated MSCs to sites of muscle injury is also believed to 
contribute to the muscle regeneration process in vivo (Corbel et al., 2003). Nonetheless, the 
depletion of satellite cells severely blocks myogenic regeneration after muscle damage, and 
hence, the satellite cells are considered to be the most significant muscle stem cell population in 
acute muscle injury (Lepper et al., 2011). Researchers have shown that as few as seven still 
myofiber-associated satellite cells engrafted to dystrophic muscle can readily regenerate 
considerable parts of host muscle tissue (Collins et al., 2005), demonstrating the enormous 
myogenic potential of the cells. Satellite cells can, in suitable conditions, be differentiated to 
osteoblasts or adipocytes, suggesting that they ultimately have a mesenchymal stem cell 
character (Asakura et al., 2001).   
When entering the cell cycle in response to a stress signal, the activated satellite cells 
immediately turn on the expression of muscle regulatory factors (MyoD, Myf5) (Cooper et al., 
1999), and are thereafter considered to be part of the proliferative myogenic progeny of satellite 
cells, the myoblasts (illustrated in Figure 9). Myoblasts can either fuse to existing muscle fibers or 
fuse with other myoblasts to form new myofibers. The satellite cell pool is replenished by 
asymmetrical division, or alternatively, activated satellite cells can lose MyoD expression and 
return to a quiescent state (Pax7+, MyoD-) (Zammit et al., 2004). Myoblasts that enter the 
terminal myogenic differentiation program exit the cell cycle and upregulate the expression of 
transcription factors myogenin and Mrf4 (which are direct targets of MyoD and Myf5), thereby 
switching on an orchestrated series of events that involves increased motility and alignment of 
myoblasts preparing to fuse, as well as expression of muscle-specific proteins. The prerequisite 
for the initiation of differentiation is cell cycle inhibition (including upregulation of cell-cycle 
inhibitors) and repression of mitotic Cdk activity, whereas cell differentiation-related Cdks 
(such as Cdk5) are activated. Thus, the initiation of differentiation is balanced by (inhibitory) 
mitotic Cdks and (permissive) differentiation Cdks.  
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3.2 Muscle repair processes 
Satellite cells can be activated by physical muscle damage (e.g. muscle injury, exercise, loss of 
innervation) or secreted factors (e.g. hormones, nutrients) to replenish muscle tissue. 
Importantly, a pool of satellite cells is always maintained in a quiescent state to ensure the 
preservation of the regenerative capacity of muscle, while other cells activate, proliferate and 
differentiate in response to muscle damage. The satellite cells become fewer with age and lose 
their myogenic potential due to the aging extracellular environment (Conboy et al., 2005), 
causing an age-dependent reduction in regenerative capacity of muscle (sarcopenia). 
In practice, the process of muscle development, differentiation and healing all involve 
activation of satellite cells and their commitment into the myogenic differentiation program. 
Small injuries, like those that arise from exercise, mainly involve the activation of a few satellite 
cells that heal the microdamage of myofibers, whereas wounds of larger areas comprises the 
regeneration of several tissue types (myofibers, connective tissue, vasculature, nerves) and 
involves an inflammatory reaction. Destructive damage, disease conditions or excessive 
inflammation (myositis) may eventually lead to extensive myofiber death, sustained fibrosis and 
accumulation of adipocytes between myofibers, which impair normal muscle function and its 
contractile capacity. The injury-evoked inflammation is a crucial part of the healing process: 
macrophages and leukocytes, which are attracted to muscle in response to injury, are essential 
for phagocytosis of dead myofiber debris, but the inflammation also promotes activation of 
myogenic satellite cells and fibroblasts, which secrete transient (as well as fibrosis-related) 
extracellular matrix (reviewed in Mann et al., 2011; Yin et al., 2013; Chang and Rudnicki, 2014).  
Muscle dystrophies derive from mutations of a variety of genes that mutually cause fragility in 
the muscle structure. Duchenne muscular dystrophy (DMD) is a recessive X-linked severe, but 
yet relatively common (1/3500 males), muscle wasting disease that derives from mutations in 
the muscle structural protein dystrophin. DMD causes severe progressive muscle wasting that 
will eventually cause premature death of the patient due to wasting of vital muscles, such as 
heart and those involved in breathing. The disruption of the dystrophin gene in mice (often 
referred to as mdx-mice) suitably recapitulates many DMD symptoms and is a commonly used 
mouse model in muscle wasting disease research. Another less common myopathy is Emery-
Dreifuss muscular dystrophy, which is caused by lamina-disrupting mutations in genes that 
Figure 9 The expression of myogenic transcription factors during differentiation. Satellite cells are characterized by 
Pax7 expression, which is immediately lost upon commitment to differentiation. Pax7+, MyoD+ activated cells can also 
return to quiescence to maintain the stem cell pool. The molecular signature of proliferating myoblasts reflects their 
individual differentiation state. Eventually, at the stage of myotube formation, myogenin (MyoG) expression is 
downregulated from the newly formed myonuclei.  
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encode lamin A/C or emerin, causing both skeletal and cardiac myopathy. The mechanisms of 
nuclear lamina-related muscular dystrophies are not well understood. Most myopathies 
progress slowly and do not affect the patient´s life expectancy, while others (such as DMD) 
dramatically shorten patient life-span. The differences in severity rise from different 
mechanisms, although the diseases have in common the continuous myofiber regeneration, 
fibrosis and adipocyte accumulation, as well as chronic inflammation of the muscle, which 
eventually depletes the myogenic stem cell pool, leaving the muscle incapable of repair. The 
progress of muscle dystrophy is a multi-cause process and the mechanisms of the cells involved 
are complex and poorly understood at a molecular level. On one hand, the muscle fibers are 
weak, while the myogenic cells lose their potential to self-renew or differentiate, which causes a 
gradual decline in muscle mass. Simultaneously, other cell types show an increased fibroblast 
and adipocyte differentiation potential, leading to the persistent problem of chronic fibrosis 
within muscle tissue. Muscle fibrosis is one of the key challenges in muscle dystrophies as it 
cannot currently be treated, or even restrained. At present, there is no treatment against muscle 
dystrophy, but especially muscle mass-supporting stem cell therapy has been successful in pre-
clinical research models (reviewed in Mann et al., 2011; Miyagoe-Suzuki et al., 2012; Bareja and 
Billin, 2013). 
Prolonged muscle damage initiated by secondary causes includes for instance sarcopenia, 
immobility-triggered atrophy, myositis and cancer- and AIDS cachexia. Although these muscle 
conditions can be more transient by nature, the muscle atrophy cannot be treated medically and 
thus they pose a serious healthcare problem due to their high prevalence. If curable, the 
recovery time from atrophy is usually long and has a huge impact on the quality of life of the 
patient.  
3.3 Laboratory models in muscle research 
Differentiation-competent immortalized muscle progenitor cell lines are frequently used to 
study muscle differentiation, one of them being the C2C12 cell line, which originates from a 
dystrophic mouse model (Yaffe and Saxel, 1977). C2C12 myoblasts differentiate promptly at 
high confluency and serum-withdrawal, after which they form multinucleated myotubes in 2D 
culture. Primary muscle progenitor cell cultures can be isolated from muscle by enzymatic 
digestion and physical disruption of muscle tissue, but have the disadvantage of the presence of 
other cell types in cultures: these cultures typically contain a combination of myoblasts, 
fibroblasts, adipocytes and other cell types, the proportions of which may vary inter-
experimentally. Pure satellite cell cultures are commonly isolated with the help of nestin (Day et 
al., 2007) or Pax7-driven (Bosnakovski et al., 2008) fluorescent reporters, or by the selection of 
CD34+/integrin α7+/CD45-/CD31-/CD11b-/Sca1- cells by cell sorting (Pasut et al., 2012). A 
higher grade of purity can alternatively be reached by culturing of satellite cells from intact 
myofibers. These myoblast cell models, all of which have their own advantages and 
shortcomings, are useful to study myoblast proliferation and differentiation. There is, however, 
no in vitro model to study muscle regeneration, given the complex interplay between tissue 
types that occurs during muscle healing. Therefore, muscle injury is often studied in rodent 
injury models. The most commonly used injury types include chemical injury (BaCl2, 
cardiotoxin), nerve injuries and physical injuries (cutting-, freeze-, or squeeze injury), all of 
which reflect slightly different injury conditions in terms of healing, inflammation and tissue 
remodeling.  
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AIMS OF THE STUDY 
Prior to this work, there had been an interest towards the nestin/Cdk5/p35 signaling complex in 
the laboratory. First, Cdk5 was found to phosphorylate nestin during myogenic differentiation, 
leading to re-organization of nestin filaments (Sahlgren et al., 2003). Later, nestin was 
discovered to constitute a regulatory scaffold for the kinase in a model of stress-induced 
apoptosis in neuronal precursor cells (Sahlgren et al., 2006). This thesis aimed to question the 
role of nestin-Cdk5 interplay in muscle differentiation and healing. Considering the 
aforementioned work, the depletion of nestin was hypothesized to affect Cdk5 signaling also in 
myoblasts, with consequences on myoblast differentiation, muscle development and healing. 
Furthermore, nestin was hypothesized to retain its Cdk5-regulatory functions in cancer cell 
signaling, which was the research focus of the last part of this thesis. In total, this thesis consists 
of three studies that were designed as a natural continuum on the above-mentioned 
publications, and which together aimed to understand in detail the complex interplay between 
Cdk5 and the IFP nestin in development and disease. The specific objectives of the distinct 
projects were the following: 
 
I. To understand the detailed role of the nestin scaffold in regulation of Cdk5 during 
muscle differentiation.  
 
II. To assess in a broader perspective how skeletal muscle physiology and regeneration is 
affected by the genetic ablation of the nestin scaffold.  
 
III. To examine the specific functions of Cdk5 in prostate cancer, and to address whether 
the concept of nestin/Cdk5 interplay could be extrapolated into a disease context. 
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EXPERIMENTAL PROCEDURES 
Table 4 Methods utilized and reference to specific descriptions.  
 
 
1 Cell culture methods and experimental treatments 
1.1 Cell lines  
C2C12 myoblasts (I), HeLa cervical cancer cells (I), HEK293 epithelial cells (III), VCaP prostate 
cancer cells (III) and vimentin positive- and negative subclones of SW13 adenocarcinoma cells 
(I) were cultured in DMEM (Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS), 2 
mM l-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere 
of 5% CO2 at 37ºC. Subconfluent C2C12 myoblasts were induced to differentiate in DMEM 
containing 1% FCS with supplements. Myotube formation was followed as differentiation 
progressed (myotube formation occurred typically from 48 hours). LNCaP prostate cancer cells 
(III), PC-3 prostate cancer cells (III) and 22Rv1 prostate cancer cells (III) were cultured in 
RPMI-1640 media (Sigma-Aldrich) including supplements. Sodium pyruvate (Sigma-Aldrich) 
was added to LNCaP culture media to a final concentration of 1 mM. RWPE-1 prostate 
epithelial cells were cultured in keratinocyte serum free media (Life Technologies) with 5 ng/ml 
human recombinant EGF and 50 µg/ml bovine pituitary extract. LNCaP and 22Rv1 hormone 
depletion (-androgen) was conducted by exchanging medium to 10% charcoal/dextran treated 
FCS (Thermo Fisher Scientific) in phenol red-free RPMI-1640 (Gibco) with supplements. 
Hormone stimulation (+androgen) included the addition of 1 nM synthetic androgen 
mibolerone in the previous conditions. Hormone starvation/stimulation lasted 16-24 hours.  
1.2 Experimental treatments 
To study how the expression and solubility state of nestin affects p35 stability (I), HeLa cells 
and vimentin positive and negative SW13 subclones that were previously transfected (p35, 
Cdk5 and Nest-640 or GFP for HeLa and Nest-640 and p35 for SW13) were treated with 10 μM 
calcium ionophore A23187 (Calbiochem). A23187-treatment induces highly selective Ca2+ 
influx to cells, causing activation of the calcium-dependent calpain proteases and p35 cleavage. 
After controlling the viability of the cells by microscopy, samples were collected for Western 
blot analysis after 0, 2, 4 and 6 hours treatment. To address whether inhibition of PKCζ affects 
Method Further references (in this thesis) 
Cell culture I, II, III 
Cell sorting III 
Cdk5-kinase assay II, III 
Echo-MRI II 
Immunocytochemistry I, II, III 
Immunohistochemistry II 
Immunoprecipitation I, II, III 
LC-MS/MS III 
Live cell imaging III 
MTS-assay I 
Muscle injury II 
Myofiber cultures II 
Primary myoblast cultures I, II 
RT-qPCR I, III 
Statistical analysis I, II, III 
Transient transfections I, III 
Western blotting I, II, III 
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nestin protein levels during differentiation (I), C2C12 myoblasts were induced to differentiate 
while treated with control peptide (Scr-P) or PKCζ-inhibitor (pseudosubstrate; PS) (MilleGen 
Biotech) at 20 µM concentrations (de Thonel et al., 2010). Samples were harvested for Western 
blotting after 48 and 72 hours, when prominent myotubes were apparent. Inhibition of Cdk5-
activity with 10 µM roscovitine was compared to vehicle (dimethyl sulfoxide; DMSO) controls 
of similar concentrations in both C2C12 myoblasts (I) and prostate cancer cells (III). Fresh 
roscovitine was supplemented daily in differentiating myoblasts, and every two days in prostate 
cancer cells.  
Neuregulin treatment for hyperactivation of ErbB-receptor/Akt kinase signaling in prostate 
cancer cells (III) was conducted through the addition of recombinant human neuregulin-1 (100 
ng/ml) to growth media overnight (16h), after which samples were collected for Western blot. 
An equal concentration of PBS was used as control. To study protein stability in the absence of 
Cdk5 (III), protein synthesis was stalled with the translation-inhibitor cycloheximide (CHX) at 
10 µg/ml. Ethanol was used as solvent to reconstitute CHX powder, and was used as control 
vehicle at comparable concentrations.  
1.3 Transient transfections and plasmids 
Before transfection through electroporation, HeLa and SW13 cells (I) were collected in Opti-
MEM (Life Technologies). Cells were electroporated in the presence of DNA plasmids with a 
single electric pulse (220 V, 975 μF) in electroporation cuvettes using Bio-Rad Gene Pulser. 
Cells were then diluted in DMEM growth media and incubated 24-48 hours before further 
experiments. C2C12 (I) and LNCaP (III) cells were transfected with overexpression plasmids 
using JetPEI transfection reagent (PolyPlus Transfection) according to manufacturer´s 
protocol, and PC-3 cells with Lipofectamine LTX with PLUS reagent (Invitrogen) according to 
instructions of the manufacturer. Overexpression plasmids are listed in Table 5. Transient 
downregulation of Cdk5 (III) or nestin (I, unpublished) by siRNA in C2C12, LNCaP, PC-3, 
HEK293 or 22Rv1 cells was performed using Lipofectamine RNAiMAX transfection reagent 
(Invitrogen) according to instructions of the manufacturer in antibiotic-free cell culture media. 
siRNA oligos were purchased from Qiagen (species specific GeneSolution for nestin or Cdk5 
downregulation, as well as All Stars scrambled negative control) and used at a final 
concentration of 50 nM. All cells were incubated a minimum of 24 hours after transfection 
before further experiments.   
Table 5 The origin of DNA constructs used in experiments. 
1.4 Cell proliferation assays 
In the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay to assess proliferation (I), C2C12 cells were transfected with nestin or 
scrambled siRNA, re-suspended the next day and plated on 12-well plates in equal numbers. 
After 24 hours, a solution of MTS (Promega) and phenazine methosulfate (Sigma-Aldrich) was 
added to the cells, and the optical density was measured with Victor2 plate reader (PerkinElmer) 
after one and two hour incubation. As MTS is converted to a colored formazan product in 
DNA construct Origin Reference 
CA-Akt-GFP (Peuhu et al., 2010) III 
DN-Cdk5 (D145N) Kind gift from Professor Harish Pant I 
Nest-640-GFP (Sahlgren et al., 2006) I 
p35 Addgene I, III 
pcDNA Kind gift from Professor Harish Pant I, III 
pEGFP Clontech I, III 
WT-Cdk5 Kind gift from Professor Harish Pant III 
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metabolically active cells, colorimetric analysis of cell cultures can be utilized to study the 
metabolic state of cells, which is higher in faster proliferating cells.  
To study cell population size in prostate cancer cells with and without Cdk5 (III), LNCaP and 
PC-3 cells were plated in equal amounts, transfected with siRNA, and counted every 24 hours 
with the trypan blue exclusion-technique in a Bürker cell counting chamber. VCaP cells were 
transfected similarly and counted after 0 and 72 hours. For double transfection, LNCaP or PC-3 
cells were first transfected with overexpression plasmids overnight, and Scr or Cdk5 siRNA the 
following night, after which the cells were incubated for 48 hours and finally counted. Western 
blotting lysates were collected from all experiments to verify transfection efficiency.   
For live cell imaging (III), LNCaP and 22Rv1 cells were plated, transfected overnight and then 
continuously imaged with a phase contrast Cell-IQ imaging platform (CM Technologies) with 
CO2 supply at 37ºC. Cell confluency of at least three separate areas was quantified using Cell-IQ 
Analyser-software (CM Technologies) with constant settings, and results plotted as relative area 
growth.   
2 Mouse strains and tissue preparation 
Nestin-/- and wild type mice (II) (Mohseni et al., 2011) were maintained in pathogen-free 
facilities at Central Animal Laboratory of Turku University in a 12:12h light-dark cycle and 
were provided with standard pelleted chow and tap water. Mice were sacrificed by CO2 
asphyxiation and cervical dislocation. Nestin knockout mice were in C57BL/6-background. 
Vimentin knockout and wild type mice (Colucci-Guyon et al., 1994) as well as FVB-n mice (I) 
were housed in a similar environment. For analysis of body composition (II), live animals were 
analyzed with EchoMRI body composition analyzer twice per measurement, of which the mean 
was calculated.  
2.1 Primary muscle myoblast cultures 
Primary mouse myoblasts from P3 FVB-n and vimentin knockout or wild type mice (I) were 
isolated from limb skeletal muscles. The muscle tissue was chopped and digested in 0.2% 
collagenase XI (Roche diagnostics) and 0.1% trypsin at 37°C for 60 minutes. Cells were filtered, 
centrifuged 1000 x g for 5 minutes and reconstituted in growth media (15% FCS, 2 mM l-
glutamine, penicillin/streptomycin, 2.5 ng/ml fibroblast growth factor-β [Promega] in Hams-
F10 [Sigma]) and plated on plastic. When cells reached 80% confluency, differentiation was 
induced by addition of 2% FCS/DMEM and supplements.  
Primary mouse P3 myoblasts from nestin wild type and knockout mice (II) were isolated 
according to (Danoviz and Yablonka-Reuveni, 2012) from limb skeletal muscles with some 
modifications. Briefly, muscles were isolated, minced and digested in a solution of dispase II 
(StemCell Technologies) and collagenase A (Roche Diagnostics) for 60 minutes at 37°C. 
Myoblasts were released by serial trituration and filtration of the slurry. Cells were then 
centrifuged 1000 x g for 10 minutes and were reconstituted in growth media (20% fetal bovine 
serum, 10% horse serum, 1% chicken embryo extract in high glucose DMEM with standard 
supplements and 1 mM sodium pyruvate). Myoblasts were plated on gelatin-coated cell culture 
dishes or growth factor-reduced Matrigel-coated coverslips (BD Biosciences). Isolation of 
primary myoblasts from adult (2 month old) nestin-/- and wild type mice (II) from tibialis 
anterior (TA), extensor digitorum longus (EDL) and gastrocnemius muscles was executed 
according to Danoviz and Yablonka-Reuveni (2012) following the protocol described above. 
Differentiation of primary myoblast cultures was induced at 80% confluency by serum 
depletion (1% horse serum in DMEM including supplements).  
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2.2 Myofiber isolation  
To study satellite cell function, live myofiber isolation (II) was performed according to (Pasut et 
al., 2012). Concisely, intact EDL muscles were isolated from adult mice and digested in 0.2% 
collagenase I (Calbiochem) solution for 60 minutes at 37°C, or until loose myofibers appeared 
from the muscle structure. The muscles were rinsed and serially titrated until more than 100 
live myofibers were released from the muscle. Single myofibers were plated on Matrigel-coated 
dishes for attached cultures, horse serum-coated plastic for floating cultures or fixed 
immediately in 3% paraformaldehyde (PFA), and immunolabeled following the protocol for 
fixed cells. 
2.3 TA-muscle injury  
For assessment of muscle regeneration of nestin knockout mice (II), the mice were anesthetized 
with vaporized isoflurane. The left TA muscle was injured by half of its thickness by a 
transverse incision with a razor blade through the skin in the TA midpoint. The other TA 
muscle served as an internal control. The skin was sutured and 0.1 mg/kg intraperitoneal 
buprenorfine (Temgesic; Reckitt Benckiser Healthcare) (0 and 8 h post-operatively) and 5 
mg/kg subcutaneous carprofen (Rimadyl; Pfizer Animal Health) (0, 24 and 48 h post-
operatively) were used as analgesics. Animals were allowed to move freely in their cages and 
were housed with littermates until the time of sacrifice, after which muscles were collected and 
immediately fixed in 3% PFA.   
3 Immunoprecipitation and cell fractionation 
After collecting equal numbers of cells for immunoprecipitation, pellets were lysed 30 minutes 
on ice in lysis buffer. The following lysis buffers were used; for immunoprecipitation of nestin 
(I): 50 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.05% SDS, 5 
mM EDTA, 5 mM EGTA, Complete Protease Inhibitor Cocktail (Roche Diagnostics); for 
immunoprecipitation of p35 (I), AR (III), Cdk5 (III) or Akt (III): 50 mM Tris (pH 7.5), 150 mM 
NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA, 5 mM EGTA including protease and 
phosphatase inhibitor cocktail. Samples were then centrifuged at 15000 × g for 10 min at 4°C. 
Supernatants were pre-cleared using protein A-Sepharose beads (Sigma-Aldrich) for at least 1 h 
at 4°C under rotation. 2 µg of each antibody was then added accordingly and incubated for 1-2 
hours, after which protein A-sepharose beads were included in the mixture for further 
incubation. Last, the samples were washed three times with lysis buffer, re-suspended in 
Laemmli lysis buffer (LLB) and boiled. Immunoprecipitates were analyzed with Western 
blotting. 
In cell fractionation assays (III), LNCaP cells were collected 48 hours after transfection. Cells 
were lysed in 10 mM Tris-HCl (pH 7.5), 1.5 mM MgCl2, and 5 mM KCl with protease and 
phosphatase inhibitors for 30 minutes on ice, after which lysates were cleared with 720 × g 
centrifugation for 3 minutes. The cytosolic (supernatant) and membrane fractions (pellet) were 
collected after separation (20000 × g, 30 minutes), after which membrane fractions were washed 
once (20000 × g, 30 minutes). LLB was added to samples, and they were finally boiled and 
analyzed with Western blotting. 
4 Western blotting 
For Western blot analysis (I, II, III), cells were harvested in LLB and boiled. Lysates were 
resolved by sodium dodecylsulphate-polyacrylamid gel electrophoresis (SDS-PAGE) and 
transferred to nitrocellulose (Protran, Sigma-Aldrich) (I) or polyvinyl difluoride (Millipore) (II, 
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III) membranes using the wet-tank transfer method (Hoefer). Membranes were blocked in 5% 
fat-free milk and incubated with primary and HRP-conjugated secondary antibodies (Table 6), 
and proteins were visualized using enhanced chemiluminiscence (GE Healthcare) on X-ray film 
(Fujifilm). Western blots in (I) were subjected to densitometric quantification using ImageJ 
software.  
Table 6 List of antibodies used and their specific application.  
Antibody Manufacturer (clone/number) Application Reference 
Actin Sigma-Aldrich (AC-40) WB I, III 
Akt Cell Signaling (#9272) WB, ICC III 
p-Akt Ser473 Cell Signaling (#9271) WB III 
AR Santa Cruz (N-20) WB, ICC III 
p-AR Ser308 Santa Cruz (sc-26406-R) ICC III 
β-catenin BD Biosciences (14) WB, ICC III 
Caspase-3 Cell Signaling (#9662) WB III 
Cdk5 Thermo Scientific (DC34) WB, IP I, II, III 
Cdk5 Santa Cruz (C-8) WB, IP II 
Desmin Santa Cruz (RD-301) WB I 
Desmin Cell signaling (#4024) WB, ICC II 
GAPDH Cell Signaling (#14C10) WB III 
GFP BD Clontech (JL-8) WB, IP I 
p-GSK3β Ser9 Cell Signaling (#9336) WB III 
Hsc70 StressGen (SPA-815) WB I, III 
Ki-67 AbCam (15580) WB I 
MHC Santa Cruz (H-300) WB I 
MyoD Santa Cruz (C-20) ICC II 
Myogenin Santa Cruz (M-225) WB I 
Nestin BD Pharmingen (611659)  WB I, II 
Nestin BD Pharmingen (556309), Rat 401 IP, ICC, IHC I, II 
Nestin AbCam (10C2) WB unpublished 
p-nestin Thr316 (Sahlgren et al., 2003) WB I 
p21 Santa Cruz (C-19) WB, ICC I, III 
p27 Santa Cruz (C-19) WB I, III 
p35/p25 Santa Cruz (C-19) WB, IP I, II, III 
PARP-1 Sigma-Aldrich (C-2-10) WB III 
Pax7 DSHB ICC II 
PCNA Sigma-Aldrich (P-8825) WB I 
S6 Cell Signaling (#2217) WB III 
p-S6 Ser235/236 Cell Signaling (#4858) WB III 
Troponin T Sigma-Aldrich (JLT-12) WB, ICC I, II 
Vimentin BD Pharmingen (550513) WB I, II 
Vimentin Cell signaling (D21H3) WB, ICC II 
Vimentin Sigma-Aldrich (V9) WB I 
Anti-rabbit HRP Promega WB secondary ab I, II, III 
Anti-rat HRP GE Healthcare WB secondary ab I, II, III 
Anti-mouse IgG HRP GE Healthcare WB secondary ab I, II, III 
Anti-mouse IgG1 HRP Southern Biotechnology WB secondary ab I, II, III 
Anti-mouse IgG2a HRP Southern Biotechnology WB secondary ab I, II, III 
Anti-mouse IgG2b HRP Southern Biotechnology WB secondary ab I, II, III 
Anti-mouse Alexa 488, 555, 633 Invitrogen ICC secondary ab I, II, III 
Anti-rabbit Alexa 488, 546, 633 Invitrogen ICC secondary ab I, II, III 
5 Immunocytochemistry and immunohistochemistry  
For immunocytochemistry (ICC), cells were plated on coverslips and processed as described for 
each experiment (I, II, III). Briefly, cells were fixed with 3% PFA, rinsed in phosphate buffered 
saline (PBS) and permeabilized with 0.5% Triton X-100 for 5-10 minutes. Samples were then 
washed with PBS and blocked in 1-5% BSA for at least 60 minutes, after which samples were 
incubated in primary antibodies according to specific needs (I, II, III). After three washes, 
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samples were incubated in secondary species specific Alexa fluorescent probe-conjugated 
antibodies (Invitrogen), diluted 1:500-1:1000. All antibodies are presented in Table 6 and used as 
described in specific references (I, II, III). After four consecutive washes, cells were mounted in 
Vectashield with DAPI (Vector laboratories) (I), or ProLong Gold with DAPI (Life 
technologies) (II, III). Same protocol was used for immunolabeling of myofibers, where single 
myofibers were transferred from one solution to another. Confocal images were produced using 
Zeiss LSM 510 META and Zeiss LSM 780 laser scanning confocal microscopes at the Cell 
Imaging Core at Turku Centre for Biotechnology. Images were processed with ImageJ, 
Bioimage XD and Zen Software (Zeiss) software.  
For immunohistochemistry (IHC) (II), muscle samples were collected and fixed in 3% PFA, 
dehydrated and embedded in paraffin. 2 µm thick sections were cut and collected on Superfrost 
plus slides (Thermo Scientific). Samples were stained with hematoxylin and eosin, or specific 
antibodies. IHC samples were imaged with Pannoramic 250 Slide Scanner (3DHISTECH) and 
analyzed with Case Viewer and Pannoramic Viewer software (3DHISTECH). The analysis of 
muscle fiber size and injured area was done manually using Pannoramic Viewer.  
6 Flow cytometry 
Transfected cells (III) were trypsinized, collected and re-suspended in propidium iodine buffer 
(40 mM Na-Citrate, 0.3% Triton X-100, 50 mg/ml propidium iodine [Sigma-Aldrich]) for 10 
minutes at room temperature. Samples were then analyzed in duplicates with LSRII flow 
cytometer (BD Biosciences) with HTS platform at Turku Centre for Biotechnology. The 
fraction of nuclear fragmentation events (sub G1) was gated for as a measure of cell death. 
7 Cdk5 kinase activity  
Primary myoblasts from 3 months old male mice (II) were induced to differentiate for 24 h, 
after which the cell were collected in PBS, and the cell pellet was lysed for 30 minutes in lysis 
buffer on ice (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.05% 
SDS, 5 mM EDTA, 5 mM EGTA, Complete Protease Inhibitor Cocktail [Roche Diagnostics], 
PhosSTOP Phosphatase Inhibitor Cocktail [Roche Diagnostics]), and samples were centrifuged. 
Prostate cancer cells (III) were treated and lysed as above. The soluble fraction was pre-cleared 
with sepharose G beads (GE Healthcare) and incubated with Cdk5 antibody (DC34) for one 
hour. Protein G sepharose was added and samples were incubated under rotation for 2.5 hours. 
Samples were washed once with lysis buffer and two times with kinase reaction buffer (50 mM 
HEPES pH 7.2, 0.1 mM EDTA, 0.1 mM EGTA, and 5 mM MgCl2). A mixture of ATP and 3 µCi 
radioactively labelled [γ-32P] ATP was added to the beads to a final concentration of 100 µM. 
Histone H1 (Sigma-Aldrich) or AR were utilized as Cdk5 substrates. Kinase reaction took place 
at 30°C for 30 minutes, and was discontinued by the addition of LLB and boiling. The samples 
were run on 12.5% SDS-PAGE and stained with Coomassie brilliant blue. After drying, the 32P-
labelled substrates were visualized on X-ray film. 
8 In vitro phosphorylation and mass spectrometry 
For analysis of endogenous AR PTMs (III), androgen stimulated VCaP and calyculin A-treated 
(50 nM, 10 minutes) AR overexpressing HEK293 cells (Rytinki et al., 2012) were collected and 
lysed, after which AR was immunoprecipitated as described above in the presence of protease 
and phosphatase inhibitors (Roche). Immunoprecipitates were resolved on SDS-PAGE, gels 
were stained with Coomassie brilliant blue, and the appropriate bands were excised from the 
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gels. In-gel digestion with trypsin, phosphopeptide enrichment by TiO2 affinity 
chromatography and analysis by liquid chromatography tandem mass spectrometry (LC-
MS/MS) were performed as described previously (Imanishi et al., 2007) with some 
modifications. For LC-MS/MS analysis of the digests with and without enrichment, an EASY-
nLC II nanoflow liquid chromatograph coupled to LTQ Orbitrap Velos mass spectrometer and 
an EASY-nLC 1000 coupled to a Q Exactive mass spectrometer (Thermo Fisher Scientific) were 
used. Database search was performed against Swiss-Prot database (Homo sapiens) using 
Mascot 2.4.1 (Matrix Science) via Proteome Discoverer 1.4 (Thermo Fisher Scientific). Label-
free quantification was performed using Progenesis LC-MS 4.1 (Nonlinear Dynamics).  
For identification of in vitro Cdk5 phosphorylation sites on AR (III), AR was 
immunoprecipitated from VCaP cells as described before. Immunoprecipitates were then 
washed in kinase reaction buffer (10 mM HEPES [pH 7.2], 60 mM NaCl, 0.5 mM CaCl2, 2.5 
mM EGTA, and 2 mM MgCl2). A mixture of ATP (Sigma-Aldrich) and 3 µCi [γ-32P] ATP 
(final concentration 100 µM) and purified active Cdk5/p25-complex (a kind gift from Professor 
Sin-Ichi Hisanaga) was added to the beads. The kinase reaction took place at 30 °C for 30 min, 
after which LLB was added, samples boiled, and samples treated as described above for 
identification of endogenous AR PTMs by mass spectrometry.  
For identification of in vivo Cdk5 phosphorylation sites on the AR (III), Cdk5 was 
downregulated with siRNA in LNCaP cells and incubated for 48 hours. Cells were then 
collected in ice-cold PBS and subjected to AR immunoprecipitation in the presence of 
phosphatase inhibitors as described previously, run on 7.5% SDS-PAGE and analyzed by LC-
MS/MS as described for VCaP and HEK293 cells.  
9 Statistical analysis 
GraphPad Prism 5.0 statistics software was used to analyze statistical significance where needed 
(I, II, III) and analysis method was chosen according to experimental requirements (indicated 
in each experiment). p<0.05 was considered significant and marked with *; p<0.01 marked with 
**; p<0.005 marked with ***. Results are presented as mean±standard error of the mean 
(S.E.M.) and n≥ 3.  
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RESULTS AND DISCUSSION 
1 Cdk5-nestin crosstalk adjusts myogenic differentiation (I) 
Previous reports clearly indicated that nestin plays an important role in the regulation of the 
apoptotic functions of Cdk5 (Sahlgren et al., 2006). In addition, both proteins were found to be 
expressed in muscle (Sahlgren et al., 2003). At the time of this work, two other laboratories 
manifested an interest towards nestin-mediated scaffolding of Cdk5 at NMJs (Mohseni et al., 
2011; Yang et al., 2011). In contrast to the neuromuscular models, the specific objective of this 
project was to answer whether nestin regulates the activity of Cdk5 to drive the pace of 
myogenic differentiation, given that nestin is prominent in mesenchymal stem cells and 
expressed in differentiating myotubes. Although the studied tissue types are the same, there is 
clear distinction in NMJ development and muscle differentiation both functionally and 
temporally. To address the differentiation signaling aspect, differentiating C2C12 mouse 
myoblasts were primarily utilized as a model system.  
1.1 Nestin fine-tunes the pace of muscle differentiation 
Nestin is dynamically expressed during myoblast differentiation, starting from the proliferating 
myoblasts. To address the specific role of nestin during myogenic differentiation, nestin protein 
was downregulated using RNA interference (RNAi) in proliferating C2C12 myoblasts, after 
which differentiation was induced by serum withdrawal. We observed that the absence of nestin 
caused an increase in the expression levels of early cell cycle-exit markers (p21, p27) and the 
myogenic transcription factor myogenin, and the cells also showed enhanced expression of 
muscle structural proteins (troponin t, myosin heavy chain; MHC), which are strongly induced 
upon initiation of differentiation (I: Figure 1). On the contrary, myoblast proliferation was not 
altered by the downregulation of nestin (I: Figure 1). The assessment of differentiation was 
executed both by Western blotting, as well as counting of MHC-positive differentiating C2C12 
cells. Although efficient transfection was difficult to obtain in primary cells, nestin 
downregulation also promoted differentiation of freshly isolated myoblasts (I: Figure 3). While 
nestin downregulation seemed to enhance the differentiation pace, the reverse could be 
observed when nestin was overexpressed: the expression of differentiation markers was clearly 
suppressed after Nest-640 transfection compared to GFP control (I: Figure 2). As the true effect 
of nestin on differentiation may have been partly masked by the weak transfection efficiency of 
Nest-640 in the heterogeneous Western blot lysates, differentiating cells were quantified by 
immunolabeling of the differentiation markers MHC and troponin-t. The expression of the 
GFP-tagged Nest-640 was found to strongly delay (or nearly abolish) differentiation compared 
to GFP controls, when GFP/MHC and GFP/troponin t double positive cells were counted (I: 
Figure 2). Thus, when nestin is found in excess amounts in proliferating myoblasts, the process 
of differentiation is severely hampered.  
Together these results suggest that nestin is not a passive bystander in muscle precursors, but 
that it is rather required for the fine adjustment of initiation of the differentiation process. Due 
to its expression in proliferative cells, nestin is often expected to affect cell division. Instead, we 
found that nestin acts on the cell cycle of myoblasts only after induction of differentiation, as its 
depletion causes premature differentiation after a stimulus, and as nestin siRNA did not affect 
myoblast proliferation. By standing at the gates of differentiation, nestin seems to regulate the 
earliest events of differentiation, the cell cycle exit, which is crucial for commitment of 
differentiation. The precocious cell cycle exit, as seen by increased cell cycle inhibitor 
56 
 
Results and Discussion 
expression in nestin siRNA transfected myoblasts, also results in earlier expression of muscle 
structural proteins as the differentiation process as a whole is accelerated. These experiments 
demonstrated for the first time an unexpected role for nestin in cell differentiation, rather than 
proliferation. As nestin is widely and specifically expressed in mesenchymal stem cells in 
numerous tissues (Table 3), its role in initiation of differentiation of other cell types would be 
highly interesting to assess. Although the expression pattern of nestin during muscle 
differentiation is unique, suggesting it may play a role at several levels in this particular system, 
it is possible that the presence and balance of nestin in mesenchymal stem cells may determine 
differentiation of other cell lineages as well.  
1.2 The importance of the nestin scaffold in regulation of p35 turnover in myoblasts 
Cdk5 activity is known to be required for muscle cell differentiation (Lazaro et al., 1997). To 
establish a link between the observed nestin-associated effects on differentiation and Cdk5, the 
activity of Cdk5 was constrained by inhibition with roscovitine, as well as with the expression of 
DN-Cdk5, alongside nestin downregulation with specific siRNA. While nestin knockdown 
cultures differentiated at a faster pace than Scr control cells according to expectations, the 
abrogation of Cdk5 activity with either method effectively counteracted the hastening effect of 
nestin ablation (I: Figure 5), suggesting that the proteins do in fact act in the same signaling 
pathway. Thus, similarly to that which Sahlgren and colleagues (2006) showed to occur in dying 
neuronal progenitor cells, the depletion of nestin seemed to cause an increase in Cdk5 activity, 
which in the muscle context would translate into a faster differentiation pace. To provide 
verification for this hypothesis, the protein levels of Cdk5 activators were analyzed in nestin-
modulated myoblasts. Supportive to our hypothesis, downregulation of nestin did increase the 
cleavage of p35 to the more stable p25 (I: Figure 6), a process known from previous reports to 
be required for C2C12 differentiation and generation of adequate Cdk5 activity (de Thonel et 
al., 2010). Overexpression of Nest-640 did in turn decrease p25 generation at the whole 
population level, again a process presumably masked by the low transfection efficacy (I: Figure 
6). At the single cell level, the hampered p25 generation would be expected to have strong 
inhibitory effects on the initiation of the differentiation program. Unfortunately, the absence of 
suitable tools, such as antibodies that would allow the assessment of p35 kinetics through 
microscopy at the single cell level, debilitates the detailed examination of the exact signaling 
events. Our results, together with previously published data did, however, support that nestin 
regulates p35/p25 turnover in differentiating myoblasts, and consequently Cdk5 activation at 
the right time, and in the correct place within the cell.  
Nestin is a minor IFP in muscle in terms of protein abundance and requires a polymerization 
partner to form filaments. It is known from before that nestin exists in both soluble and 
filamentous pools, the stoichiometry of which changes dynamically during myoblast 
differentiation due to phosphorylation (Sahlgren et al., 2003). Thus, we asked ourselves whether 
the solubilization of nestin has actual consequences for p35 signaling. To address this issue, we 
utilized vimentin positive (v+) and negative (v-) subclones of SW13 adenocarcinoma cells. As 
the SW13 cells do not express other IFPs that would permit nestin filament formation, Nest-640 
remains completely soluble in v- cells, while it incorporates at least partially into normal 
filaments in v+ cells. Interestingly, co-transfection of Nest-640 and p35, and the following p35 
co-immunoprecipitation from both v+ and v- cell lines, demonstrated that soluble nestin (in v- 
cells) enhances Cdk5/p35 complex formation (I: Figure 6). The association of Cdk5 and p35 
driven by soluble nestin also has a stabilizing effect on p35 after calpain activation with A23187 
(I: Figure 6), suggesting that when Nest-640 is transfected into myoblasts (or HeLa cells [I: 
Figure 6]), p35 is stabilized by the soluble Nest-640 particles. This nestin-mediated 
sequestration of p35 is likely to perturb the initiation of myoblast differentiation. When p35 
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cannot be cleaved to p25, differentiation does not occur. Similarly, Cdk5/p35 complex 
formation has been reported to decrease p25 generation in neurons (Kamei et al., 2007). 
Whether the effect of nestin occurs at the level of Cdk5 activation or re-localization (both of 
which are affected by p25 generation [Patrick et al., 1998, Asada et al., 2008]) cannot be 
answered at this moment, as not even the myogenic substrates of the kinase are understood.  
These results did highlight the important effect of nestin solubility on Cdk5 activity; a feature of 
IFs often overlooked. The PTMs of IFs not only affect the localization of the proteins, but 
usually promote filament disassembly (Yamaguchi et al., 2005). We found that in the case of 
nestin, its solubilization has a function in Cdk5-mediated scaffolding, and it seems to act to re-
direct kinase activity or suppress hyperactivation of the kinase to prevent unwanted activities 
that may be harmful for the differentiation process. Thus, when nestin is targeted with siRNA 
in myoblasts, also the soluble pool of nestin is depleted, leading to uncontrolled cleavage of p25 
and stimulation of differentiation. Similar features of other IFPs have been described; not only 
in relation to phosphorylation, which has been under intense investigation, but also other 
factors regulate the solubility and signaling properties of IFs. For example, the regulation of 
lamin solubility and its displacement to the nucleoplasm by LAP2α is a decisive factor in 
myoblast cell cycle exit (Gotic et al., 2010). Recently there has been a great interest to 
understand how substrate stiffness regulates (at least partly through phosphorylation) the 
assembly of both cytoplasmic and nuclear IFs (Murray et al., 2014; Swift et al., 2013) with 
prominent consequences on cell fate. Thus, the solubility of IFPs has become a widespread 
interest in the research community. 
Another intriguing detail is the nature of the filament structures that nestin forms. As described 
in the review of literature, soluble nestin-vimentin differentially regulates IDE activity (Chou et 
al., 2009), not only stressing the importance of nestin solubility in regulation of IDE enzymatic 
activity, but also underscoring the need of an appropriate polymerization partner even in a 
non-filamentous state. On the other hand, also vimentin expression and turnover is regulated 
by nestin, at least under particular circumstances (Chou et al., 2003; Eliasson et al., 1999). With 
the help of primary myoblasts isolated from vimentin null mice, we found that the ablation of 
vimentin did cause an increase in the differentiation pace, presumably through alteration of 
nestin dynamics during differentiation (I: Figure 4). Although nestin protein levels were not 
greatly decreased in vimentin-/- myoblasts, the filament properties of nestin could be 
dramatically different, even if nestin looks similar in WT and vimentin-/- myoblasts under the 
microscope, at least at later stages of differentiation when desmin expression has been induced 
(Figure 10). Whether nestin forms filaments with vimentin or desmin, is probably a matter of 
temporal regulation, as 
vimentin is substituted by 
desmin during differentiation. 
Preferentiality of nestin 
polymerization partners in 
muscle has not been 
addressed. In general, the 
knockout of desmin has little 
effect on the appearance of 
nestin (Carlsson et al., 1999), 
highlighting the dynamic 
compensation of individual 
IFs by other family members.  
In terms of cytoskeletal 
regulation of Cdk5, it is 
Figure 10 Nestin in proliferating and differentiating primary vimentin-/- 
myoblasts. Initially, when proliferating vimentin null myoblasts have low 
expression levels of desmin, the nestin cytoskeleton forms truncated filaments 
(left panel). In differentiated vimentin knockout myotubes, where desmin 
levels are generally high (48 h), the nestin cytoskeleton forms long filaments 
that follow the shape of the myotubes, similar to vimentin WT myotubes (not 
shown). 
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tempting to speculate that other IF substrates (such as lamins or neurofilaments) may 
constitute a similar scaffold for the kinase that impact cell fate determination. Similarly to IFs, 
also actin seems to form a regulatory scaffold for Cdk5/p39; if actin polymerization is disturbed 
by cytochalasin D treatment, p39 is dramatically reorganized and Cdk5 activity increased 
(Humbert et al., 2000). Although the mechanism is very different, other cytoskeletal elements 
play a crucial role in correct Cdk5 regulation, especially in neurons, but perhaps also in other 
model systems.   
1.3 Cdk5 talks back: self-regulation through nestin 
Intriguingly, a further level of complexity of the regulatory function of the nestin scaffold 
system is added by Cdk5 itself. It is known that the Cdk5-mediated phosphorylation of nestin 
promotes solubilization of the filament structure (Sahlgren et al., 2003; Sahlgren et al., 2006). If 
Cdk5 activity is inhibited in differentiating myoblasts, phosphorylated nestin (p-Thr316) is 
diminished together with the soluble nestin pool (Sahlgren et al., 2003). As soluble nestin 
attracts Cdk5/p35 complex formation to protect p35 from calpain-induced deregulation, it 
seems that Cdk5 can modify its own activation through acting on the solubility state of nestin. 
This hypothesis is difficult to study in differentiating myoblasts due to the presence of many 
simultaneous IFPs that change dynamically during the process, all of them affecting the nestin 
cytoskeleton in their own way. It is however important to note, that the levels of soluble and 
phosphorylated nestin are elevated during differentiation (Sahlgren et al., 2003), suggesting that 
restriction of Cdk5 activity in an auto-regulatory feedback-loop might be required at later 
stages of differentiation. During myotube formation, the nestin cytoskeleton is actively re-
modelled, also including an increase in nestin protein levels before it is abolished completely 
from mature muscle. Interestingly, if Cdk5 activity is inhibited directly (with roscovitine or 
DN-Cdk5), or indirectly through PKCζ (with PS peptide inhibitor), nestin levels are held low, 
as differentiation is not initiated at all, and the characteristic up-regulation of nestin protein 
levels during differentiation does not occur (I: Figure 7). It is possible, that the up-regulation of 
nestin during differentiation (which is initiated by Cdk5 itself) is required for temporally 
appropriate regulation of Cdk5 activity, and the nestin cytoskeleton may serve different 
purposes during different time points of the differentiation process.  
Thus, the nestin-mediated scaffolding of Cdk5 during muscle differentiation closely resembles 
its cytoprotective function during neuronal apoptosis (Sahlgren et al., 2006): when nestin is 
depleted, p35 is uncontrollably processed to p25, leading to hyperactivation of Cdk5 with the 
outcome of increased cell death or 
increased myogenic differentiation 
(Figure 11). In the NMJ system, the 
role of nestin in regulation of Cdk5 
is slightly different due to intrinsic 
distinctions between the systems. 
For example, p25 is not known to 
have a function at the NMJs. 
Whereas nestin siRNA increases 
p25 cleavage in differentiating 
myoblasts (a process associated 
with Cdk5 hyperactivation), nestin 
depletion (or mutation of the 
Cdk5-phosphosite) decreases both 
membrane bound and total Cdk5 
activity at NMJs (Yang et al., 2011), 
Figure 11 Cdk5-nestin crosstalk determines muscle 
differentiation, NMJ clustering and neuronal apoptosis. Cdk5 
regulates the turnover of its own scaffold through phosphorylation, 
which consequently enhances Cdk5/p35 complexing, at the expense 
of p25 generation during differentiation and apoptosis. At the NMJ, 
only p35 has been found to be involved in Cdk5 activation. 
Depending on the model system, the promotion of Cdk5/p35 has 
different effects on the cellular outcome.    
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which eventually prevents NMJ dispersion. In other words, (phosphorylated) nestin is first 
required for activation of Cdk5/p35 at NMJs. Activated Cdk5 phosphorylates and increases 
soluble nestin at NMJs (Yang et al., 2011), leading to further Cdk5/p35-complex formation at 
the membrane. Thus, in both models soluble nestin causes Cdk5/p35 stabilization. At NMJs, 
soluble nestin/Cdk5/p35 is required for normal NMJ development, and depletion of nestin 
would disturb Cdk5 activation. On the other hand, we know that calpain-mediated p25 
generation is required for muscle differentiation (de Thonel et al., 2010). When (hypothetically 
soluble) nestin is depleted from differentiating myoblasts, p35 is uncontrollably cleaved by 
calpains, causing an increase in Cdk5/p25 generation, which promotes differentiation. When 
nestin is overexpressed using the Nest-640 construct, the balance of nestin filaments is severely 
hampered. A noticeable fraction of the overexpressed Nest-640 remains soluble (I: 
Supplementary figure 2), and it can be hypothesized, that this particular fraction severely 
interferes with proper Cdk5 activator turnover. However, further experiments using phospho-
deficient nestin-mutants would be a good addition to pinpoint the exact role of Cdk5-mediated 
phosphorylation in its auto-regulation during muscle differentiation. Thus, the activity of Cdk5 
is dynamically regulated by the kinase itself, through nestin, in a complex auto-regulatory 
feedback loop.   
This work demonstrated for the first time the involvement of nestin in regulation of a 
differentiation process. Through intricate means, nestin and Cdk5 were found to regulate each 
other in a highly balanced system, which is prone to signaling inputs in a dynamic 
environment. Similar IFP-kinase interactions have been described in various contexts, 
highlighting that the IFPs, their interactions as well as their often unnoticed assembly state, are 
important fine-tuners of signaling processes that determine cellular fate. Through its actions on 
Cdk5 and its activators, nestin negatively controls the cell cycle exit (or perhaps promotes a less 
differentiated state) after a permissive differentiation stimulus has been granted. Besides Cdk5, 
it is equally plausible that the functions nestin reach to yet unidentified proteins. Also, whether 
nestin acts at the doorways of differentiation in other cellular systems, needs to be addressed in 
future experiments.  
2 Nestin regulates skeletal muscle homeostasis and regeneration in vivo (II) 
While the previous study focused on the molecular signaling functions of the nestin scaffold 
with regards to Cdk5 regulation mainly in C2C12 myoblasts, the aim of the following study was 
to address how the genetic knockout of the nestin gene affects skeletal muscle, and therefore, 
body homeostasis. Whereas the nestin deficient mouse was described to have a NMJ 
organization defect, the authors did not observe other prevalent phenotypes or dysfunctions 
(Mohseni et al., 2011). In addition, skeletal muscle as such was described as having no 
phenotype under normal conditions. As many IFP knockout models appear normal until they 
are challenged, our main aim was to study skeletal muscle under stress in mice lacking nestin. 
2.1 Gender and age-dependent variability in myoblast p35 expression  
Data from myoblasts (I) indicated that the transient downregulation of nestin in C2C12 
myoblasts increased the processing of p35 to p25 upon serum withdrawal, thereby accelerating 
the progress of differentiation. Therefore, primary myoblast cultures were initially isolated from 
WT and nestin deficient mice, and differentiated in low-serum media to examine their behavior 
in relation to previous results. Contrary to our expectations, there was no significant change in 
expression of differentiation markers between WT and nestin null myoblasts (II: Figure 1), and 
myoblasts from both genotypes seemed to form myotubes well in culture. Hence, 
differentiation seemed to occur regardless of the nestin status of the cells. We could not detect 
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any differences in the organization or protein levels of other major IFPs in nestin null 
myoblasts that would suggest direct compensation of the lack of nestin (II: Figure 1). 
Interestingly, a similar null phenotype of differentiating myoblasts has been observed with 
other IFP knockout model systems: when for example desmin, the major IFP in muscle, is 
genetically targeted, desmin-/- myoblasts seem to form myotubes at comparable rates to their 
wildtype counterparts (Li et al., 1997; Milner et al., 1996). On the contrary, when desmin is 
transiently downregulated in C2C12 cells, a clear defect in myoblast differentiation is discerned 
already at early stages (Li et al., 1994), pointing out that there may be some unidentified 
acquired compensatory mechanism in the desmin null mice that allow cell functioning in a 
situation that would otherwise result in excruciating chaos. Thus, it is feasible that a comparable 
situation occurs in nestin knockout myoblasts, explaining the difference of transient nestin 
downregulation compared to genetic targeting. It should also be taken into consideration that 
there may be molecular differences in the immortalized C2C12 cells compared to primary 
myoblasts that may affect the expected outcome. C2C12 cells do, however, have a similar setup 
and dynamics of the major IFPs, as well as Cdk5-related proteins, making them a convenient 
model system to study the function of nestin. 
Although the rate of differentiation was similar in all studied myoblast cultures, which were 
derived from mice of different age and gender, p35 protein levels were found slightly elevated in 
nestin knockout myoblasts from young (P3) males, and the difference was even more striking in 
adult (2 month old) male-derived myoblast cultures (Figure 12). Even though p35 levels were 
highly upregulated in male nestin null myoblasts, p25 was never found to be altered. As p25-
content is the key switch to allow Cdk5 activation and differentiation (de Thonel et al., 2010), it 
is perhaps not completely surprising that no change in differentiation could be distinguished 
either. Unexpectedly, female myoblasts never showed genotype-derived changes in p35 protein 
levels (Figure 12). The mechanism of p35 accumulation in nestin null myoblasts is not clear, but 
is not likely to be a direct consequence of nestin ablation, the effect being both gender- and age 
specific. To more directly analyze the impact of increased p35 on Cdk5 activity in nestin-/- 
myoblasts, Cdk5 was immunoprecipitated from differentiating myoblasts from adult male mice, 
and subjected to kinase activity measurements. As a result of increased p35 expression, total 
Cdk5 kinase activity towards histone was found to be dramatically increased in nestin null 
myoblasts after 24 hours of differentiation (II: Figure 1), a relatively early time point of 
differentiation when Cdk5 activity is known to increase strongly.  
It can only be speculated at this time that the highly active Cdk5 in nestin knockout myoblasts 
is sequestered by p35 mainly to the membrane and cytoplasm. As nestin null myoblasts showed 
no increased p25 generation during any time points after induction of differentiation, the 
overly active kinase would not perform its differentiation-related functions any differently from 
the wildtype situation, and hence, no change in the differentiation pace could be distinguished. 
Regardless of the mechanism utilized to target nestin (by siRNA in I, or genetically in II), which 
seem to differently affect p35 turnover, the absence of the nestin scaffold in myogenic tissue 
causes deregulation of Cdk5 activity in both cases. To fully understand the myogenic signaling 
of Cdk5, it would be essential to analyze the substrates of the kinase in muscle, and to 
understand completely the distinction in substrate specificity between p35 and p25, i.e. why p25 
generation is essential in the first place. After all, the kinase is likely to have differentiation-
related substrates, which do not relate to its functions at the NMJ at all, as evidence supports 
that Cdk5 abrogation has direct effects on the expression of early myogenic transcription 
factors and somitogenesis (Philpott et al., 1997). Furthermore, it would be highly interesting to 
study more specifically Cdk5 activity levels in other tissues in the nestin null mice. Such 
dramatic changes in kinase activity, as observed in the myoblasts, could be detrimental under 
particular circumstances, such as apoptosis or during tissue-specific stress (e.g. in kidneys), or 
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alternatively, in Cdk5-related disease contexts (e.g. diabetes or cancer). As p35 levels did not 
reveal great variation in muscle lysates, it is probable that a specific stimulus (such as myoblast 
activation in this case, or a stress situation in other organs) may be required to distinguish 
altered Cdk5 signaling and related phenotypes in the nestin null mouse.  
 
 
2.2 Nestin-/- mice have less lean mass and show signs of spontaneous muscle regeneration 
Regardless of the unexpected myoblast data, we wanted to make a comprehensive analysis of 
nestin-/- mice with emphasis on skeletal muscle, and a series of follow-up experiments were 
designed to cover the remaining questions regarding muscle health and stem cell function. 
First, the weight of male mice was measured from the age of 1 month onwards. During the first 
time point (age 4 weeks), the nestin-/- mice were indistinguishable from the control animals, but 
from the time they reached sexual maturity (circa 8 weeks onwards), nestin deficient mice 
started to appear smaller in terms of total body weight. At the age of 3 months, the weight 
difference was small, but recurring (less than one gram, statistically significant) (II: Figure 2). 
At an old age (>15 months) nestin-/- male mice weighed significantly less (divergence more than 
7 grams by average) (II: Supplementary figure 1), including some remarkably lean individuals. 
To understand the basis of the observed differences, mice of different age and gender were 
examined with EchoMRI body composition analyzer for lean and fat mass distribution. While 
the mean fat mass was not significantly different, nestin-/- male mice did show significant 
reductions in lean mass at the age of 3 months and in the age group >15 months (II: Figure 2, 
Supplementary figure 1). The body weight and body composition analysis revealed a similar 
trend for 12 week old females (II: Supplementary figure 1), demonstrating the gender-
independent nature of the lean nestin-/- phenotype. As an interesting note, the lesser body 
weight of nestin-/- mice seems to stem nearly directly from the reduced amount of lean mass, at 
least when genotypic mean values are compared.  
To further dissect the cause of the lean mass phenotype, individual skeletal muscles from the 
back limbs of mature male mice were weighed, some of which were found to be significantly 
lighter in weight. Both the TA (mainly a fast twitch muscle) and EDL (fast twitch) muscles 
Figure 12 Expression of p35 in proliferating and differentiating primary nestin-/- myoblasts. Myoblast cultures were 
isolated from mice of different age and gender and induced to differentiate, after which samples were analyzed for p35 
expression using Western blotting. p35 levels did not differ greatly in male (A) or female (B) pup (P3) myoblast cultures, 
except slight elevations of p35 in knockout (KO) male pups compared to wildtype (WT). p25 is not visible due to short 
exposure of the film. On the contrary, nestin null male adult myoblasts showed great up-regulation of p35 in all time 
points analyzed when compared to WT samples (C), whereas this trend was never observed in females (D). p25 
generation can be faintly detected at 24 hours in both males and females, but never showed genotype-dependent 
differences. The p35 double band likely represents differentially modified PTM isoforms.  
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weighed significantly less in nestin-/- mice, whereas the slow soleus showed no marked weight 
alterations between genotypes (II: Figure 3). TA and soleus are typical weight bearing muscles. 
As the size of individual myofibers was similar in WT and nestin null mice (II: Figure 3), the 
myofibers do seem to mature normally, and hence, a defect maturation is not a likely 
explanation for the difference in muscle weight. Furthermore, the amount of Pax7+ satellite 
cells in nestin knockout muscle was comparable to the WT (II: Figure 1), suggesting that the 
lean muscles of mice lacking nestin are not a consequence of satellite cell deficiency either. 
When examining the detailed histology of nestin null TA, EDL and soleus muscles, we were 
greatly surprised to find an increased incidence of myofibers containing centrally located nuclei 
in TA and soleus muscles (II: Figure 4), indicating that there is a spontaneous 
degeneration/regeneration cycle in nestin deficient muscle. A mild regenerative phenotype was 
not observed by Mohseni and co-authors (2011), possibly due to the fact that the muscle 
phenotype varies with muscle types, and can therefore be easily missed. Furthermore, it was 
obvious that the severity of the muscle regeneration/degeneration phenotype varied between 
individuals, as it was found to be more severe in certain animals, and more evident in particular 
muscles. We could not detect other signs of severe muscle malfunction, such as intramuscular 
fat accumulation or spontaneous fibrosis, which can be typically found in more difficult muscle 
conditions (II: Figure 4).  
Thus, in contrast to what was previously reported, we found that nestin-/- mice do show a 
reduction in muscle mass and have a mild spontaneous regenerative skeletal muscle phenotype. 
The cause of the mild regenerative phenotype observed in nestin null mice remains to be 
identified, but seems to stem from the properties of the mature myofibers. As we could not 
observe differences in satellite cell numbers, and as the differentiation as measured by myoblast 
commitment and in 2D-cultures was apparently normal, the regeneration does not seem to 
stem from aberrant myoblast behavior (II: Figure 1). Given that nestin null muscle develops 
normally (Mohseni et al., 2011), and that any differences in body weight seems to come with 
age (and does not originate from differences in myofiber size per se), it seems as myofibers 
indeed develop and mature normally. Based on these observations, it seems particularly clear 
that the observed lean muscles and the increased number of regenerating myofibers in nestin 
knockout mice derive from myofiber-intrinsic defects that are likely to accumulate during 
minor muscle stress, such as exercise. As innervation of muscle is a major pathway that 
determines muscle growth, it is possible that the defective NMJs of nestin knockout mice 
(Mohseni et al., 2011) may contribute to the observed phenotype. On the other hand, the 
regenerating fibers were often dispersed evenly throughout the muscle, suggesting that the 
phenotype is not caused by impaired neuronal input. As nestin is found in large quantities at 
myotendinous junctions as well, it is possible that it may play a role in the mechanosensing 
properties of the muscle, which is only revealed when the muscle is under stress. Therefore, it is 
possible that muscle lacking nestin is more fragile to tissue stress, which is the case of many 
other IFPs. However, these questions need to be addressed more carefully with further 
experimental data.   
2.3 Muscle healing after injury is delayed in nestin-/- mice 
Finally, to study the functionality of nestin deficient muscle during ultimate stress, a muscle 
injury model was established. In brief, muscle injury was induced under anesthesia by a 
transverse cut in the TA muscle and the mice were allowed to recover freely motile in their 
cages until the time of sacrifice. Based on immunohistochemical staining of nestin during 
different time points of recovery after injury, nestin was first upregulated in proliferating 
myoblasts in the site of injury after 2-3 days. Later, when regenerating myofibers started to 
dominate the wound area (after one week), nestin was detectable in the newly forming 
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myotubes, and could be detected until day 28 after injury (II: Figure 5). Given the long-lasting 
expression of nestin in our model system, day 28 was finally selected as the end-point to study 
whether there is a difference in muscle healing between genotypes. The degree of regenerating 
muscle was determined by the area occupied by regenerating myofibers (identified by centrally 
located myonuclei) compared to the total muscle area, and was found to be greatly increased in 
nestin null muscle, suggesting that nestin is required for proper muscle healing (II: Figure 5). 
The muscle scar area was histologically indistinguishable between genotypes, suggesting that 
also the impaired regeneration stems from a myofiber-intrinsic defect (II: Figure 5), and is 
likely to originate from same causes as the spontaneous regeneration. We could not observe 
histological changes in the early time points in regenerating muscle between WT and nestin 
null muscle (Figure 13), which suggests that myofiber degeneration and differentiation occurs at 
similar times in both genotypes.  
 
 
Figure 13 Early stages of muscle regeneration in WT and nestin null muscle. The TA muscle of WT and nestin null 
(KO) muscle was subjected to a cut injury, and the injury was allowed to heal for indicated time points. Samples were 
collected for H&E staining. Both genotypes showed similar pattern of early regeneration at a histological level, i.e. death 
and degeneration of injured myofibers, which appear light and fragmented under the microscope (day 2), immune cell 
infiltration (particularly evident at day 3), and finally, myotube formation through myoblast fusion (day 7). Large images 
are 2 x 2 mm, and inserts 0.5 x 0.5 mm in size.  
 
Together these results highlighted that nestin is required for maintenance of normal muscle 
homeostasis, and that its absence delays muscle healing. Although the phenotype is not severe, 
the results do indicate that nestin is an IFP that will affect muscle condition and health. The 
genetic ablation of other IFPs has revealed their functions in many aspects of muscle biology. 
Desmin seems to be a major IFP required for myoblast commitment, but it is also an active 
organizer of muscle architecture (Agbulut et al., 2001; Li et al., 1994; Li et al., 1997; Milner et al., 
1996). Recent studies of two separate synemin knockout mouse models revealed that this IFP is 
involved in maintenance of membrane integrity and muscle structure (Garcia-Pelagio et al., 
2015; Zhenlin et al., 2014). Also keratin 19 seems to act as a structural component of muscle 
(Stone et al., 2007). IFs are also essential parts of the cell adhesion structures that maintain 
tissue integrity during stress; a fundamental function of IFs which will inevitably affect tissue 
stress tolerance. Therefore, it seems as the IFs are especially important for skeletal muscle 
integrity, probably by acting as organizing building blocks of this highly stress-prone organ, at 
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least partly through their scaffolding functions exerted towards signaling proteins. In this sense, 
the functions of nestin that have portrayed it as a signaling scaffold for Cdk5 during 
differentiation, as well as its role in maintaining mature and regenerating muscle (perhaps 
through Cdk5-dependent mechanisms as well), suit well in the proposed functions of other IFs 
in skeletal muscle. However, all IFPs seem to have highly specialized and unique functions, as 
demonstrated by the various muscle phenotypes of IFP knockout animals. 
3 Cdk5 controls prostate cancer cell proliferation through Akt and AR (III) 
Although prostate cancer genomics is complicated by the heterogeneity of the tumors, it can be 
roughly stated that some of the most common genetic lesions in aggressive prostate cancer are 
found in AR, TP53, PTEN, and SPOP (a subunit of a E3 ubiquitin ligase), and RB1, but also 
include gene fusions between TMPRSS2 and the Ets family of transcription factors (e.g. 
TMRPSS2-ERG fusion products) (Barbieri et al., 2012; Taylor et al., 2010). Most therapeutic 
approaches against prostate cancer are targeted towards the AR, but the tolerance against these 
drugs in CRPC calls for the need of novel strategies. There is, therefore, a great need to 
understand prostate cancer development and progression in terms of gene alterations and 
signaling pathways that contribute to cellular oncogenic behavior. 
3.1 Nestin - a Cdk5 scaffold in prostate cancer? 
Prior to initiation of this work, there were indications pointing towards seemingly separate 
roles for both Cdk5 and nestin in prostate cancer cell motility (Kleeberger et al., 2007; Strock et 
al., 2006), but only limited information existed on the role of the proteins in prostate cancer 
proliferation. Since then, several publications have added to the knowledge of both Cdk5 and 
nestin in cancer, however leaving often considerable gaps regarding their specific signaling 
functions. Interestingly, both nestin (Reimer et al., 2009) and Cdk5 (Kino et al., 2007; Kino et 
al., 2010) have been separately implicated in regulation of members of the steroid hormone 
receptor-family: the Cdk5-mediated N-terminal phosphorylation of GR (Ser203, Ser211) was 
associated with suppression of receptor activation through altered GR/co-activator interactions 
(Kino et al., 2007). Thus, Cdk5 was found to affect the specificity of GR targets, thereby fine-
tuning its signaling capacity. Phosphorylation of GR Ser203 and Ser266, detected with 
phospho-specific antibodies, was also increased in vimentin-positive subclones of glioma cells 
(where nestin remains filamentous) compared to subclones lacking vimentin (soluble nestin) 
(Reimer et al., 2009). As manipulation of the vimentin cytoskeleton has direct consequences on 
nestin solubility and stability, the Cdk5-related scaffolding properties of nestin (if relevant) 
would be altered in this model system. Given the strong link between nestin and Cdk5 in 
muscle and neuronal models (Sahlgren et al., 2003; Sahlgren et al., 2006), it is inviting to raise 
the question whether the nestin-dependent GR regulation could involve a Cdk5-dependent 
mechanism. With this hypothesis in mind, I speculated further whether a similar connection 
could exist in prostate cancer, where the steroid hormone receptor AR is one of the key drivers 
of prostate carcinogenesis. Steroid hormone receptor PTMs are known to play a crucial role in 
receptor transactivation, localization, stabilization and target gene selection. Thus, the first 
purpose of this project was to assess whether Cdk5 could regulate AR together with (or 
independently of) nestin in prostate cancer cells.  
The possible role of nestin as a Cdk5 scaffold in prostate cancer is an obvious question with 
regards to the theme of this thesis. However, a few key observations suggest that nestin-
mediated scaffolding of Cdk5 is not unconditionally crucial for Cdk5 functions in prostate 
cancer. Firstly, nestin is not very abundantly expressed in prostate cancer cells and is found 
prominently in filamentous organization only in PC-3 cells, and at lesser extent in DU-145 
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prostate cancer cells (Kleeberger et al., 2007). 22Rv1 prostate cancer cells do express nestin, but 
its organization is atypical and appears dotted under the microscope. In patient samples, nestin 
was found to be expressed in the cancer cells of high grade metastatic lesions as well as the 
primary tumors themselves (Kleeberger et al., 2007), and the authors argued that nestin 
expression correlates with advanced disease. On the contrary, all tumor cells in the prostate 
cancer samples in the Human Protein Atlas-web resource (Uhlén et al., 2005) appear nestin 
negative after analysis with four different antibodies, whereas the tumor stroma showed nestin 
immunoreactivity (www.proteinatlas.org; accessed 12.5.2015). Therefore, nestin expression in 
prostate tumor cells in situ remains unclear. Kleeberger and co-authors (2007) also reported 
that nestin mRNA is faintly induced by androgen deprivation in LNCaP prostate cancer cells, 
whereas long term androgen starvation failed to induce nestin at protein levels in our hands (J. 
Lindqvist, J. Eriksson, unpublished data). As nestin is not found in all cell lines (i.e. LNCaP) 
where Cdk5 in turn is found, the proteins are likely to be regulated by separate means. In 
addition, Cdk5 does not seem to affect nestin protein levels or organization significantly in PC-
3 cells, nor has an interaction been observed between the two proteins (J. Lindqvist, J. Eriksson, 
unpublished data). Therefore, the nestin scaffold does not seem to be essential for Cdk5 
functions in prostate cancer cells.   
3.2 Cdk5 phosphorylates AR and guides its target gene specificity 
Regardless of the less convincing nestin-Cdk5 connection in prostate cancer, experiments 
focusing solely on Cdk5 were pursued, as Cdk5 has several phosphorylation motifs on AR, 
including serines 81, 94, 256, 308, 424 and 524 in the AR N-terminal domain, and Ser650 in the 
ligand-binding domain (Chen et al., 2006). Between the N-terminal domain and ligand binding 
domain lays the AR DNA-binding domain, essential for AR-mediated transcriptional 
regulation. The AR is activated in a multistep process through ligand binding (i.e. by 
testosterone, 5α-dihydrotestosterone or similar compounds), which causes dimerization and 
nuclear translocation of the receptor complex. In the nucleus, AR binds to androgen response 
elements in the DNA, thereby modulating transcription of its target genes. Additionally, AR 
activation is regulated by molecular interactions of co-factors that bind to the activation 
function 1-domain (spanning amino acids 101-370 in the N-terminal domain). Thus, the AR 
N-terminal domain is crucial for maximal AR activity, and so it eventually fine-tunes the 
androgen response (reviewed by Helsen and Claessens, 2014). 
To investigate potential Cdk5 phosphorylation sites on AR, sensitive mass spectrometry was 
chosen as a screening method. AR was immunoprecipitated from VCaP cells, phosphorylated 
in vitro with recombinant Cdk5/p25-complex, and analyzed by mass spectrometry (III: Figure 
2). Compared to non-phosphorylated samples (-kinase) Ser308 was the only identified 
phosphorylation site induced by Cdk5/p25, and counteracted by roscovitine. To confirm the 
phosphorylation of Ser308 in vivo, LNCaP cells were subjected to Cdk5 or control siRNA, after 
which AR was immunoprecipitated and analyzed for altered phosphosites, revealing that Ser308 
phosphorylation was indeed suppressed in cells lacking Cdk5 (III: Table 1, Supplementary 
figure 3). The presence of p-Ser308 in LNCaP cells grown in regular growth media was 
confirmed by immunolabeling (III: Figure 2), and the staining pattern was found to partly 
overlap with Cdk5. While this set of experiments demonstrated that Cdk5 phosphorylates AR 
Ser308 both in vitro and in vivo, only little is known of the biological significance of Ser308 
phosphorylation. The only recognized kinase for Ser308 to date is Cdk11p58/cyclin D3 (Zong et 
al., 2007). Contrary to other Cdks in prostate cancer, Cdk11p58/cyclin D3-activity has a 
negative impact on androgen-dependent proliferation and AR activity measured by luciferase 
reporter (Zong et al., 2007). Furthermore, the effect of the kinase on AR activation was shown 
to depend on Ser308, since S308A mutation counteracted the outcome of the kinase on AR 
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activity (Zong et al., 2007). However, the evidence does not directly support that Ser308 
phosphorylation would block AR transactivation, as a phospho-mimicking mutant was never 
studied and because the phospho-deficient mutant did not increase AR activity further. It is 
possible, that a yet unidentified mechanism initiated by Ser308 could play a role in AR 
regulation. As an interesting note, S308A mutation causes the abrogation of two metabolically 
labelled phosphopeptides in the phosphopeptide mapping-experiments that originally 
identified this particular phosphosite in vivo (Gioeli et al., 2002), opening the possibility that 
Ser308 could certainly be regulating a sequential cascade of other PTMs. Thus, the role of 
Ser308 phosphorylation should be investigated in more detail, especially as it lies in the 
regulatory activation function-1 domain that coordinates AR activity and interactions. 
While this project was ongoing, a separate report from another laboratory suggested, after 
phosphoantibody-analysis, that Cdk5 promotes AR Ser81 phosphorylation (Hsu et al., 2011). 
Ser81 phosphorylation is important mainly for AR stability, and the site is also phosphorylated 
by other Cdk family members (Cdk1 and Cdk9) (Chen et al., 2006; Chen et al., 2012b). In 
reality, it is likely that several kinases (Cdk1, Cdk5, Cdk9) contribute to the maintenance of the 
exceptionally high phosphorylation stoichiometry of Ser81 (Gioeli et al., 2002), a 
phosphorylation site crucial for receptor stability (Chen et al., 2006), localization and chromatin 
binding (Chen et al., 2012b). Our results added to the knowledge by demonstrating a second 
Cdk5 phosphorylation site, Ser308, on AR. In the in vivo context, Cdk5 can almost certainly 
phosphorylate several AR residues (both Ser81 and Ser308) depending on the cellular 
circumstances, thereby initiating a unique PTM-fingerprint that has implications for AR 
functions. By analyzing a broad range of known AR targets, we found that in the absence of 
Cdk5, some AR target genes were suppressed, while others were induced or unchanged, 
highlighting that Cdk5 plays a complex role in AR target gene specification (III: Figure 2, 
Supplementary figure 4). In contrast to previous publications (Hsu et al., 2011), our results 
imply that Cdk5 can also have adverse effect on specific AR targets, which resembles the Cdk5-
mediated regulation of GR (Kino et al., 2007). It is possible, that in the absence of Cdk5, AR co-
activator or co-repressor complexes do not form normally, thus giving rise to the altered gene 
selectivity of the AR, which has consequences on the proliferative androgen pathway.  
3.3 Cdk5 regulates prostate cancer cell proliferation 
To study the function of Cdk5 in prostate cancer, a number of different cell lines were initially 
utilized to provide a comprehensive view of Cdk5 functions. In Table 7, where the molecular 
signature of the used cell lines is summarized, the term androgen response refers to the capacity 
of androgens to stimulate cell proliferation. In 22Rv1 prostate cancer cells, androgen 
stimulation does induce AR stabilization and activation, but does not increase their 
proliferation: in this case, the term “androgen responsive” is applied. Although present in most 
cells, the AR is altered in all utilized cell lines. A mutation in the LNCaP AR ligand binding 
domain causes both promiscuous activation by other steroid hormones and anti-androgens, as 
well as activation and nuclear localization of AR in the absence of ligands (Veldscholte et al., 
1990). VCaP cells on the other hand, express as much as 12 times more AR than LNCaP cells, 
which makes the cells extremely sensitive to androgens (Waltering et al., 2009). The cell lines 
are also different in terms of p53 status. Thus, the cell lines have distinct molecular 
characteristics that reflect different stages of prostate carcinogenesis, and these distinctions 
were taken into consideration when interpreting experimental results.  
To study the proliferation of prostate cancer cells, Cdk5 was downregulated using RNAi, and 
cells were counted or followed with live cell microscopy. The absence of Cdk5 was found to 
dramatically abrogate the proliferation of LNCaP, 22Rv1 and PC-3 cells (III: Figure 1, 
Supplementary figure 1, Supplementary videos 1-8), while VCaP was the only cancer cell line 
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not to respond to Cdk5 modulation (III: Figure 6). Also, overexpression of WT-Cdk5 increased 
cell population size in LNCaPs (III: Figure 1), suggesting that Cdk5 can boost proliferation, at 
least to a certain extent, in the cancer cells that from the beginning have a high metabolism. The 
cells did not show signs of increased apoptosis. When taking into consideration the specific 
molecular characteristics of the used cell lines, two key features could be distinguished. Firstly, 
the impact of Cdk5 siRNA on the proliferation of the AR-null PC-3 cell line was not less 
effective than its effect on the AR-positive LNCaP and 22Rv1. Thus, it seemed as the AR status 
of the cells did not matter for the effect of Cdk5 on proliferation. This was rather surprising, 
since we and others found that Cdk5 does regulate AR through phosphorylation, which is one 
of the major growth-promoting pathways in prostate cancer. Next, the intact Phosphatase and 
tensin homolog (PTEN) status and the virtually non-existent Akt activity of VCaP cells at basal 
levels (Ha et al., 2011) seemed particularly eye-catching. Genetic aberrations that cause 
hyperactivation of the PI3K-Akt pathway in prostate cancer also include PIK3CA-mutations in 
addition to PTEN, and 1/3 of advanced prostate cancers have mutation in either one (Sun et al., 
2009). Although 22Rv1 cells have normal PTEN, they are characterized by an activating 
mutation in PIK3CA encoding the catalytic p85α-subunit of PI3K; a mutation that leaves the 
Akt kinase hyperactive. Thus, the fact that the only Cdk5 siRNA non-responsive cancer cell line 
was independent of Akt, suggested that this signaling pathway should be examined more closely 
in relation to Cdk5. 
3.4 Complex Cdk5-Akt-androgen interplay in prostate cancer cells  
LNCaP cells were utilized as the main model system to study the signaling pathways 
downstream of Cdk5 due to their wide expression of signaling proteins, as opposed to other cell 
lines. Cdk5 was downregulated in LNCaP cells that were either depleted from all hormones or 
stimulated with synthetic androgen, as LNCaP cell proliferation is under strict regulation of the 
androgen receptor. In the absence of Cdk5, active (phosphorylated) Akt (Ser473) was strongly 
repressed (III: Figure 3). Similarly, several of its downstream targets were suppressed/activated 
accordingly. The Cdk5-dependent regulation of Akt targets was, however, found to be variably 
androgen dependent; while p-Akt and p-GSK3β (Ser9; indicating activation of the kinase) levels 
were equally low after Cdk5 siRNA in both androgen starved and androgen stimulated 
conditions, phosphorylation of ribosomal protein S6 (p-S6, Ser235/236) was highly androgen 
dependent. Androgen treatment caused by itself a stabilization of S6 and an increase in its 
phosphorylation, denoting hormone dependent activation of the mTOR-S6 kinase-S6 growth-
promoting signaling pathway. It seems as in the presence of hormones, the inhibitory effect of 
Cdk5 downregulation is actively counteracted by simultaneous AR feedback into the strongly 
growth-promoting mTOR pathway. Although the growth-promoting pathways regulated by 
Cdk5 can translate differently, depending on the specific protein expression pattern of the cell 
lines used, the effect of Cdk5 on p-Akt is androgen independent, which is particularly obvious 
Table 7 Molecular signature of utilized prostate cancer cell lines. 
 
LNCaP VCaP 22Rv1 PC-3 
AR status positive (mutated) positive (amplified) positive (mutated) null 
Androgen 
response 
androgen   
dependent 
androgen 
dependent 
androgen 
responsive 
androgen 
independent 
p53 status WT mutated mutated null 
PTEN status mutated WT WT null 
Origin lymph node metastasis vertebral metastasis 
carcinoma 
xenograft bone metastasis 
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Figure 14 Effect of Akt inhibitor VIII on Cdk5 activity. Akt 
kinase activity was inhibited in LNCaP cells using 1µM Akt 
inhibitor VIII (Calbiochem) for 24 hours. Akt inhibitor VIII 
binds to the PH-domain of Akt, and therefore disturbs the 
membrane binding and the phosphorylation-mediated 
activation of the kinase. After treatment, Cdk5 was 
immunoprecipitated from DMSO and Akt inhibitor-treated 
samples (Akt i VIII) and subjected to kinase activity 
measurements in vitro using histone H1 as substrate and [γ-32P] 
ATP incorporation as a measure of Cdk5 activity. Cdk5 activity 
was not affected by Akt inhibition.   
in the AR null PC-3 cell line (III: Figure 
3), and true for those prostate cancer 
cells that possess hyperactive Akt. Last, 
the relationship between Cdk5 and the 
multipurpose kinase Akt was further 
questioned through measuring Cdk5 
activity after Akt inhibition, results 
which revealed that abrogation of Akt 
does not affect Cdk5 activity (Figure 14). 
Therefore Cdk5 can be placed upstream 
of Akt in the signaling hierarchy of 
prostate cancer cells, and not vice versa.   
To understand better the mechanism of 
Cdk5-mediated Akt regulation, the 
intracellular localization of Akt was 
studied. When Akt is activated, it 
associates with phosphatidylinositols in 
the plasma membrane, where the kinase 
is activated through phosphorylation on 
serines 308 and 473. Therefore, the membrane localization of Akt is crucial for its activation. 
Using subcellular fractionation and imaging, we found that the membrane localization of Akt 
was indeed disturbed when Cdk5 was silenced (III: Figure 4). Furthermore, Cdk5 and Akt could 
be co-immunoprecipitated from LNCaP cells, suggesting that there is a direct interaction 
between the two proteins (III: Figure 4). Considering these results, Cdk5 seems to act as a 
crucial regulator of Akt activity in prostate cancer cells: without Cdk5, Akt activation at the 
membrane does not occur, and the growth-promoting effects of Akt are strongly suppressed. 
The Cdk5-Akt regulatory axis was further validated with rescue experiments, where expression 
of constitutively active (myristoylated) Akt partially rescued the growth retardation of Cdk5 
downregulated LNCaP cells (III: Figure 6). Although the same experimental setup could not be 
repeated in the transfection-sensitive PC-3 cells, the roscovitine-induced lag in proliferation of 
PC-3 cells could be overcome when CA-Akt was expressed (Figure 15). Thus, regardless of the AR 
status of the cell, the effect of Cdk5 dysfunction in cell proliferation can be rescued by 
restoration of membrane bound, constitutively active Akt.  
The results propose that Cdk5 is a key regulator of prostate cancer proliferation through its 
multimodal and simultaneous actions on both AR and Akt signaling. Although the Akt-
pathway was ultimately the prime target of Cdk5-induced prostate cancer proliferation, the 
Cdk5-dependent regulation of AR is likely to be important in those cells, where AR is present. 
As many of the AR target genes that were found to be regulated by Cdk5 in an androgen-
dependent manner are central cancer-associated proteins (III: Figure 2), this mode of regulation 
should not be underestimated. Especially in vivo, individual patients or even one single tumor 
will contain cells that differ in their proteome, and that rely on different mechanisms for 
survival. In this setting, Cdk5 will theoretically have the capability to act in several cell types in a 
pro-proliferative manner.  
Results and Discussion 
Given the strong effects of 
Cdk5 inhibition on cell 
proliferation, we further 
questioned what effect Cdk5 
downregulation would have 
on the cell cycle. In fact, the 
many growth-promoting and 
anti-apoptotic key signaling 
pathways in carcinogenesis 
are significantly intertwined. 
Akt is known to negatively 
regulate p53 stability through 
the direct phosphorylation of 
the p53 E3 ubiquitin ligase 
Mdm2 (Zhou et al., 2001). 
Therefore, the state of the 
p53-p21 signaling axis was assessed. As could be expected from the repressed Akt signaling, the 
downregulation of Cdk5 strongly upregulated the cell cycle inhibitors p53 (at protein level) and 
p21 (at protein and mRNA level) (III: Figure 5), which is reflected also in the strong cell cycle 
arrest of LNCaP cells in response to Cdk5 siRNA. Interestingly, p21 mRNA is also influenced 
by the androgen status: the Cdk5 siRNA-mediated cell cycle suppression is slightly alleviated in 
hormone-stimulated cells that are primed to proliferate faster, once again illustrating the 
complex relationship between the signaling pathways in the prostate cancer cell cycle. Thus, the 
lack of Cdk5 seemed to induce a p21-dependent cell cycle arrest, which is reflected in the 
altered cell proliferation. As an important note, the p53-p21 signaling is not a general Cdk5-
regulated pathway, as PC-3 cells, which are equally Cdk5-dependent in terms of proliferation, 
are p53 null. Rather, the p53-p21 signaling provides yet another mode of action for the 
inhibited Akt and AR pathways in LNCaP cells to efficiently disturb proliferation. Especially 
when Cdk5 was inhibited with 10 µM roscovitine (III: Supplementary figure 2), which will 
target all cells in a population, compared to transfections that are effective only on a 
subpopulation, the growth-inhibitory effect of roscovitine was much stronger in LNCaP cells 
compared to PC-3. Therefore, it seems as LNCaP cells are more sensitive to Cdk5 inhibition, 
perhaps through the tripartite actions on these three 
imperative cancer-sustaining pathways. It is attractive to 
speculate that when Cdk5 is efficiently inhibited in 
LNCaP cells, its simultaneous effects on both Akt 
(including the strong p53/p21 upregulation) and AR, 
which the cells are in general highly dependent on, makes 
the cells especially sensitive to Cdk5 inhibition, with 
drastic consequences on proliferation. The androgen 
independent PC-3 cells, on the other hand, show similar 
degree of proliferation inhibition after both Cdk5 siRNA 
(III: Figure 1) and 10 µM roscovitine treatment (III: 
Supplementary figure 2). Importantly, titration of 
roscovitine concentrations demonstrated its efficiency 
already at lower concentrations than what was used in the 
original study (2.5–5 µM), when other Cdks would 
remain virtually unaffected (Figure 16).  
Figure 16 Effect of roscovitine on LNCaP 
population size. Cells were plated in equal 
amounts, treated with DMSO or various 
concentrations of roscovitine, and counted 
after 48 hours. Cell population size is 
displayed as relative growth (compared to 
the 0 h time point). At concentrations 10 
µM roscovitine and higher, the cell 
population shrinks compared to the 0h 
time point. 
Figure 15 Expression of constitutively active Akt rescues roscovitine-induced 
lag in PC-3 cell proliferation. Cells were transfected with GFP or GFP-
conjugated CA-Akt, re-plated the following day in equal numbers and 
immediately treated with DMSO or roscovitine. Cell numbers were counted 
after 48 hours. Relative proliferation indicates cell counts compared to the 0 
hour time point. Results are plotted as mean±S.E.M (One-way ANOVA). 
Western blotting verifies efficient transfection. 
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Although many facts suggested that nestin is not required for Cdk5 functions in prostate 
cancer, nestin was found to regulate the same targets as Cdk5 in 22Rv1 cells: when nestin was 
downregulated with siRNA, both p-Akt and AR levels were altered (Figure 17). Since nestin 
depletion was found to cause an increase in Cdk5-activity in neuronal (Sahlgren et al., 2006) 
and muscle cells (I), it is tempting to speculate that a similar chain of events may occur in 
prostate cancer cells. If the hypothesis held, and the nestin-Cdk5 connection acted in a similar 
manner in 22Rv1 cells as in the other tissues, an increase in p-Akt and AR levels could be 
expected in nestin knockdown cells, due to increased Cdk5 activity, as indeed was the case 
(Figure 17). Thus far, the nestin-Cdk5 connection has not been verified in 22Rv1 cells and the 
observed phenomena of similar targets may be unrelated, but it would be an interesting aspect 
to address in more detail in future experiments. LNCaP cells are, in turn, naturally nestin 
deficient, and express no vimentin either that would allow nestin filament formation to occur. 
Therefore, with the lack of convenient prostate cancers model systems, the concept of nestin-
Cdk5-AR interplay was not developed further. Instead of prostate cancer models, it could be 
more meaningful to study a possible nestin-AR interaction in a tissue like skeletal muscle, 
where both are present and have physiological functions. Also other model systems resembling 
prostate cancer, such as breast cancer models, would be interesting to approach in terms of 
Cdk5-nestin-mediated regulation of the hormonal signaling pathways. For example, breast 
cancer has many similarities to prostate cancer, where deregulated receptor tyrosine kinases are 
frequent, but where tumorigenesis is instead primarily driven by the estrogen receptor instead 
of androgen receptor. Nestin expression does in fact seem to correlate with poor prognosis in 
breast cancer (Gao et al., 2014; Piras et al., 2011). Given the emerging role of Cdk5 in breast 
cancer epithelial-mesenchymal transition (Liang et al., 2013), and our newly found role of Cdk5 
as a regulator of Akt-signaling (which is commonly deregulated in breast carcinoma), it would 
be of great interest to study the Cdk5/nestin signaling interactions in breast cancer models in 
the future.  
In the end, this work demonstrated that can Cdk5 act either separately, or simultaneously, on 
two important prostate cancer promoters, namely Akt and AR (Figure 18). It is intriguing to 
speculate that Cdk5 may offer a growth advantage for prostate cancer cells through promoting 
cell cycle progression. Cdk5 could even, under specific circumstances, compensate functionally 
for cell cycle Cdks in a cancerous environment, as the kinases have many mutual targets. Its 
multifaceted functions in neuronal cell death and nociceptive signaling have raised a 
therapeutic interest towards Cdk5 as a potential drug target in the field of neuropsychiatric 
diseases, analgesia and addiction. Given its well-reported role in cancer cell invasion and now 
proliferation, Cdk5 should be considered as a potential cancer drug target. Whereas Cdk5 
Figure 17 Nestin downregulation affects Akt and AR expression in 22Rv1 prostate cancer cells. (A) 22Rv1 cells were 
transfected with scrambled (Scr) or nestin siRNA (Nes), or left untreated (Untr), and samples were collected for 
Western blotting 48 hours later. Compared to controls, nestin knockdown increased the p-Akt/Akt ratio. (B) 22Rv1 
cells were first transfected with indicated siRNA, and then either androgen treated or starved for 24 hours. Nestin 
downregulation did cause an increase in AR protein levels regardless of hormone treatment. Androgen treatment 
stabilized the AR and caused a PTM-induced band shift, as expected. 
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inhibition in neuronal tissues may be beneficial in terms of development of novel pain relief 
medication and in the prevention of neuronal loss triggered by neurodegenerative diseases or 
ischemia, contraindications that may disturb the positive activity of Cdk5 in memory 
formation, podocyte biology or muscle differentiation are serious health risks that should be 
taken into consideration. However, roscovitine and well as other pan-Cdk inhibitors have 
generally been well tolerated in clinical trials, with minimal reported toxicity. This supports the 
fact that targeting of Cdk5 even with less-specific inhibitors or through other mechanisms 
could be a real opportunity in the drug development field. 
 
 
  
Figure 18 Cdk5 regulates prostate cancer proliferation through Akt and AR signaling. Cdk5 promotes the proliferation 
of prostate cancer cells through various mechanisms; firstly, Cdk5 phosphorylates the AR, which has target-gene selective 
effects on AR activation, and promotes prostate carcinogenesis through the androgen pathway. However, the androgen 
signaling axis is not fully required for Cdk5-mediated regulation of prostate cancer proliferation in an androgen 
independent stage. Instead, Cdk5 seems to mainly drive the proliferation of cancer cells through the multifunctional 
growth-promoting Akt kinase in both androgen dependent and independent cells. When Cdk5 is depleted from prostate 
cancer cells, Akt activation at the membrane is disturbed, and both pro- and anti-proliferative effectors of Akt are affected.  
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CONCLUDING REMARKS 
During the progress of this thesis work, there has been an apparent growing interest towards 
understanding the non-neuronal functions of Cdk5 in the research community. Not only is 
Cdk5 considered to be a stress-sensor that determines the balance between life and death of a 
neuron, but it has newly found functions in cell transcription, proliferation, differentiation, cell 
architecture and motility in a wide range of dividing and terminally differentiated cell types, 
and in physiology and disease. This thesis studied the functions of Cdk5 in two atypical settings: 
muscle and proliferating cancer cells. By utilizing in vitro and in vivo methods, nestin was 
revealed to act as a critical scaffold for Cdk5 in muscle, as was originally hypothesized. The 
presence and state of the nestin scaffold ultimately determines whether Cdk5 is allowed to 
execute its p25-dependent functions following a differentiation-permissive signal, or 
alternatively, whether the myogenic cells continue proliferation and expansion instead. In 
cancer cells, the frequently differentiation-associated Cdk5 was found to promote proliferation 
instead, indications of which have existed in literature before. When unleashed, Cdk5 activity 
has the capability to boost many essential cell cycle-related signaling pathways. Thus, cancer 
cells seem to be able to utilize Cdk5 to gain a growth advantage compared to non-cancer cells, 
which in the case of prostate cancer, was found to be realized through its simultaneous actions 
on Akt and AR. Therefore, Cdk5 not only promotes initiation of differentiation processes, as 
noted already in early experiments, but the kinase can also advance cell proliferation in a 
disease context (Figure 19). Contrary to expectations, nestin did not appear to be a pre-requisite 
for the functions of Cdk5 in prostate cancer, although its modulation may affect the signaling 
capacity of the kinase in certain cell models. 
Also the field of IFs is changing, as we are coming to understand the complexity of the 
phenotypes of the many knockout mouse models that were originally defined as “normal”. An 
example was described yet again using the nestin knockout mouse: although appearing grossly 
normal, closer inspection of skeletal muscles of nestin null mice revealed underlying 
complications in skeletal muscle homeostasis and healing. Therefore, the results suggest that 
nestin plays a novel role in maintenance of muscle integrity. Although IFs play a significant role 
in the preservation of tissue integrity, studies on knockout and knock-in models of a variety of 
IF proteins are collectively suggesting that their function not only occur at the cellular level, but 
reaches from homeostasis of the whole body to regulation of metabolism, and ultimately 
disease. In intricate and unexpected ways they suppress, activate and modify cell signaling 
pathways through modulation of protein kinases and other signaling proteins, with broad-
ranging consequences on tissue function and well-being.  
Figure 19 Cdk5 balances between cell proliferation and differentiation. Cdk5 has multiple newly found functions in 
determination of cell fate: Cdk5 activity promotes the progress of differentiation processes in neurons and muscle, 
whereas deregulated Cdk5 activity in cancer can support cell division instead. The signaling capacity of Cdk5 can be 
modified by the bi-directional relationship with the nestin scaffold, which fine-tunes the processes that Cdk5 is involved 
in.  
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